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Abstract 
 
The 1,3-dipolar cycloaddition, as a powerful method, was widely applied in the regio- 
and stereoselective synthesis of heterocycles and their ring-opened acyclic derivatives. 
In this work, a novel gold(I)-catalyzed 1,3-dipolar cycloaddition of 2-(1-alkynyl)-2-
alken-1-ones with N,N’-cyclic azomethine imines is described, which provides a 
practical, efficient, regiospecific, and highly diastereoselective route to novel 
heterobicyclic highly substituted furo[3,4-d]pyridazines. Furthermore, 
enantioselective gold(I)-catalyzed cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with 
N,N’-cyclic azomethine imines is also developed by using Taddol-derived phosphine-
phosphite ligands, the so-called SchmalzPhos ligands. Under optimized reaction 
conditions, a variety of optically active highly substituted furo[3,4-d]pyridazines 
could be synthesized with excellent yields and high enantioselectivities. 
 
 
 
 
 
 
 
 
 
 
 
 
Kurzzusammenfassung 
 
Die 1,3-dipolare Cycloaddition ist eine wichtige Transformation für die regio- und 
stereoselektive Synthese von Heterocyclen und deren offenkettigen Derivaten. In 
dieser Arbeit wird eine neuartige Gold(I)-katalysierte 1,3-dipolare Cycloaddition von 
2-(1-Alkinyl)-2-alken-1-onen mit N,N -´cyclischen Azomethin-Iminen beschrieben, 
die einen praktischen, effizienten sowie hoch regio- und diastereoselektiven Zugang 
zu neuen hochsubstituierten heterobicyclischen Furo[3,4-d]pyridazinen ermöglicht. 
Des Weiteren wird eine enantioselektive Gold(I)-katalysierte Cycloaddition von 2-(1-
Alkinyl)-2-alken-1-onen mit N,N -´cyclischen Azomethin-Iminen unter Verwendung 
Taddol-basierter Phosphin-Phosphit-Liganden (SchmalzPhos-Liganden) beschrieben. 
Unter optimierten Bedingungen gelang die Synthese einer Vielzahl optisch aktiver 
hoch substituierter Furo[3,4-d]pyridazine mit exzellenten Ausbeuten und hohen 
Enantioselektivitäten. 
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1. Introduction 
1.1. Phosphorus-containing ligands 
Phosphorus-containing ligands as one of the most important ligand-classes are widely 
used in modern organic synthesis. A lot of examples have been reported over the last 
50 years on this subject. As is well-known, asymmetric catalysis is an extremely 
powerful, economically feasible tool for the synthesis of enantiomerically pure 
compounds in the development of pharmaceuticals, agrochemicals and flavors. In 
addition, in the past decades, due to the high ability of the phosphorus atom to 
coordinate to most transition metals, many chiral phosphorus-containing ligands have 
been synthesized and used in enantioselective catalysis, offen exhibiting remarkable 
enantioselectivity and reactivity.
1, 2 
1.1.1. Phosphorus-containing ligands in asymmetric catalysis 
Chiral phosphorus ligands have been successfully used in a wide variety of transition 
metal catalyzed asymmetric reactions and have established themselves among the 
most versatile ligands in asymmetric metal catalysis. Chiral ligands provide a chiral 
environment to metals, the structure of the chiral ligands is the key for the asymmetric 
induction. Based on the electronic structure, the phosphorus group can be easily 
modified via replacement of the P-C bonds with P-O and P-N, leading to different 
types of phosphorus-containing ligands (Figure 1). According to the coordination 
mode, the P-derivatives can also be differentiated into different types (Figure 1).
3
 
Phosphorus ligands with a chiral rigid backbone that provide a chiral environment to 
metals have played and still play an important role as metal binders in asymmetric 
catalysis. Numerous highly selective and active chiral phosphorus ligands have 
already been developed and used in many different catalytic reactions, some of them 
even being used in industrial processes. 
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Figure 1. Various trivalent phosphorus compounds. 
 
An early example of chiral phosphorus ligands in asymmetric catalysis was reported 
in asymmetric hydrogenation of olefins by Knowles
4 
in 1968, after the discovery of 
the Wilkinson hydrogenation catalyst [RhCl(PPh3)3] in 1966.
5 
The earliest examples of 
chiral monophosphines in enantioselective hydrogenation only gave a poor 
enantioselectivity (15% ee). Four years later, an improved monophosphine ligand 
CAMP (1) was disclosed in the hydrogenation of dehydroamino acids (88% ee).
6
 
Starting with the first bisphosphine ligand DIOP (2) for the Rh-catalyzed asymmetric 
hydrogenation by Kagan
7
, bisphosphorus ligands increasingly attracted much more 
the attention of organic chemists. Compared to monodentate phosphines, 
bisphosphorus ligands could lead to improved enantioselectivity. Then, a C2-
symmetric chelating bisphosphine ligand, DIPAMP (3), was introduced by Knowles.
8
 
 
Catalysts
 
based on DIPAMP afforded a high catalytic efficiency in the Rh-catalyzed 
asymmetric hydrogenation of dehydroamino acids, thus DIPAMP was quickly used in 
the industrial asymmetric synthesis of the drug L-DOPA (Scheme 1). Additionally, P-
chiral phosphorus ligands were not the only choice for achieving high 
enantioselectivity, and ligands with backbone chirality could also provide excellent 
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enantioselectivity in asymmetric catalysis. This provides a further approach to the 
design and synthesis of numerous chiral phosphorus ligands in asymmetric catalysis.  
 
Figure 2. Various chiral phosphorus ligands. 
 
 
 
Scheme 1. The asymmetric synthesis of L-DOPA. 
 
Following the successful application of DIPAMP, thousands of efficient chiral 
phosphorus ligands have been developed in the past decades. For example, Noyori 
reported the excellent diphosphine ligand BINAP (6), which was successfully applied 
in the Ru-catalyzed asymmetric hydrogenation of various functionalized olefins and 
ketones.
9
 For this beautiful work, Noyori was awarded the Nobel Prize together with 
Knowles and Sharpless in 2001. Inspired by the excellent results of BINAP, other 
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outstanding atropisomeric biaryl bisphosphine ligands were developed such as 
BIPHEMP, MeO-BIPHEP, BIMOP, FUPMOP, MOC-BIMOP and their modified 
derivatives.
10
 Further more, Burk developed a highly effective chiral phospholane 
class of ligands called DuPhos (7) and BPE (8).
11
 Excellent enantioselectivities were 
achieved in the Rh-catalyzed hydrogenation of various functionalized olefins (Figure 
2). 
With the development of asymmetric catalysis, more and more chemists focused on 
the design, preparation, and study of new efficient chiral phosphorus ligands. In the 
past decades, a number of new chiral phosphorus ligands have been developed with 
significant structural diversities and have also been used in transition metal 
transformations. Most of these ligands can be divided into the following categories: 
chiral bisphosphane ligands, modifications of DuPhos, BPE and DIOP, chiral 
ferrocene-based bisphosphane ligands, bisphosphinite ligands, bisphosphonite ligands, 
bisphosphite ligands, chelating aminophosphine, amidophosphine, phosphoramidites, 
and chiral N, P ligands etc.
3, 12, 13
 Here, just two examples are depicted, the first 
example is the very famous Trost ligand (9), which was developed by Trost for the 
allylic alkylation. This C2-symmetric bisphosphine Trost ligand was also widely used 
in other transition metal-catalyzed enantioselective reactions and yielded 
exceptionally good results. Another category are the chiral non C2-symmetrical 
ferrocene-based bisphosphane ligands such as the Josiphos ligand (10), which has 
been found to be very effective for the Rh-catalyzed hydrogenation of 
acetamidocinnamate, dimethyl itaconate, and β-ketoesters.14 Some of the Josiphos 
ligands have been used in industrial asymmetric synthesis. For example, ligand 11 has 
been applied in the asymmetric hydrogenation for the commercial synthesis of (+)-
biotin,
15
 and ligand 12 has been used in the Ir-catalyzed hydrogenation of 13 for the 
synthesis of the herbicide (S)-metolachlor.
16
 (Scheme 2) 
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Figure 3. Trost ligand and Josiphos-type ligands. 
 
 
 
Scheme 2. Synthesis of (S)-metolachlor. 
 
1.1.2. Modular phosphine-phosphite ligands introduced by Schmalz 
Phosphine-phosphites are an important class of chiral bidentate phosphorus ligands 
and have been widely used in various asymmetric transformations. Compared to 
symmetric bidentate ligands, phosphine-phosphites are nonsymmetric ligands 
containing two phosphorus atoms with different electronic and steric environment. In 
1993, the first examples of seminal phosphine-phosphites (15, 16) were reported by 
Takaya
17
 and Pringle,
18
 respectively. Ligands 15 and 16 are similar in structure: two 
phosphorus groups are situated on diverse carbon backbones with both of them 
containing an axis as the stereogenic element. BINAPHOS (15) is the most widely 
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studied phosphine-phosphite ligand in enantioselective catalysis. Based on the 
outstanding catalytic properties of BINAPHOS, numerous phosphine-phosphinite 
ligands have been developed.
13
 Furthermore, starting from chiral pool-derived 
compounds such as L-ascorbic or D-isoascorbic acids and D-(+)-xylose, many 
phosphine-phosphite ligands were prepared.
19 
 
 
Figure 5. Chiral phosphine-phosphites. 
A new type of phosphine-phosphite ligands was synthesized by Van Leeuwen in 2000 
(20, 21) based on enantiomerically pure epoxides and phosphorus-containing carbon 
nucleophiles or nucleophilic phosphorus reagents.
20
 The stereogenic carbon center 
resulting from the epoxide ring-opening reaction provided a stereogenic phosphorus 
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atom or a conﬁgurationally stable biaryl unit. Vidal-Ferran21 and Bakos22 also 
prepared several phosphine-phosphite ligands derived from enantiomerically pure 
epoxides, 22 and 23, respectively. 
 
 
Figure 6. Phosphine-phosphite ligands derived from enantiomerically pure epoxides. 
 
 
 
Figure 7. Phosphine-phosphite ligands. 
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Recently, several other phosphine-phosphite ligands have been synthesized and also 
been used in many asymmetric transformations. For example, 24 (derived from 
BINOL), 25 ((R,R)-1, 2-diphenyl-1’, 2’-ethanediol), 26, 27, 28 and 29 etc.23-25 
Today, a large number of efficient chiral phosphine-phosphite ligands with diverse 
structures have been prepared, and their application in asymmetric catalysis has been 
extensively studied in both academic research and industry. However, there are still 
many unsolved challenges in this field such as the difficultly of preparing many 
effective chiral ligands, the lack of effective chiral ligands for numerous reactions and 
the substrate dependence of enantioselectivities in many reactions. So the design and 
synthesis of effective chiral ligands is still an important task for organic chemists. In 
this situation, Schmalz developed a new class of modular phosphine-phosphite ligands 
30, which are accessible starting from substituted phenols (31) (Scheme 3).
26
 
 
 
Scheme 3. Modular synthesis of phosphine-phosphite ligands according to Schmalz. 
 
The ligands of type 30 can be conveniently prepared in only four steps (Scheme 3) 
starting from substituted phenols (31). The first step is an ortho-bromination of the 
phenol using NBS. The resulting bromophenols are converted with a chlorophosphine 
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and then protected in situ with borane. Then intermediate 33 is treated with nBuLi to 
smoothly induce the migration of the phosphanyl group to airstable phosphine 34. In 
the last step, the desired ligands of type 30 are synthesised by the reaction of the 
phosphine 34 with PCl3 and a chiral diol (TADDOL, TARTROL or BINOL) under 
basic conditions.
26, 27
 This was a breakthrough in methodology for the modular 
synthesis of phosphine-phosphite ligands. This general approach has many advantages, 
for example, the borane protecting group helps to avoid oxidation of the phosphorus, 
the used chemicals are inexpensive and commercially available, and another notable 
advantage is the modular design of the ligands. Following this approach, a ligand 
library can be easily prepared by using various substituted phenols, a chiral diol, and 
chlorophosphine. 
These modular phosphine-phosphite ligands are a valuable tool for asymmetric 
catalysis, since their backbone structure, and the electronic and steric properties are 
variable in the process of the ligands synthesis. This ligand library provides more 
opportunities for chemists to search for a suitable ligand for asymmetric 
transformations in particular, and also helps to understand the impact of structural, 
electronic, and steric properties of ligands in asymmetric catalysis. These ligands have 
recently been successfully applied in a number of relevant C-C-bond forming 
transformations (Scheme 4). For instance, excellent results were obtained in the Cu-
catalyzed 1,4-addition
28
 and the allylic substitution reactions of Grignard reagents,
29
 
the Rh-catalyzed hydroformylation,
30
 and the intramolecular [4+2] cycloaddition
 
reactions,
31 
the Ni-catalyzed hydrocyanation,
32
 and also in the Co-catalyzed 
hydrovinylation.
33
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Scheme 4. Selected applications of the modular phosphine-phosphite ligands. 
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1.2. 1,3-dipolar cycloaddition reaction 
The addition of a 1,3-dipole to a dipolarophile for the synthesis of five-membered 
rings is a classic reaction in organic chemistry. Because starting materials are easily 
available, usually high yields and efficiency, high regio- and stereocontrollability, and 
product variety are achieved. Therefore, 1,3-dipolar cycloaddition reactions are often 
used as a key step in the syntheses of many natural products and pharmaceuticals. In 
1883, the first 1,3-dipole diazoacetic ester was discovered by Curtius.
34
 Following the 
discovery of 1,3-dipoles, Buchner described the first 1,3-cycloaddition reaction of 
diazoacetic ester with an α, β-unsaturated ester in 1888.35 
Currently, the 1,3-dipolar cycloaddition, as a powerful method, is widely applied in 
the regio- and stereoselective synthesis of heterocycles and their ring-opened acyclic 
derivatives.
36
 Although the development of the 1,3-dipolar cycloaddition has in recent 
years entered a new stage, the synthesis of enantiomerically pure heterocycles, control 
of the stereochemistry in the addition step is still an important research challenge for 
chemists. It is well known, the stereochemistry of the 1,3-dipolar cycloaddition 
reaction can be controlled by either choosing the appropriate substrates or by 
controlling the reaction with a metal complex or a chiral organic compound acting as 
a catalyst.
37
 The regio-, diastereo-, and enantioselectivity of the 1,3-dipolar 
cycloaddition reaction can usually be controlled by using a chiral catalyst. To find a 
suitable catalytic system is still a rather difficult task in many cases. 
1.2.1. The mechanism of the 1,3-dipolar cycloaddition reaction 
In the 1960s, the mechanistic investigation and the synthetic application of this 
reaction was established, primarily through the work of Huisgen. The most accepted 
mechanism of the 1,3-dipolar cycloaddition is the concerted pericyclic cycloaddition 
mechanism proposed by Huisgen.
38
 The 1,3-dipolar cycloaddition reaction involves 
the 4 π electrons from the dipole and the 2 π electrons from the dipolarophile. The 
electrons of the 1,3-dipole react with the dipolarophile in a concerted manner. The 
INTRODUCTION 
21 
 
1,3-dipolar cycloaddition reaction proceeds though thermally and symmetry allowed 
[π4s + π2s] mechanism as a thermal six-electron Hückel aromatic transition state 
according to the Woodward-Hoffmann rules.
39
 It also means that all bonds are created 
simultaneously, but not necessarily to the same extent at a certain time (Scheme 5). 
 
 
Scheme 5. The mechanism of the 1,3-dipolar cycloaddition reaction. 
 
 
 
Scheme 6. Stereochemistry of the cycloaddition products. 
The stereochemistry of the cycloaddition product is a good proof for this point. By 
starting from a trans-dipolarophile the trans-isomer of 53 will also be yielded, the cis-
dipolarophile reacts with the dipole furnishing exclusively cis-53 (Scheme 6). On the 
other hand, similar to the Diels-Alder reaction, the 1,3-dipolar cycloaddition transition 
state can be considered as a cyclopentadienide based on a 6-membered cyclic 
benzene-like Diels-Alder transition state. Here a lone pair replaces one of the double 
bonds of the diene 4-electron component. The neutral 5-membered ring aromatic 
compounds have at least one heteroatom, the most useful 1,3-dipolar cycloaddition 
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reactions have at least one heteroatom in the 1,3-dipole unit. 
Depending on the frontier molecular orbitals theory (FMOT), the transition state of 
the concerted 1,3-dipolar cycloaddition reaction can be controlled by three different 
interaction types. The first type is LUMOdipole interacting with the HOMOdipolarophile, 
the second type is  HOMOdipole interacting with the LUMOdipolarophile, the last type is a 
combination of both interactions.
40
 Scheme 7 is an example of a HOMOdipole-
LUMOdipolarophile-controlled reaction. The reaction of a dipole (benzylidenamino-
malonic acid diethyl ester) with dipolarophile (crotonaldehyde) can occur in an endo 
or exo mode resulting in two diastereomeric endo/exo products, endo-56 and exo-56, 
respectively.  
 
 
Scheme 7. Example of an endo and an exo approach of a LUMOdipolarophile-
HOMOdipole-controlled reaction. 
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1.2.2. Types and classification of 1,3-dipoles 
 
 
Figure 8. Types and classification of 1,3-dipoles. 
The 1,3-dipole, also called ylide, can basically be divided into two different types: the 
allyl anion type and the propargyl/allenyl anion type. The allyl type is a bent structure 
such as azomethine imines, azomethine ylides, nitrones and nitro compounds, bearing 
a nitrogen atom in the middle of the dipole, carbonyl ylides and carbonyl imines, 
bearing an oxygen atom in the middle of the dipole. However, the propargyl/allenyl 
type is linear in geometry such as nitrilimines, nitrile oxides, diazo-alkanes, nitrile 
ylides, and azides. Both types of 1,3-dipoles share four electrons in the π-system over 
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three atoms. Nitrogen, carbon, oxygen or sulfur are the most common atoms 
incorporated in the 1,3-dipole.
40, 41
 
1.2.3. Catalytic asymmetric 1,3-dipolar cycloadditions 
The 1,3-dipolar cycloaddition is a classical reaction widely applied in the synthesis of 
many important 5-membered heterocycles such as furans, triazoles, isoxazoles, 
pyrrolidines, pyrazolone, and others.
36, 37, 40, 41
 In the past decades, many efficient and 
selective catalytic systems have been developed for the 1,3-dipolar cycloaddition 
reaction. Especially nitrones, azomethine imines or azomethine ylides as 1,3-dipoles 
have widely drawn attention because of their high regio-, diastereo-, and 
enantioselectivity in reactions with dipolarophiles. A considerable number of metal 
complex catalysts and organocatalysts have been used to obtain the desired products 
with high regio-, diastereo-, and enantioselectivity.  
The 1,3-dipolar cycloaddition reaction of nitrones with dipolarophiles such as alkenes, 
leading to isoxazolidines, has received considerable attention in asymmetric synthesis 
over the past 30 years.
41, 42 
The isoxazolidines derived from nitrone 1,3-dipolar 
cycloadditions can in turn can be easily converted to β-amino acids, β-amino alcohols, 
or β-lactams.10 In the 1,3-dipolar cycloaddition reaction of nitrones with alkenes three 
contiguous asymmetric centers can be formed. As already discussed in the mechanism 
section, the relative stereochemistry at C-4 and C-5 is always controlled by the 
geometric relationship of the substituents on the alkene. (Scheme 8) 
 
 
 
Scheme 8. The 1,3-dipolar cycloaddition reaction of nitrones with alkenes. 
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The first catalytic asymmetric 1,3-dipolar cycloaddition of nitrones was reported by 
Scheeren
43
 in 1994, where chiral oxazaborolidines were used to catalyze the reactions 
of nitrones 61 with ketene acetals 62 to afford exo selectively isoxazolidines such as 
63 in high yield with high diastereoselectivity and moderate enantioselectivity. 
(Scheme 9) 
 
 
 
Scheme 9. The first catalytic asymmetric 1,3-dipolar cycloaddition of a nitrone. 
 
 
 
Scheme 10. Chiral Yb-catalyzed 1,3-dipolar cycloaddition of nitrones. 
Since then, many successful asymmetric 1,3-dipolar cycloadditions of nitrones were 
reported for the synthesis of 5-membered heterocycles and derivatives. For example, 
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in 1998 Kobayashi reported that a chiral Yb(III) catalyst 64 derived from BINOL and 
a chiral tertiary amine yield the endo cycloadduct 67 with high enantioselectivities 
(Scheme 10).
44
 In the same year, Kanemasa used a Ni(II)/DBFOX 68 complex also 
giving the desired endo isoxazolidines with excellent enantioselectivities.
45
  
 
Figure 9. Examples of catalysts or ligands used in the asymmetric 1,3-dipolar 
cycloaddition of nitrones. 
One year later, (S)-TolBINAP-palladium(II) nitrile complex 69 was prepared and used 
in the asymmetric 1,3-dipolar cycloaddition of nitrones to α,β-unsaturated carbonyl 
compounds and carboxylic acid derivatives to give isoxazolidine derivatives in high 
yields with high enantioselectivities.
46
 The catalytic system of copper as a metal salt 
combined with a chiral ligand was also widely used in asymmetric 1,3-dipolar 
cycloadditions. For example, Jasperse reported that the use of Cu(OTf)2 in 
combination with chiral bisoxazoline 70 afforded cycloadducts with high exo- and 
enantioselectivities.
47
 Other metal salts combined with a chiral ligand as a catalyst 
found also a wide application in the asymmetric 1,3-dipolar cycloaddition of nitrones, 
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e.g., Ti(IV)-TADDOL-complex 71, BINOL-AlMe complex 72, AgSbF6/(S)-tBuBox, 
Bis(oxazolinyl)pyridine/Cerium(IV) complex 73, Co (Ⅱ)/TOX complex (74), Fe and 
Ru complexes, etc.
48-55
  
 
 
Scheme 11. The first enantioselective organocatalytic 1,3-dipolar cycloaddition reaction. 
Chiral Lewis acid catalysis was widely used in the asymmetric 1,3-dipolar 
cycloaddition. The first enantioselective organocatalytic 1,3-dipolar cycloaddition was 
reported by MacMillan in 2000, when a chiral secondary amine catalyst 75 promoted 
the highly enantioselective 1,3-dipolar cycloaddition of nitrones to give endo 
cycloadducts 78 (Scheme 11).
56
 Following this report, a number of chiral 
organocatalysts such as 79,
57, 58
 80,
59
 81,
60
 82
61
 have been applied for the catalytic 
asymmetric 1,3-dipolar cycloaddition reaction.  
 
Figure 10. Examples of organocatalysts used in the asymmetric 1,3-dipolar 
cycloaddition of nitrones. 
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Azomethine imines, as the allyl anion type 1,3-dipole, are also widely used in 
catalytic asymmetric 1,3-dipolar cycloadditions. The first example of a catalytic 
asymmetric 1,3-dipolar cycloaddition of azomethine imines was reported in 2003 by 
Fu.
62
 (Scheme 12). Cu(I)/chiral phosphaferrocene-oxazoline 83 was used to catalyze 
the reaction of N,N’-cyclic azomethine imines and alkynes to give enantioenriched 
pyrazolines 86. 
 
 
Scheme 12. Chiral Cu-catalyzed 1,3-dipolar cycloaddition of azomethine imines with 
alkynes. 
In the past 10 years, the catalytic asymmetric 1,3-dipolar cycloaddition of azomethine 
imines as 1,3-dipole part was further studied. Different types of azomethine imines 
and catalysts such as a Ni(II)/binaphthyldiimine complex 87,
63
 Ti(IV)/(S)-BINOL 
complex,
64
 iminium catalysts (88,
65
 79,
66, 67 
and 89
68
) and a chiral Brønsted acid 
catalyst 90 
69
 were developed in the catalytic asymmetric 1,3-dipolar cycloaddition. In 
addition to nitrones and azomethine imines, other 1,3-dipoles such as azomethine 
ylides,
10, 70-73
 azides,
74
 nitrile oxides (generated in situ),
75
 nitrile imines (generated in 
situ),
76
 carbonyl ylides (generated in situ),
77
 diazo compounds,
78
 and CO2
79
 were also 
widely used in the asymmetric 1,3-dipolar cycloaddition reaction.  
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Figure 11. Examples of catalysts used in the asymmetric 1,3-dipolar cycloaddition. 
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1.3. Gold-catalyzed cyclization/cycloaddition reactions 
The transition metal gold, especially complexes of type L-Au
+
X
-
, not only shows high 
electrophilic affinity for alkynes, arenes, allenes, and even alkenes, but also acts 
simultaneously as a Lewis acid for the activation of electrophiles. Because of their 
high electrophilic affinity and carbophilic Lewis acid character, gold complexes are 
extraordinary tools and are widely used for a growing number of synthetic 
transformations under mild conditions with both high yields and chemoselectivity. 
1.3.1. General introduction of gold-catalyzed 
cyclization/cycloaddition reactions 
In the past decades, gold-catalyzed organic transformations have emerged as efficient 
and consolidated tools for the synthesis of complex and highly functionalized 
molecules due to their novel reaction mode.
80, 81
 The reaction patterns of most of the 
gold-catalyzed processes rely on the following four types: 1) π-activation, 2) Lewis 
acid catalysis, 3) the generation of carbenoid intermediates, and 4) the generation of 
Au
3+
 intermediates (Figure 12). 
 
 
 
Figure 12. Reactivity in gold catalysis. 
 
C-C multiple bond compounds such as alkynes, allenes, and olefins coordinating to 
gold complexes and generating π-activation adducts are one of the most common 
reactivity patterns in gold catalysis. Most of the used C-C multiple bond substrates are 
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alkynes. The reason why the use of gold π-activation reactions is so popular is not 
only its activity and effectiveness, but also the good functional group compatibility. In 
the past ten years, a number of gold-induced π-activation reactions have been reported, 
for example, metathesis, cycloisomerization reactions of enynes and related substrates, 
and hydrofunctionalization of alkenes, alkynes, and allenes with carbon-heteroatom 
nucleophiles.
80-83
 The first example of enantioselective gold catalysis involving π-
activation was reported by Echavarren in 2005, when methylenecyclopentanes were 
prepared by the gold-catalyzed enantioselective alkoxycyclization of 1,6-enynes 
(Scheme 13).
84
 This example is also the first successful application of chiral bis(gold) 
complexes in enantioselective catalysis. The enantioselectivity of this reaction was 
sensitive to the Au/Ag ratio. For example, in the presence of 2 mol% of 91 and 4 mol% 
of AgSbF6, the reaction gave the alkoxycyclization product 93 in only 14% ee. 
However, when the ratio of 91 to AgSF6 is 1:1.25, the reaction gave the product 93 in 
53% ee.  
 
 
Scheme 13. Gold-catalyzed enantioselective alkoxycyclization of 1,6-enynes. 
 
Allenes, like alkynes, are highly valuable synthetic substrates for the preparation of 
organic compounds because of their high activity in organic reactions. In recent years, 
gold-catalyzed nucleophilic cyclizations of functionalized allenes have received much 
more attention as a powerful tool for synthesizing carbo- and heterocycles by 
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intramolecular attack of carbon and heteroatom nucleophiles. Because of the special 
structure of the allenes and the regioselectivity of the nucleophilic attack, theoretically 
four diﬀerent cyclization products can be obtained, but via intermediates a or d the 
ﬁve- or six- membered rings are the main products in most cases (Scheme 14). The 
first gold-catalyzed addition of a heteroatom nucleophile has been disclosed by 
Hashmi in 2000,
85
 followed by a number of gold-catalyzed nucleophilic cyclizations 
of allenes with high yields and regioselectivities.
86 
For example, Widenhoefer reported 
a gold-catalyzed enantioselective intramolecular hydroarylation of 2-(allenyl)indole 
93 to give the substituted indole derivative 94 with 88% yield and 92% ee.
87
 (Scheme 
15) 
 
 
Scheme 14. Gold-catalyzed nucleophilic cyclization reactions of  an allenes. 
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Scheme 15. Gold-catalyzed enantioselective intramolecular hydroarylation of allene 
with indole. 
 
 
 
Scheme 16. The reactions of aldehydes with isocyanoacetate. 
In contrast to gold activation of π-bonds for the addition of nucleophiles, only few 
examples of Lewis acid reaction patterns of gold catalysis were described. The earliest 
example of the Lewis acid reaction pattern of gold catalysis was disclosed by Ito and 
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Hayashi in 1986,
88
 when [Au(CNCy)2]BF4 and chiral ferrocenylphosphine ligand 95 
catalyzed reactions of aldehydes with isocyanoacetate produced the cycloadducts with 
high diastereo- and enantioselectivities (Scheme 16). NMR studies suggested that the 
transition state of this reaction is a four coordinate (bisphosphine) Au(I) intermediate 
99.
89
  
However, these publications did not result in the large-scale use of chiral Au-
complexes as catalysts for the activation of polar functionalities. In 2007, an 
enantioselective 1,3-dipolar cycloaddition of mesoionic azomethine ylides with 
electron-deficient alkenes was reported by Toste (Scheme 17).
90
 The key step for this 
transformation is the generation of a 1,3-dipolar species via activation of a cyclic 
azlactone 101 by a cationic Au(I). Compared with the reactions reported by Hayashi, 
the ratio of phosphorus to gold stoichiometry is 1:1, rather than 2:1. 
 
Scheme 17. Gold catalyzed enantioselective [3+2] dipolar cycloaddition. 
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In recent years, a number of remarkable transformations via gold-activation of 
propargyl esters to form gold vinyl carbenoid species have been described. In the 
presence of gold catalysts, a nucleophilic intramolecular attack of the carboxyl unit to 
the gold-activated alkyne complex can occur. The propargyl esters can undergo a 1,2- 
or 1,3-acyloxy migration to give α, β-unsaturated gold carbenoid species 105 or a gold 
allene complex 106 (Figure 13).
91
 In most instances, when the propargyl ester is a 
terminal alkyne (R = H), the 1,2-shift takes place to give an alkenyl-gold carbenoid 
species 105. In contrast, for internal alkynes the 1,3-acyloxy migration is preferred 
affording allene species 106 (Figure 1, R ≠ H), which can be additionally attacked to 
afford a wide range of gold-catalyzed transformations. Theoretical studies showed 
that the reactivity of the system depends not only on the substrate but also on the 
particular type of gold catalyst.
92
 
 
 
Figure 13. Gold-catalyzed 1,2- or 1,3-acyloxy migrations of propargyl esters. 
Several groups, especially the Toste group, have utilized these systems to develop new 
types of gold-catalyzed reactions, in particular the reaction of intermolecular 
/intramolecular cyclopropanation via 1,2-acyloxy migration. For example, they 
described a gold-catalyzed enantioselective cyclopropanation of alkenes with 
propargyl esters.
93
 (Scheme 18) This publication is the first example exploiting an 
asymmetric gold system for the synthesis of chiral cyclopropanes. The reactions are 
highly stereoselective and show a good tolerance for olefin substitutions (from mono- 
to tetra-substituted alkenes). In addition, they showed that it is possible to trap the 
intermediate gold carbenoids by external nucleophilic oxidants, specifically diphenyl 
sulfoxide.
94
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Scheme 18. Gold(I)-catalyzed stereoselective olefin cyclopropanation. 
 
Although only limited examples of gold catalysis via Au (III) intermediates have been 
reported, these seminal works provide more opportunities for the development of 
novel transformations involving redox-active gold catalysts. Usually, access to Au (III) 
intermediates via oxidative addition of Au (I) complexes requires strong F
+
 or I
3+
 
oxidants.
95, 96
 The seminal work of gold-catalyzed Sonogashira coupling reactions 
was reported by Wang
97
 and Corma,
98
 respectively. Recently, Toste reported a method 
providing access to sp
2
-sp
3
 coupled products by gold-catalyzed net redox-neutral 
cross-coupling reaction.
99
 Overall, the development of this system stimulated a 
considerable interest chemists and provided a powerful strategy for the development 
of novel gold-catalyzed reactions. 
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1.3.2. Gold-catalyzed cyclization/cycloaddition reaction of 1,3-dipoles 
In recent years, gold complexes have emerged as excellent catalysts for the promotion 
of novel types of cyclization/cycloaddition reactions.
82
 In the process of gold 
complexes activating alkenes, alkynes and allenes, gold-stabilized carbocationic 
intermediates are usually involved. Late transition metals such as Rh, Ru, and Pd have 
been successfully applied to trigger the formation or to modulate the reactivity of 
dipoles participating in cycloaddition reactions. Recently, the area of gold catalysis 
involving 1,3-dipoles as reaction partners in cycloaddition reactions received much 
more attention. A number of remarkable gold-catalyzed 1,3-dipolar cycloaddition 
processes have been reported as a powerful method to access polycyclic scaffolds.
100 
 
In the following section, I summarize some of the most recent contributions of gold-
catalyzed 1,3-dipolar cycloaddition processes, organized according to the type of 
unsaturated system that is initially activated by the electrophilic gold complex. 
1.3.2.1. Gold-catalyzed cycloaddition reactions of 2-(1-alkynyl)-2-alken-1-ones  
In 2004, Larock described a new method for the synthesis of highly substituted furans 
by gold(III)-catalyzed heterocyclization of 2-alkynylenones with external 
nucleophiles.
101
 According to the proposed mechanism, the gold complexes first 
activate the C-C triple bond, and subsequent nucleophilic attack of the carbonyl 
function on the triple bond generates a cyclic oxonium intermediate. An 
intermolecular nucleophilic addition of an nucleophile at the activated carbocation 
moiety leads to a furyl-[Au] species and subsequent protonation of the carbon-gold 
bond affords the furan and gold catalyst (Scheme 19). 
INTRODUCTION 
38 
 
 
 
Scheme 19. Gold(III)-catalyzed heterocyclization of 2-alkynylenones. 
In 2006, a gold(I)-catalyzed reaction of 1-(1-alkynyl)-cyclopropyl ketones with 
nucleophiles was reported by Schmalz.
102
 Two conceivable mechanisms were 
proposed for this transformation (Scheme 20). In cycle A, gold complexes first 
coordinate to the triple bond and enhance the electrophilicity of the triple bond. 
Nucleophilic attack of the carbonyl oxygen on the electron-deficient triple bond with 
the regioselective cleavage of the cyclopropane produces a carbocation intermediate 
115. Nucleophilic attack on the carbocation 115 and subsequent protonation of the 
organogold intermediate gives product 114 and regenerates the catalyst. In an 
alternative mechanism gold acts as both a Lewis acid and a transition metal. 
(PPh3)AuOTf first acts as a Lewis acid forming a chelate complex 117 as a primary 
intermediate, then a regioselective homo-Michael-type addition of a nucleophile to 
produce 118. Subsequent coordination of the alkynyl moiety to [Au] induces a 
cyclization of the carbonyl oxygen on the triple bond giving 116, followed by 
protonation of the resulting organogold intermediate 116 to afford 114 and to 
regenerate the catalyst. 
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Scheme 20. Possible mechanisms of the gold-catalyzed transformations. 
 
Following these seminal reports, 2-(1-alkynyl)-2-alken-1-ones has been developed for 
the synthesis of highly substituted furans and pyrroles via transition metal catalyzed 
cascade reactions, since such ketones are very easily activated by transition metals to 
give a furyl-[M] species and are readily available from simple alkenones and terminal 
alkynes (Scheme 21). In recent years, gold complexes have been extensively used to 
activate 2-(1-alkynyl)-2-alken-1-ones forming the carbocationic furyl-gold 
intermediates and subsequently coupled together with another transformation step to 
obtain cyclic compounds, for example, furan fused-ring systems. 
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Scheme 21. Synthesis and activation of 2-(1-alkynyl)-2-alken-1-ones. 
 
Heterocyclization/[3+3] cycloaddition reactions 
Several research groups, especially Zhang’ group, have utilized this system to develop 
the gold-catalyzed heterocyclization/[3+n] cycloaddition cascade reactions of 2-(1-
alkynyl)-2-alken-1-ones. In 2009, a mild Au(I)-catalyzed cascade 
heterocyclization/[3+3] cycloaddition reaction of 2-(1-alkynyl)-2-alken-1-ones 111 
with nitrones 65 giving highly substituted fused heterobicyclic furo[3,4-d][1,2]-
oxazines 119 was reported (Scheme 22).
103
 The reaction tolerates different groups on 
both reacting partners affording the corresponding cycloadducts 119 in good yields 
and high diastereoselectivities. A plausible mechanism is also shown in Scheme 22. 
Subsequently, several chiral ligands such as (R)-C1-tunephos 120,
104
 (R)-MeO-dtbm-
biphep 121,
104
 and chiral sulfinamide monophosphine ligands 122
105
 were 
investigated in the above Au(I)-catalyzed diastereoselective cascade reaction. A 
variety of substituted optically active heterobicyclic furo[3,4-d][1,2]-oxazines 119 
could be achieved with excellent yields and high enantioselectivities (up to 99% ee) 
(Scheme 23).  
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Scheme 22. Gold-catalyzed [3+3] cycloaddition reaction between 2-(1-alkynyl)-2-
alken-1-ones 111 and nitrones 65. 
 
 
 
Scheme 23. Chiral ligands for the asymmetric synthesis of furo[3,4-d][1,2]oxazines 119. 
 
Heterocyclization/[3+4] cycloaddition reactions 
Using α,β-unsaturated imines or 1,3-diphenylisobenzofuran instead of nitrones to trap 
the furyl-[Au] 1,3-dipole intermediate was also successful to yield the cycloadduct, by 
the [3+4] cycloaddition.
103, 106
 The proposed mechanism of gold-catalyzed [3+4] 
cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with α,β-unsaturated imines is depicted 
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in Scheme 24.
103
 The furyl-[Au] 1,3-dipole intermediate reacts with imine 124 to 
generate iminium species 126, further to give 127 via a intramolecular cyclization. 
Subsequently, the cleavage of the C-C bond of the C2 ring produces intermediate 128, 
which further cyclizes yielding the corresponding furo[3,4-c]azepines 125.  
 
 
 
Scheme 24. Gold(I)-catalyzed [4+3] cycloaddition of 2-(1-alkynyl)-2-alken-1-ones 
123 and α,β-unsaturated imines 124. 
 
Heterocyclization/[3+2] cycloaddition reactions with olefins 
Using (E)-1-methyl-3-styryl-1H-indole 129 as the dipolarophile, 2-(1-alkynyl)-2-
alken-1-ones 123 was further applied in a highly regio- and diastereoselective gold(I)-
catalyzed tandem heterocyclization/[3+2] cycloaddition for the synthesis of highly 
substituted cyclopenta[c]furans 130 (Scheme 25).
107
 Highly substituted cyclopenta[c]-
furan cycloadduts 130 were achieved in 68-96% yield and >20:1 diastereomeric ratio. 
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Furthermore, (E) and (Z) olefins afforded the same compounds under the reaction 
conditions, meaning that the reaction proceeds through a stepwise formal [3+2] 
cycloaddition pathway as shown in Scheme 25. Similar to 2-(1-alkynyl)-2-alken-1-
ones, 2-(1-alkynyl)-2-alken-1-one oximes were also used for the synthesis of highly 
substituted pyrroles via the gold-catalyzed heterocyclization/[3+n] cycloaddition 
tandem reaction.
108
  
 
 
Scheme 25. Diastereoselective synthesis of cyclopenta[c]furans 130. 
 
1.3.2.2. Gold-catalyzed cycloaddition of cyclopropyl-containing alkynyl ketones 
with nitrones 
With similar substrates as those described in Scheme 20, cyclopropyl-containing 
alkynyl ketones could undergo gold activation to generate 1,4-dipole gold-furan 
intermediates, which could be trapped by a series of nucleophilic components to give 
cycloadducts (Scheme 26). A [4+n] annulation process using nucleophilic 
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components such as indoles, ketone/aldehydes and nitrones enables the formation of 
6- and 7-membered rings in good yields and excellent regioselectivities (Scheme 26). 
 
 
Scheme 26. Gold(I)-catalyzed [4+n] cycloaddition of cyclopropyl-containing alkynyl 
ketones. 
 
Wang and co-workers reported a formal gold-catalyzed [4+3] cycloaddition of 1-(1-
alkynyl)cyclopropyl ketones 131 and nitrones 65 for the synthesis of 5,7-fused 
bicyclic [3,4-d][1,2]oxazepines in good to excellent yields with excellent 
diastereoselectivity.
109
 The proposed mechanism for this transformation is depicted in 
Scheme 27. Under the described conditions, a nucleophilic attack of the carbonyl 
oxygen on the gold-activated alkyne was carried out to give 1,4-dipole  gold-furan 
intermediate 133, followed by ring-opening of the cyclopropane ring by nucleophilic 
attack of the nitrone 65 to produce a carbocation intermediate 134, further to give 132 
via an intramolecular cyclization. The high diastereoselectivity may be a result of the 
favored chair-like conformation of intermediate 134. The gold-catalzyed [4+3] 
cycloaddition reaction of 1-(1-alkynyl) cyclopropyl oximes with nitrones for the 
synthesis of highly substituted pyrrolo[3,4-d][1,2]oxazepines was also reported in 
2012.
110
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Scheme 27. Gold-catalyzed [4+3] cycloaddition of 1-(1-alkynyl)cyclopropyl ketones 
131 and nitrones 65. 
 
1.3.2.3. Gold-catalyzed cycloaddition of 1,6-enynes with nitrones 
The ready accessibility of 1,n-enynes makes them very attractive building blocks. In 
the presence of gold catalysts, 1,n-enynes (e.g., 1,6-enynes) undergo a variety of 
skeletal rearrangements to generate cyclopropyl gold(I) carbene-like intermediates, 
which could be trapped by a series of nucleophilic components, rather than the 
commonly observed alder-ene type rearrangements under the catalysis of palladium 
and rhodium complexes. So far, several 1,n-enynes have been applied in gold-
catalyzed cycloadditions for the synthesis of complicated hetero- and carbocycles. For 
example, in 2012, Liu and coworkers reported a gold-catalyzed [2+2+3] cycloaddition 
of 1,6-enynes with nitrones to give the highly substituted 1,2-oxazepane derivatives 
with good to excellent diastereo- and enantioselectivity.
111
 The proposed mechanism 
rationalizing the stereochemistry of the resulting cycloadducts 136 is depicted in 
Scheme 28. The substrates 135 and 65 are less flexible in conformation and facilitate 
the initial cyclization. In the presence of a gold complex, a highly efficient endo-dig 
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cyclization takes place to give an initial cyclopropyl gold carbenoid
112
 which 
subsequently transforms to alkenylgold carbocation,
113, 114
 which is attacked by 
nitrone 65 in a concerted pathway, thus giving the cycloadduct 136 with excellent 
diastereoselectivity. Other substrates such as 1,5-enynes,
115
 nitroalkynes,
116
 and N-(o-
ethynylphenyl)imine derivatives,
117
 that have a similar structure as 1,6-enynes were 
also studied in gold-catalyzed cycloadditions give to the corresponding cycloadducts. 
 
 
 
Scheme 28. Gold-catalyzed [2+2+3] cycloadditions of 1,6-enynes with nitrones. 
 
1.3.2.4. Gold-catalyzed cycloadditions of propargyl esters with nitrones 
As described in figure 13, propargyl esters can undergo a 1,2-acyloxy migration in the 
presence of gold catalysts to give α, β-unsaturated gold carbenoid species 106, which 
can be additionally attacked to perform a wide range of gold-catalyzed 
transformations. In 2009, the first example of a formal cycloaddition between alkenyl 
gold carbenoids that resulted from gold catalyst activation of propargyl esters and 1,3-
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dipoles was reported by Toste.
118
 The proposed mechanism for this transformation is 
depicted in Scheme 29. As a ligand PicAuCl (i.e. 2-picolinate) was used in this case. 
 
 
 
Scheme 29. Gold-catalyzed [3+3]-cycloaddition of propargyl esters and azomethine imines. 
 
1.3.2.5. Gold-catalyzed cycloadditions of allenes with nitrones 
In the presence of gold catalysts, allenes can be activated in a very chemoselective 
way, triggering of different types of cycloaddition processes. One example of gold-
catalyzed cycloadditions involving allenes has been discribed in the previous section 
(Scheme 15). In 2013, the group of Chen described an enantioselective intermolecular 
[3+2] dipolar cycloaddition of N-allenyl amides with nitrones by gold catalysis.
119 
 
The proposed mechanism is based on an activation of the allene to give a cationic 
metal species which is attacked by nitrone 65 in a concerted pathway, thus giving the 
cycloadduct 141 with excellent enantioselectivity (Scheme 30). A similar 
transformation was also reported by Liu in gold-catalyzed cyclization-cycloaddition 
cascade reactions of allenyl acetals with nitrones.
120
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Scheme 30. Gold-catalyzed enantioselective intermolecular [3+2] dipolar 
cycloaddition of N-allenyl amides with nitrones. 
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2. Objectives 
The first catalytic asymmetric 1,3-dipolar cycloaddition of nitrones was reported by 
Scheeren
43
 in 1994. Since then, many successful asymmetric 1,3-dipolar 
cycloadditions were reported for the synthesis of 5-membered heterocycles and 
derivatives. Though many metal complex catalysts and organocatalysts have been 
successfully used in asymmetric 1,3-dipolar cycloaddition, there are still many 
unsolved challenges in this field. One of the biggest challenges is to find a suitable 
catalyst for a particular reaction. This process often requires ligand screening and 
individual optimization. Recently, our research group developed a new class of 
modular phosphine-phosphite ligands 30, which are accessible starting from 
substituted phenols (Figure 14, for the synthesis of this type of ligands see Scheme 3). 
These modular phosphine-phosphite ligands have recently been successfully applied 
in a number of asymmetric catalyses (Scheme 4). One aim of this work was to further 
investigate their potential in other, more challenging transition-metal-catalyzed 
transformations. 
 
Figure 14. Modular phosphine-phosphite ligands of type 30. 
In form of its complexes, the transition metal gold not only shows high electrophilic 
affinity for alkynes, arenes, allenes, and even alkenes, but also acts simultaneously as 
a Lewis acid for the activation of electrophiles. Recently, several gold-catalyzed 1,3-
dipolar cycloaddition processes have been reported as a powerful method to access 
polycyclic scaffolds.
100
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2-(1-alkynyl)-2-alken-1-ones as reaction partners for the synthesis of highly 
substituted furans and pyrroles via gold-catalyzed cascade reactions received much 
more attention, since such ketones are very easily activated by a gold catalyst to give 
furyl-[Au] intermediates and are readily available from simple alkenones and terminal 
alkynes. The carbocationic furyl-gold intermediates represent interesting 1,3-dipoles 
which can be trapped by other dipolar reagents to yield polycyclic compounds 
containing a furan ring. (Scheme 31) 
 
Scheme 31. Gold-catalyzed cycloaddition of 2-(1-alkynyl)-2-alken-1-ones. 
The aim of this work, on the one hand, was to develop gold-catalyzed cycloadditions 
of 2-(1-alkynyl)-2-alken-1-ones with azomethine imines for the synthesis of highly 
substituted furo[3,4-d]pyridazines (Scheme 32); on the other hand, to investigate the 
application of Schmalzphos ligands in order to explore this type of gold-catalyzed 
transformations enantioselective. 
 
Scheme 32. Gold-catalyzed cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with 
azomethine imines. 
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3. Results and discussion 
3.1. Synthesis of chiral phosphine-phosphite ligands 
3.1.1. Synthesis of tartaric acid derivatives 
The synthesis of TADDOL was performed according to the method developed by 
Seebach.
121, 122
 In the first step, the precursor of TADDOL (145) is readily obtained by 
acid-catalyzed transacetalization. The commercially available (+)-dimethyl L-tartrate 
143 is treated with acetone in the presence of boron trifluoride etherate as an acid 
catalyst. Product 144 is then reacted with aryl an Grignard reagent to give the desired 
TADDOL (145). 
 
 
Scheme 33. Synthesis of TADDOL. 
 
3.1.2. Synthesis of borane-protected phosphine phenols 
Scheme 34. Improved and general synthesis of ortho-phosphanylphenol 34. Reagents 
and conditions: a). i-Pr2NH, NBS, CH2Cl2, reflux; b). DABCO, Ph2PCl, BH3·THF, 
CH2Cl2, 0 °C; c) n-BuLi, THF, 0 °C. 
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The borane-protected phosphine phenols of type 34 were synthesized according to the 
method developed by Schmalz (Scheme 34).
26
 The first step is a selective ortho-
bromination of the phenol with NBS in the presence of catalytic amounts i-Pr2NH 
using CH2Cl2 as the solvent. The resulting bromophenols are converted with a 
chlorophosphine and then protected in situ with borane. Then, borane-protected 
phosphinite 33 is treated with n-BuLi to smoothly induce the migration of the 
phosphanyl group to an airstable ortho-phosphanylphenol 34. Although the ortho- and 
para-dibrominated side products of type 32  ´ can be formed in the bromination step, 
these side products did not have an impact on the further reaction steps, since during 
the last stage (n-BuLi induced bromine-lithium exchange fries rearrangement) both 32 
and 32  ´ are converted to the same product of type 34 (Scheme 35).
27
 This can be 
regarded as a ‘self-purification’ process resulting from bromine-lithium exchange at 
para-position followed by protonation during work-up. Following the above 
mentioned approach, a series of borane-protected phosphine phenols were synthesized 
in good yields (Figure 15). 
 
 
Scheme 35. Conversion of dibrominated side products of type 32  ´into the desired 
ortho-phosphanylphenol 34 in a ‘self-purification’ process. Reagents and conditions: 
a). DABCO, Ph2PCl, BH3-THF, CH2Cl2, 0 °C; b) n-BuLi, THF, 0 °C. 
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Figure 15. Borane-protected phosphine phenols. 
 
3.1.3. Synthesis of chiral phosphine-phosphite ligands 
With the chiral diol building blocks and ortho-phosphanylphenols in hand, the chiral 
phosphine-phosphite ligands were synthesized in good yields according to the 
modular synthesis method described in scheme 3. In the last step of the synthesis 
(Scheme 36), the BH3-protected ortho-phosphanylphenol 34 was first reacted with 1.2 
equiv. of PCl3 in dichloromethane at room temperature in the presence of an excess of 
sublimed DABCO, which serves both as a base and as a nucleophile to take over the 
BH3 group. The resulting dichlorophosphite intermediate was then reacted with a 
chiral diol (TADDOL or BINOL) to afford the corresponding phosphine-phosphite 
ligand. Following this method, various TADDOL- and BINOL-derived ligands of 
type 30 were reliably obtained in good yields. Details for the synthesis of ligands are 
given in the experimental section. 
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Scheme 36. Synthesis of chiral phosphine-phosphite ligands. Reagents and conditions: 
a). DABCO, PCl3, CH2Cl2, 0 °C; b) chiral diol, 0 °C. 
 
 
 
Figure 16. The chiral phosphine-phosphite ligands synthesized in this thesis work. 
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3.2. AuPPh3Cl-catalyzed intermolecular 
cyclization/[3+3]cycloadditions of 2-(1-alkynyl)-2-alken-1-
ones with azomethine imines  
3.2.1. Synthesis of substrates  
3.2.1.1 Synthesis of 2-(1-alkynyl)-2-alken-1-ones 
 
Scheme 37. Synthesis of 2-(1-alkynyl)-2-alken-1-ones. Reagents and conditions: a). 
Br2, Et3,N, CH2Cl2, 0 °C; b). (PPh3)4Pd, CuI, Et3,N, THF, r.t.; c). MeLi, THF, -78 °C; 
d). MnO2, THF, r.t. 
The preparation of 2-(1-alkynyl)-2-alken-1-ones has been well described in the 
literature.
101, 123, 124
 The approach for the synthesis of 2-(1-alkynyl)-2-alken-1-ones is 
shown in scheme 37. First, the Z-α-bromocinnamaldehyde derivatives of type 148 
were prepared via the bromination of cinnamaldehyde derivatives of type 147 and 
bromide in a 1:1.2 ratio in CH2Cl2.
123
 The resulting Z-α-bromocinnamaldehyde 
derivatives of type 148 were then converted into the α-alkynyl enals of type 149 by 
reaction with an alkyne in the Sonogashira coupling conditions.
124
 The resulting α-
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alkynyl enal 149, usually obtained as yellow oil, was subjected to the nucleophilic 
addition by treatment of a solution in THF at -78 °C with an excess (1.5 eq.) of MeLi 
to smoothly afford the corresponding nucleophilic addition product 150. Without 
purification, the addition products of type 150 were then converted into desired 2-(1-
alkynyl)-2-alken-1-ones by oxidation reaction with an excess (20 eq.) of MnO2 in 
THF. Following this method, different 2-(1-alkynyl)-2-alken-1-ones of type 146 were 
reliably obtained in good yields (Figure 17). 
 
 
 
Figure 17. 2-(1-alkynyl)-2-alken-1-ones of type 146. 
 
3.2.1.2. Synthesis of azomethine imines 
All pyrazolidin-3-one ylides were prepared following the reported procedures from 
the corresponding aldehydes.
125, 126
 First, methacrylate (or methyl methacrylate) was 
added to the solution of hydrazine hydrate in ethanol under 0 °C, then the mixture was 
heated to reflux for 10 h. Then the crude pyrazolidin-3-one (or 4-methyl pyrazolidin-
3-one) was achieved by removing the solvent and the volatile components under 
reduced pressure. The resulting product, without any purification, was then reacted 
with various aldehydes in methanol to give the desired pyrazolidin-3-one ylides 
(Scheme 38). Following this procedure, various pyrazolidin-3-one ylides of type 138 
were reliably obtained in good yields (Figure18). 
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Scheme 38. Synthesis of pyrazolidin-3-one ylides. Reagents and conditions: a):. 
EtOH, 0 °C to reflux; b) ArCHO, MeOH, r.t. 
 
 
Figure 18. Various pyrazolidin-3-one ylides. 
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3.2.2. Optimization of the reaction conditions 
The reaction of ketone 146a and benzylidene-5-oxopyrazolidin-2-ium-1-ide (138a) 
was chosen as the model system (Scheme 39). Thus, we started our investigation by 
examining the cycloaddition of ketone 146a and 138a in the presence of various metal 
catalysts (Table 1). By optimizing various gold complexes and silver salts, 
Ph3PAuCl/AgOTf was found to be the best combination for this transformation. The 
desired product rac-151a was obtained in 69% yield with 99:5 selectivity for the trans 
diastereomer (Table 1, entry 2). No product was detected without the addition of 
silver complex (Table 1, entry 1). Furthermore, the ratio of gold(I)-complex/silver 
also affect the selectivity. Increasing the ratio of gold(I)-complex/silver from 1:1 to 
1:2 caused the diastereomeric ratio of the product to decrease from 95:5 to 79:21 
(Table 1, entries 2, 5-6). 
 
 
 
Scheme 39. Gold-catalyzed cycloaddition of ketone 146a with azomethine imine 138a. 
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Table 1. Optimization of catalyst in the reaction shown in Scheme 39. 
 
Entry AuLCl (2.5 mol%)  AgX (X mol%)  rac-151a [%]
a
 d.r.
b
 
 
1  AuPPh3Cl  --  --  ---  
2  AuPPh3Cl  AgOTf (2.5)
 
 69  95:5  
3  AuPPh3Cl  AgSbF6(2.5)
 
 62  81:19  
4  AuPPh3Cl  AgBF4(2.5)  35  88:12  
5  AuPPh3Cl  AgOTf (3.75)
 
 68  83:17  
6  AuPPh3Cl AgOTf (5)
 
 64  79:21  
7  SMe2AuCl/dppe (2:1)
 
 AgOTf (2.5)
 
 58  69:31  
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 2.0 mL CH2Cl2, 24 h at r.t.  
a 
Isolated yield based on 146a; 
b
 Determined by GC-MS  
 
Table 2. Optimization of solvent. 
 
Entry  Solvent  rac-151a [%]
a
 d.r.
 a
 
1  CH2Cl2 69  95:5  
2  CH2ClCH2Cl 72  93:7  
3  Chloroform  65  75:25  
4 CH3CN 73 >99:1 
5 MeOH  55  83:17  
6  Toluene 0  --  
7  Diethylether  0 --  
8 THF  0 --  
9  EtOAc  trace  --  
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 2.5 mol% AuPPh3Cl/AgOTf (1:1), 2.0 mL 
solvent, 24 h at r.t.  
a 
Isolated yield based on 146a; 
b
 Determined by GC-MS  
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The screening of the solvent was carried out under the following conditions 
established in our initial studies: 0.2 mmol scale, 2.5 mol% AuPPh3Cl/AgOTf (1:1) as 
the catalyst at room temperature. As shown in Table 2, the cycloaddition reaction 
afforded higher yield with better diastereomeric ratio of the product when CH2Cl2, 
CH2ClCH2Cl or CH3CN was used as the solvent (Table 2, entries 1, 2, and 4). The 
reaction in chloroform and MeOH led to less efficiency in terms of chemical yields 
(Table 2, entries 3 and 5). When toluene, diethylether, THF, or EtOAc was used as the 
solvent, no product was observed (Table 2, entries 6-8). 
 
Table 3. Optimization of temperature. 
 
Entry Solvent  Temperature (° C) rac-151a [%]a
 
 d.r.
b
 
1  DCM  40  76  85:15  
2  DCE  40  75  83:17  
3  DCM  RT  69  95:5  
4  DCE  RT 72  93:7  
5 CH3CN RT 73 >99:1 
6  DCM  0 71  >99:1  
7  DCE  0  69  >99:1  
8 CH3CN 0 68 >99:1 
9  DCM  -10  56  >99:1  
10  DCE  -10  39  >99:1  
11 CH3CN -10 41 >99:1 
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 2.5 mol% AuPPh3Cl/AgOTf (1:1), 2.0 
mL solvent, 24 h.  
a 
Isolated yield based on 146a. 
b
 Determined by GC-MS. 
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As shown in table 2, CH2Cl2, CH2ClCH2Cl and CH3CN provided the similar good 
results during the solvent screening. Thus, to check the temperature effect, CH2Cl2, 
CH2ClCH2Cl and CH3CN were examined in the model system. Performing the 
reaction in CH2Cl2 or CH2ClCH2Cl at lower temperatures (40 °C to -10 °C) led to an 
increased diastereoselectivity but a decreased yield. When CH3CN was used as the 
solvent, 73% yield was obtained with >99:1 selectivity for the trans diastereomer at 
room temperature (Table 3, entry 5). The catalyst loading was also checked in the 
model system. As shown in table 4, when the catalyst loading was increased from 1.5 
mol% to 5 mol%, the yield was obviously increased without decreased selectivity 
(Table 4, entries 1-4). Performing the reaction at 8 mol% AuPPh3Cl/AgOTf (1:1) did 
not further increase the yield but decrease the yield and selectivity (Table 4, entry 5).  
Table 4. Optimization of amount of catalyst. 
 
 
 
Entry  mol% Catalyst  151a [%]a d.r.
b
 
 
1  1.5
 
 63  97:3  
2  2.5
 
 73  >99:1  
3  3.5
 
 84  >99:1  
4  5
 
 91  >99:1  
5  8 88 99:1  
Conditions: 146a (0.2mmol), 138a (0.22mmol), 2.0mL CH3CN, 24 h at r.t. 
a 
Isolated yield based on 146a. 
b
 Determined by GC-MS 
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3.2.3. Substrate scope 
With the above optimized conditions in hand (5 mol% AuPPh3Cl/AgOTf (1:1), 
CH3CN as solvent, room temperature), the cyclization/[3+3]cycloaddition of a variety 
of N,N′-cyclic azomethine imines with (E)-3-benzylidene-5-phenylpent-4-yn-2-one 
146a were explored (Scheme 40). The reaction is highly tolerant of various 
substituents at azomethine imines. In most cases, both electron-donating and electron-
withdrawing substituents on the benzene ring of substituted azomethine imines 
afforded the corresponding highly substituted furo[3,4-d]pyridazines rac-151 in good 
to excellent yields (81-96%) with up to >99:1 diastereoselectivity under standard 
conditions (Scheme 40, rac-151a-i). However, product rac-151j did not form after 24 
h at standard conditions. (Scheme 40, rac-151j). The position of the substituent at the 
benzene ring seems to have little influence on the product yield and 
diastereoselectivity. The reactions of 138q and 138r with ketone 146a proceeded to 
afford the corresponding cycloadducts (rac-151r and rac-151s, respectively) in 
excellent yields and diastereoselectivities. 
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Scheme 40. Gold-catalyzed cycloaddition of ketone 146a with azomethine imines 138. 
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Furthermore, the scope of 2-(1-alkynyl)-2-alken-1-ones was investigated, and the 
results are shown in Scheme 41. The R
1
 substitutents of 146 have larger effects on the 
yield and diastereoselectivity of the reaction than the R group of 146. Compared to 
146a, 2-(1-alkynyl)-2-alken-1-ones substituted with a n-Butyl group or n-Propyl 
group underwent smooth reactions with 138a, giving the desired products rac-151u 
and rac-151v in relatively lower yields (70% and 74%, respectively). 
 
 
 
Scheme 41. Gold-catalyzed cycloaddition of ketone 146 with azomethine imine 138a. 
 
In addition, the reactions of 2-(1-alkynyl)-2-alken-1-ones with N,N′-cyclic azomethine 
imines were very clean and the [3+2] cycloadducts were not formed, indicating that 
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this transformations are regiospecific and chemospecific. Simultaneously, the relative 
conﬁguration of rac-151a and rac-151f were determined by single-crystal X-ray 
analysis, as depicted in Figure 19. 
 
 
 
Figure 19 X-ray crystal structures of rac-151a (left) and rac-151f (right). 
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3.3. Enantioselective gold(I)-catalyzed intermolecular 
cyclization/[3+3]cycloadditions of 2-(1-alkynyl)-2-alken-1-
ones with azomethine imines 
Having successfully employed an achiral phosphine gold(I) chloride catalyst for the 
intermolecular cyclization/[3+3]cycloadditions of 2-(1-alkynyl)-2-alken-1-ones with 
azomethine imines, we next focused on the enantioselective reaction of 2-(1-alkynyl)-
2-alken-1-ones with azomethine imines. 
3.3.1. Screening of chiral ligands 
3.3.1.1. Screening of commercially available chiral ligands 
The experiments began with screening a selection of commercially available chiral 
ligands as potential catalysts in the cycloaddition of 2-(1-alkynyl)-2-alken-1-one 146a 
and benzylidene-5-oxopyrazolidin-2-ium-1-ide 138a (Scheme 42). The results are 
listed in Table 5. 
 
 
 
Scheme 42. Gold-catalyzed cycloaddition of ketone 146a with azomethine imine 138a. 
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Table 5. Screening of commercially available chiral ligands in the reaction shown 
Scheme 42. 
 
 
Entry Ligand 151a [%]a ee. [%]
b
 
 
1 2 trace -- 
2 9 18 31 
3 10 31 28 
4 11 19 35 
5 152 5 -- 
6 153 18 5 
7 107 30 30 
8 154 40 21 
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 5 mol% Me2SAuCl, 5 mol% AgOTf, 2.5 
mol % ligand, dichloromethane 2.0 mL, 24 h at r.t. 
a 
Isolated yield based on 146a 
b
 Determined by chiral HPLC. 
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We began our research by examining the cycloaddition of ketone 146a and 
azomethine imine 138a in the presence of the (S,S)-DIOP derived gold(I) complex at 
standard conditions. Unfortunately, the desired product 151a was not obtained from 
this reaction (Table 5, entry 1). When using Trost ligand in this reaction, the desired 
product 151a can be achieved with 18% yield and 31% ee (Table 5, entry 2). Chiral 
ferrocene ligands have been widely used in many types asymmetric catalysis.
127 
Based 
on this, chiral ferrocene ligands were also examined in this reaction but did not lead to 
improved enantioselectivity (Table 5, entries 3-5). Subsequently, under the same 
reaction conditions, other ligands, such as (R)-BINAP (153), (R)-SEGPHOS (107) 
and (R)-DTBM-SEGPHOS (154) were also examined in the hope of finding a better 
ligand for this reaction. All the ligands gave poor yield (18-40%) and low ee (5-30%). 
3.3.1.2 Screening of Phosphoramidite ligands 
Monodentate chiral phosphoramidites were introduced in 1994.
128
 Subsequently, 
chiral phosphoramidites have attracted the interest of more and more chemists 
because its remarkable application in asymmetric catalysis. Now, phosphoramidites 
have been widely used in asymmetric catalysis as a highly versatile and readily 
accessible class of chiral ligands.
3
 
Several chiral phosphoramidite ligands were examined in the cycloaddition of ketone 
146a and azomethine imine 138a under standard conditions. The results are 
summarized in Table 6. Among the phosphoramidites with different substituents at 
the nitrogen atom, compared ligands 155-160, the most sterically hindered 
phosphoramidite 160 gave 34% ee (Table 6, entry 6), while the least sterically 
hindered ligand 155 no product achieved (Table 6, entry 1). Ligand 161 also led to 
disappointing results. These results suggest that phosphoramidites is not a suitable 
ligand for the cycloaddition of 2-(1-alkynyl)-2-alken-1-ones and azomethine imines.  
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Table 6. Screening of phosphoramidite ligands in the reaction shown Scheme 42. 
 
 
Entry Ligand 151a [%]
a
 ee. [%]
b
 
 
1 155 trace -- 
2 156 trace -- 
3 157 26  11  
4 158 31  8  
5 159 33  28  
6 160 41  34 
7 161 8 9  
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 5 mol% Me2SAuCl, 5 mol% AgOTf, 5 
mol % ligand, dichloromethane 2.0 mL, 24 h at r.t. 
a 
Isolated yield based on 146a 
b
 Determined by chiral HPLC. 
RESULTS AND DISCUSSION 
70 
 
3.3.1.3. Screening of chiral phosphine-phosphite ligands 
During the examination of a series of chiral ligands, such as (S,S)-DIOP, (R)-BINAP, 
(R)-SEGPHOS, ferrocene-based ligands (Josiphos), (R)-DTBM-SEGPHOS, and 
phosphoramidites that are derived from 3,3’-disubstituted BINOL derivatives, 
unfortunately no satisfactory enantioselectivity was observed. The best results of the 
reaction of 2-(1-alkynyl)-2-alken-1-one 146a and azomethine imine 138a gave the 
corresponding product 151a in only 41% and 34% ee (Table 6, entry 6). 
In this situation, our investigation was triggered by the consideration that phosphine-
phosphites of type 30 might be suitable ligands for the gold-catalyzed cycloaddition 
of 2-(1-alkynyl)-2-alken-1-ones and azomethine imines. These ligands, which are 
accessible starting from substituted phenols (31) in only four steps (Scheme 43, the 
details was described in Scheme 3),
26, 27
 have recently been successfully applied in 
several other metal-catalyzed reactions,
28-33
 and their modular nature allows a facile 
structural fine-tuning for individual applications. 
 
Scheme 43. Modular synthesis of phosphine-phosphite ligands. 
 
First of all, in a series of experiments we tested eleven of our ligands (30a-30i, 30r 
and 30s) in the gold-catalyzed cycloaddition of ketone 146a and azomethine imine 
138a under standard conditions. The results are summarized in table 7. We were 
happy to find that our ligands indeed performed very well and we obtained 
cycloadduct 151a with an encouraging yield and selectivity (up to 71%, 54% ee) 
(Table 7). The substitution pattern of the ligand backbone had effect on the ligand 
performance. The most sterically hindered ligand 30i gave 54% ee (Table 7, entry 9) 
while the least sterically hindered ligand 30a only gave 19% ee (Table 7, entry 1). In 
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this initial screening, ligands 30g and 30i were found to be more active and selective 
than others.  
 
Table 7. Screening of some chiral phosphine-phosphite ligands. 
 
Entry Ligand (L*) 151a [%]
a
 ee [%]
b 
1 30a 30 19 
2 30b 32 18 
3 30c 35 23 
4 30d 48 32 
5 30e 43 21 
6 30f 49 42 
7 30g 65 49 
8 30h 39 19 
9 30i 71 54 
10 30s 52 47 
11 30t 49 51 
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 5 mol% Me2SAuCl, 5 mol% AgOTf, 2.5 
mol % ligand, dichloromethane 2.0 mL, 24 h at r.t. 
a 
Isolated yield based on 146a 
b
 Determined by chiral HPLC. 
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Employing ligands 30g and 30i, the effect of the solvent on the reaction result was 
investigated (Table 8). The cycloaddition reaction afforded higher yield with better 
enantioselectivity of the product when CH3CN was used as the solvent (Table 8, 
entries 3 and 6). Compared to ligand 30g, ligand 30i was found to be more active and 
selective for this transformation (Table 8, entry 6). 
Table 8. Screening of some solvents according to Scheme 42. 
 
Entery Ligand (L*) Solvent  151a [%]
a
 ee [%]
b 
1 30g CH2Cl2 65 49 
2 30g CH2ClCH2Cl 53 46 
3 30g CH3CN 68 61 
4 30i CH2Cl2 71 54 
5 30i CH2ClCH2Cl 61 50 
6 30i CH3CN 79 67 
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 5 mol% Me2SAuCl, 5 mol% AgOTf, 2.5 
mol % ligand, solvent 2.0 mL, 24 h at r.t. 
a 
Isolated yield based on 146a. 
b
 Determined by chiral HPLC. 
 
While we had obtained encouraging results (up to 79% yield with 67% ee) under mild 
conditions (r.t., CH3CN), the enantioselectivities were still not satisfying. Thus, five 
additional phosphine-phosphite ligands were examined under standard conditions 
(Table 9). These ligands were prepared according to the modular synthetic Scheme 3 
by changing the aryl substituents at the Taddol unit. All of the reactions for which 
30m-30q were used as ligands revealed that the structural modification of the Taddol 
unit led to significant variations in the outcome of the reactions. The substitution 
pattern of the ligand backbone had effect on the ligand performance. For example, 
using 30m instead of 30q results in an increase in the ee of 151a from 72% to 83% 
(Table 9, entries 1 and 5), whereas an obvious drop in enantiomeric excess was 
observed for 151a when 30n was used instead of 30q (Table 9, entries 1 and 2). When 
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the ligand 30m was used, 151a could be obtained in very good enantioselectivity (82% 
ee) with 85% yield (Table 9, entriy 1); this results are a significant improvement 
compared to our previous outcome.  
Table 9. Further screening of chiral phosphine-phosphite ligands. 
 
Entry  Ligand (L*) 151a[%]
a
 ee[%]
b 
1 30m 85 83 
2 30n 76 59 
3 30o 71 69 
4 30p 69 58 
5 30q 70 72 
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 5 mol% Me2SAuCl, 5 mol% AgOTf, 2.5 
mol % ligand, CH3CN 2.0 mL, 24 h at r.t. 
a 
Isolated yield based on 146a. 
b
 Determined by chiral HPLC. 
Furthermore, a series of chiral ligands, such as (S)-BINOL-derived phosphine-
phosphite ligands (30j-30l), TARTROL-derived phosphine-phosphite ligand (163), 
and biphosphine ligand (162) were also examined in this enantioselective gold-
catalyzed cycloadditions, but unfortunately, no better enantioselectivity was observed 
than with ligand 30m (Table 10). We therefore used ligand 30m for the further 
optimization of the reaction conditions. 
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Table 10. Performance of new chiral ligands in the asymmetric cycloaddition of 
ketone 146a. 
 
 
 
Entry  Ligand  (L*) 151a [%]
a
 ee [%]
b 
1 30j 31 8 
2 30k 40 19 
3 30l 51 40 
4 162 27 28 
5 163 38 36 
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), 5 mol% Me2SAuCl, 5 mol% AgOTf, 2.5 
mol % ligand, CH3CN 2.0 mL, 24 h at r.t. 
a 
Determined by GC-FID. 
b
 Determined by chiral HPLC. 
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3.3.2 Optimization of temperature and amount of catalyst 
Having established the most suitable ligands for the enantioselective synthesis of 
151a, the influence of temperature and amount of catalyst of this transformation was 
investigated. The results are summarized in Table 11. 
Table 11. Optimization of temperature and amount of catalyst. 
 
 
Entry  Temperature (°C)  L*[AuCl]2 
(mol%) 
AgOTf 
(mol%) 
151a [%]
a
 ee [%]
b 
1 40 2.5 2.5 87 73 
2 r.t. 2.5 2.5 85 83 
3 -10 2.5 2.5 72 84 
4
c
 -20 2.5 2.5 59 82 
5 r.t. 1.25 1.25 43 80 
6 r.t. 5 5 89 85 
7 r.t. 7.5 7.5 86 83 
8 r.t. 5 7.5 81 79 
9 r.t. 5 10 82 69 
10
 d
 r.t. 5 5 87 80 
Conditions: 146a (0.2 mmol), 138a (0.22 mmol), x mol % of catalyst (ligand/Me2SAuCl = 
1:2), CH3CN 2.0 mL, 24 h at speciﬁed temperature.  
a 
Determined by GC-FID. 
b
 Determined by chiral HPLC.  
c
 Reaction lasts 32 hours. 
d
 Ligand/Me2SAuCl = 1.1:2  
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As Table 11 indicates, when the reaction temperature was changed from r.t. to 40 °C, 
a significant decrease of the enantioselectivity was observed. While decreasing the 
reaction temperature did not have a major effect on the ee value, the yields obviously 
decreased (Table 11, entries 1-4). Therefore, in the following reactions the 
temperature was maintained at r.t. Subsequently, the effect of the catalyst loading on 
the reaction result was investigated. The results show that the amount of catalyst 
obviously influenced the yield while the enantioselectivity was little affected (Table 
11, entries 2, and 5-7). 
In recent years, some literature reported that monocationic [LAu2ClX] species (L = 
bidentate ligand, for instance, bisphosphine ligand; X = weak counteranion, for 
instance, OTf), which were generated in situ from a 1:1 mixture of [LAu2Cl2] and a 
AgX activator, gave better enantioselectivity than these bicationic [LAu2X2] species 
in the process of enantioselective gold catalysis.
104, 129
 These results indicated that the 
second gold site might either just exert a steric influence or be involved in a second 
interaction with the substrate. Based on this, the influence of the ratio of 
L[AuCl]2/AgOTf on the reaction outcome was investigated. As we had expected, 
increasing the ratio of L[AuCl]2/AgOTf from 1:1 to 1:2 caused the enantiomeric 
excess of the product to decrease from 85 to 69 (Table 11, entries 6, 8, and 9). Similar 
results were also been reported in the gold-catalyzed cycloaddition reactions.
104, 129
 
Furthermore, changing the ratio of ligand/Me2SAuCl to 1.1:2 did not have a major 
effect on the enantiomeric excess value.  
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3.3.3. Substrate scope 
With the optimized conditions in hand (Table 11, entry 6), the substrate scope of this 
tandem cyclization/[3+3]cycloadditions reaction was then explored. First, a broad 
range of electron-poor and -rich aromatic substrates 138 was investigated as 
summarized in Scheme 43. Much to our delight, diversely substituted azomethine 
imines 138 produced corresponding optically active products 151 in 83%-95% yields 
with good to excellent enantioselectivities (65-96% ee) under standard conditions 
(Scheme 43). Noticeably, it was found that the substituents on the aromatic substrates 
138 influenced the elution order of the product enantiomers. Compared to substituted 
azomethine imines with electron-withdrawing groups, other azomethine imines which 
are substituted by electron-donating groups such as Me, OMe, and tBu, gave opposite 
elution order of the enantiomers of 151, but 138e, 138g and 138p (4-F, 4-Br, and 2-Cl 
substituted, respectively) are two exceptions. However, product 151q did not form 
after 24 h at standard conditions (Scheme 43, 151q). 
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NOTE: The absolute configuration of 151e and 151s was determined by X-ray crystallography. If 
the main enantiomer eluted as the second enantiomer peak in the chiral HPLC, the ee-values are 
given as ‘positive’ values. In case the main enantiomer eluted first the ee-values are given as 
‘negative’ values. 
Scheme 43. Gold-catalyzed cycloaddition of 146a with azomethine imines 138. 
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Furthermore, the scope of 2-(1-alkynyl)-2-alken-1-ones was investigated, and the 
results are shown in Scheme 44. Replacing the para-proton on the benzene ring of the 
olefin moiety by methoxy group did not have a major effect on the ee value, both 
146a and 146b ketones gave the desired products in high yields with good enantio- 
and diastereoselectivity (Scheme 44, 151a and 151t). However, placing aliphatic R
1
 
substituents on the alkyne moiety of the ketone resulted in a dramatic decreases of the 
enantio- and diastereoselectivity. For example, the cycloaddition products 151u with 
R
1
 = nPr and 151v with R
1
 = nBu were obtained only in 11% and 18% ee, 
respectively. These results indicate that a certain steric bulk of R
1
 is required to 
obtained excellent enantioselectivity.  
 
 
Scheme 44. Gold-catalyzed cycloaddition of ketone 146 with azomethine imine 138a. 
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The absolute configuration of two of the products were confirmed by single-crystal X-
ray diffraction analysis of representative compounds 151e and 151s (Figure 20).  
 
Figure 20. X-ray crystal structures of compounds 151e (left) and 151s. 
 
Furthermore, to demonstrate the preparative usefulness of the developed methodology 
we applied it in a gram-scale synthesis of the highly substituted furo[3,4-d]pyridazine 
151t (Scheme 45). In this transformation, catalyst loading could be reduced to 0.15 
mol% with 5 mmol reaction scale without loss of any selectivity and efficiency, 
providing 151t in 91% yield with an enantiomeric excess of 88%. 
 
Scheme 45. Gram-scale synthesis of the highly substituted furo[3,4-d]pyridazine 151t. 
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4. Conclusions 
Given the enormous importance of enantioselective transition metal catalysis in 
organic synthesis, an active research program in our group is aiming at the 
development of modular phosphine-phosphite ligands and their application in 
asymmetric catalysis. This thesis describes the development of highly diastereo- and 
enantioselective gold-catalyzed cycloadditions of 2-(1-alkynyl)-2-alken-1-ones to 
azomethine imines using modular phosphine-phosphite ligands.  
4.1. AuPPh3Cl-catalyzed intermolecular 
cyclization/[3+3]cycloadditions of 2-(1-alkynyl)-2-alken-1-
ones with azomethine imines 
In the presence of 5 mol % of AuPPh3Cl/AgOTf (1:1), the 1,3-dipolar cycloaddition 
of 2-(1-alkynyl)-2-alken-1-ones 146 with N,N′-cyclic azomethine imines of type 138 
proceeded efficiently and provided easy access to the corresponding highly 
substituted furo[3,4-d]pyridazines rac-151 in good to excellent chemical yields with 
high levels of diastereoselectivity (Scheme 46). Features of this method include mild 
conditions, and a variety of functional groups were tolerated in both of the substrates. 
In addition, the reactions were very clean and side products formed by competing 
[3+2]-cycloaddition processes were not observed. This indicates that there 
transformations are regiospecific and chemospecific. Inaddition, the relative 
conﬁguration of rac-151a and rac-151f was determined by single-crystal X-ray 
analysis, as depicted in Figure 19.  
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Scheme 46. AuPPh3Cl-catalyzed [3+3]cycloadditions of 2-(1-alkynyl)-2-alken-1-ones 
with azomethine imines. (The numbers refer to yield and diastereomeric ratio.) 
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4.2. Enantioselective gold(I)-catalyzed intermolecular 
[3+3]cycloadditions of 2-(1-alkynyl)-2-alken-1-ones with 
azomethine imines  
After screening of a library of chiral phosphine-phosphite ligands, ligand 30m proved 
to be the best ligand for the enantioselective gold(I)-catalyzed intermolecular 
[3+3]cycloadditions of 2-(1-alkynyl)-2-alken-1-ones with azomethine imines. Under 
optimized conditions (10 mol% Me2SAuCl, 5 mol% ligand 30m, 5 mol% AgOTf, 
CH3CN, room temperature), the asymmetric cycloadditions of 2-(1-alkynyl)-2-alken-
1-ones with azomethine imines produced the corresponding highly substituted 
furo[3,4-d]pyridazines in good to excellent yields with up to 96% enantiomeric excess. 
This readily accessible ligand allowed the efficient transformation of an unsurpassed 
range of azomethine imines. Furthermore, the catalyst loading could be reduced to 
0.15 mol% on a 5 mmol scale without any loss of selectivity and efficiency, providing 
151t in 91% yield with 88% ee. This supplies an efficient and practical method for the 
synthesis of highly substituted furo[3,4-d]pyridazines. 
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Scheme 47. Enantioselective [3+3]cycloadditions of 2-(1-alkynyl)-2-alken-1-ones with 
azomethine imines under standard conditions. 
 
In conclusion, the method developed in the course of this thesis opens an efficient and 
modular access a new class of heterocyclic compounds, which may be of interest for 
pharmaceutical applications in the future. 
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5. Experimental Section 
5.1. General Conditions 
Air and moisture-sensitive reactions were conducted under an argon atmosphere using 
Schlenk technique. The glassware was flame-dried under high vacuum and allowed to 
cooled down under argon atmosphere.  
 
Solvents and Reagents 
 
Reagents and solvents were purchased from ABCR, Acros, Aldrich, Alfa-Aesar, Fluka, 
Merck or Strem and were used without further purification, unless otherwise indicated. 
THF, Et2O and toluene were freshly distilled under an argon atmosphere from 
sodium/benzophenone. CH2Cl2 was dried by distillation from CaH2 under an argon 
atmosphere prior to use. MeOH was distilled under an argon atmosphere from Mg/I2 
and stored over 3 Å molecular sieves. EtOH was distilled under an argon atmosphere 
from Na/ethyl succinate and stored over 3 Å molecular sieves. MTBE was distilled 
under an argon atmosphere from sodium/benzophenone and stored over 3 Å 
molecular sieves. 
 
Removal of solvent  
 
The solvent evaporation from reaction mixtures was done using a rotary evaporator R-
114 from Büchi (pressure 10-1013 mbar, water bath temparetute: 40 ºC ). The 
advanced drying was performed at room temperature by applying an oil pump 
vacuum. 
 
Column chromatography 
Column chromatography was performed using Silica gel for chromatography, (230-
400 mesh, 60 Å) from Acros. Analytical thin-layer chromatography (TLC) was 
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performed with commercial aluminum plates coated with Silica Gel 60-F254 from 
Merck. Chromatograms were visualized by UV light at 254 nm or staining with a 
“KMnO4 reagent” (prepared from 1.5 g of KMnO4, 10 g of K2CO3 and 1.25 mL 10% 
NaOH in 200 mL of H2O) and subsequent heating. 
 
Melting points (mp)  
 
Melting points (mp) were measured with a Büchi B-545 apparatus in open capillary 
tubes and are uncorrected. 
 
High pressure liquid chromatography (HPLC) 
 
Chromatography were measured on a Merk-Hitachi instrument. 
 
Nuclear magnetic resonance (NMR)  
 
Nuclear magnetic resonance (NMR) spectra (
1
H, 
13
C, 
11
B, 
31
P, 
19
F) were recorded in 
CDCl3 or d6-DMSO on Bruker instruments DPX 300, AV 400 or Avance II 300. 
Chemical shifts (δ) are given in delta (δ) units in parts per million (ppm) relative to 
tetramethylsilane (0.00 ppm). The fine structure of proton, fluorine and phosphorous 
signals is given as s (singlet), d (doublet), t (triplet), m (multiplet) or br (broad) Ψ 
marks pseudo-splitting patterns. In the case of 
13
C NMR, APT (attached proton test) 
spectra were recorded. 
13
C, 
31
P and 
11
B NMR spectra were recorded proton decoupled. 
To unambiguously assign the signals, 2D (H,H-COSY, HMQC and HMBC) spectra 
were recorded. 
 
Fourier transform Infrared spectra (IR) 
 
IR-spectra were recorded on a Perkin-Elmer UATR Two spectrometer using the ATR 
(Attenuated Total Reflectance) technique. Absorption bands are given in wave 
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numbers (~ cm-1). The intensity of absorption bands is given as s (strong), m (medium) 
or w (weak); br additionally indicates broad signals.  
 
Mass spectra (MS) and high resolution mass spectra  (HRMS)  
 
Mass spectra (MS) were measured with a Finnigan Incos 50 Galsxy System, and high 
resolution mass spectra (HRMS) were recorded on a Finnigan MAT 900S. The 
spectra were measured under electron impact (EI) with an ionization potential of 70 
eV or under electron spray ionization (ESI). Nitrogen for the ESI-source was 
generated by a Neslab Thermoflex 900 (Thermo Scientific) 
 
Gas-chromatography with mass selective detection (GC-MS)  
 
GC-MS was carried out using an Agilent instrument (Agilent HP6890) using a 5973 
N detector on 30 m x 0.25 mm capillary columns (Optima-1-MS from Macherey-
Nagel) with H2 as a carrier gas (1.7 mL/min, 1.2 bar). 
 
Enantiomeric analyses  
 
Enantiomeric analyses through High Performance Liquid Chromatography (HPLC) 
were conducted with HPLC units from Knauer (UV-detection at 220 nm and 254 nm) 
using Diacel Chiralpak AD-H or Diacel Chiralpak QJ.  
 
X-ray: The crystal data were recorded on a nonius-kappa CCD-diffractometer. 
 
Polarimeter 
Optical rotations were recorded at the given wavelengths with a Anton Paar MCP 200 
polarimeter at 20 °C using a 10 cm cell. The solvents and concentrations (in g/100 mL) 
are indicated. 
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5.2. Synthesis of chiral phosphine-phosphite ligands 
5.2.1. Synthesis of tartaric acid derivatives 
5.2.1.1. Synthesis of dimethyl (4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-
dicarboxylate (144) 
 
 
In a 250 mL round bottom flask, (+)-dimethyl L-tartrate 143 (17.81g, 100 mmol, 1.0 
eq.) was dissolved in 150 ml dry acetone. Subsequently, 29.6 ml (48% solution, 100 
mol, 1.0 eq.) of boron trifluoride diethyl etherate was slowly added during 30 min 
under ice cooling. The resulting mixture was stirred for another 30 min at 0 °C, then 
at r.t. for 24 h. The reaction solution was carefully poured into an aqueous saturated 
NaHCO3 (800 mL) solution, and extracted with 200 mL of ethyl acetate (3x). The 
combined organic phases washed with 200 mL of water (2x), dried over MgSO4 and 
removed the solvent under reduced pressure. The residue was subjected to column 
chromatography to give the desired 144 as a colorless oil with 71% yield. 
 
 
 
M (C9H14O6): 218.21 g/mol  
1
H NMR (300 MHz, CDCl3): δ = 4.76 (s, 3H), 3.76 (s, 6H), 1.43 (s, 6H).  
13
C NMR (75 MHz, CDCl3): δ= 169.9, 113.8, 76.9, 52.8, 26.4.  
IR (ATR) ~  [cm-1] = 2994, 1736, 1436, 1372, 1204, 1106, 1006, 855, 748.  
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GC-MS (70 eV) m/z (%) = 203 (100), 175 (3), 159 (28), 141 (19), 133 (8), 113 (11), 
101 (20), 85 (19), 73 (40), 43 (87).  
The purity and identity of the literature known product was unambiguously 
confirmed.
130
 
 
5.2.1.2. Synthesis of (4R,5R)-2,2-dimethyl-α,α,α´,α´-tetraphenyldioxolane-4,5-
dimethanol (145a) 
 
 
A flame-dried three-necked round-bottomed flask equipped with a dropping funnel 
and a reflux condenser was charged with Mg turnings (5.83 g, 240 mmol, 4.8 eq.) and 
an iodine crystal. The dropping funnel was filled with a solution of 34.5 g 
bromobenzene (220 mmol, 4.4 eq.) in 120 mL THF. This solution was slowly added 
to the Mg turnings, so that gentle reflux was maintained during the addition. 
Afterwards, the resulting mixture was heated to reflux for 1 h. Stirring was continued 
at r.t. overnight. A solution of 10.90 g (4R,5R)-dimethyl-2,2-dimethyl-1,3-dioxolane-
4,5-dicarboxylate (50 mmol, 1.0 eq.) in 100 mL THF was slowly added to the 
Grignard reagent at 0 °C. Then, the resulting reaction mixture was heated to reflux for 
1.5 h. The reaction was quenched by addition of 250 mL saturated aqueous NH4Cl 
solution and the phases were separated. The aqueous phase was extracted with EtOAc 
(3x100 mL). The combined organic phases were washed with saturated aqueous NaCl 
solution, dried over MgSO4 and the solvent was removed under reduced pressure. The 
residue was purified by flash column (cyclohexane/EtOAc 10:1) to afford the desired 
145a (14.46 g, 62%) as white solid. 
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M (C31H30O4): 466.58 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.53-7.48 (m, 4H), 7.37-7.21 (m, 16H), 4.59 (s, 2H), 
3.88 (s, 2H), 1.03 (s, 6H).  
13
C NMR (APT) (75 MHz, CDCl3): δ = 145.9, 142.5, 128.5, 128.2, 127.5, 127.1, 
109.6, 80.9, 78.2, 27.2.  
IR (ATR) ~  [cm-1] = 3306, 3059, 2984, 2935, 2243, 1951, 1889, 1807, 1493, 1446, 
1368, 1168, 1045, 905, 697. 
The purity and identity of the literature known product was unambiguously 
confirmed.
130
 
5.2.1.3. Synthesis of (4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(bis(3,5-
dimethylphenyl)-methanol (145b) 
According to the procedure for 145a, Mg turnings (5.83 g, 240 mmol, 4.8 eq.) and 1-
bromo-3,5-dimethylbenzene (40.71 g, 220 mmol, 4.4 eq.) were reacted with (4R,5R)-
dimethyl-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate (10.90 g, 50 mmol, 1.0 eq.). 
The crude product was purified by flash column (cyclohexane /EtOAc 15:1) to afford 
145b (19.39 g, 67%) as white solid. 
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M (C39H46O4): 578.79 g/mol  
1
H NMR (300 MHz, CDCl3): δ = 7.17 (s, 4H6), 6.92 (s, 4H), 6.84 (s, 4H), 4.56 (s, 
2H), 3.79 (s, 2H), 2.34 (s, 12H), 2.24 (s, 12H), 1.08 (s, 6H).  
13
C-NMR (75 MHz, CDCl3): δ = 145.7, 142.9, 137.1, 136.6, 129.3, 128.5, 126.5, 
125.6, 109.1, 81.0, 78.1, 27.3, 21.4.  
IR (ATR) ~  [cm-1] = 3312, 2984, 2915, 2862, 1787, 1705, 1600, 1453, 1366, 1331, 
1238, 1217, 1168, 1058, 1035, 968, 890, 851, 753, 736, 690. 
The purity and identity of the literature known product was unambiguously 
confirmed.
32
 
 
5.2.2. Synthesis of borane-protected phosphine phenols of type 34 
5.2.2.1. Synthesis of ortho-brominated phenols (32) 
 
 
General procedure: A flame-dried flask equipped with a Soxhlet apparatus and flushed 
with argon was charged with substituted phenols 31b-31i (1.0 eq.), diisopropylamine 
(0.1 eq.) and CH2Cl2. The thimble was filled with NBS (1.0 eq.) and the system was 
heated to reflux for 16 h. During this time, the NBS was slowly consumed. After 
cooling to room temperature the resulting mixture was treated with 2M sulfuric acid. 
The layers were separated and the aqueous layer was extracted with MTBE. The 
combined organic layers were washed with water and brine, and dried over MgSO4. 
The solvent was removed and the crude product was purified by flash chromatography. 
 
2-Bromo-6-methylphenol (32b). According to general procedure, 2-methylphenol 
(4.33 g, 40 mmol) and diisopropylamine (0.56 ml, 0.40 g, 4.0 mmol) were dissolved 
in CH2Cl2 (120 mL) and treated with NBS (7.12 g, 40 mmol) for 16 h at reflux. After 
EXPERIMENTAL SECTION 
92 
 
cooling to room temperature, the resulting mixture was treated with 2M sulfuric acid 
(120 mL). The crude product was purified by flash chromatography 
(Cyclohexane/EtOAc 40:1) to afford 32b (7.26 g, 97%) as yellow liquid. 
 
M (C7H7BrO): 187.04 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.29 (m, 1H), 7.07-6.68 (m, 2H), 5.79 (s, 1H), 2.29 
(s, 3H). 
13
C NMR (75M Hz, CDCl3): δ = 149.6, 135.6, 133.3, 1245.0, 122.1, 113.7, 22.6. 
The purity and identity of the literature known product was unambiguously 
confirmed.
26
 
 
2-Bromo-6-tert-butylphenol (32c). Compound 32c was prepared from 2-tert-
butylphenol (4.87 g, 40 mmol) according to general procedure. Pale yellow liquid, 
7.16 g, 89%. 
 
M (C10H13BrO): 201.06 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.30 (d, J = 8.1, 1H), 7.10 (d, J = 7.8, 1H), 6.75 (t, J 
= 7.8, 1H), 5.55 (s, 1H), 2.70(q, J = 7.8, 2H), 1.24(t, J = 7.8, 3H). 
 13
C NMR (75 MHz, CDCl3): δ = 150.0, 131.9, 129.5, 128.8, 121.5, 110.7, 23.7, 14.0. 
The purity and identity of the literature known product was unambiguously 
confirmed.
130
 
 
2-Bromo-6-isopropyl-phenol (32d). Compound 32d was prepared from 2-
isopropylphenol (4.33 g, 40 mmol) according to general procedure. Pale yellow liquid, 
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8.26 g, 96%. 
 
M (C9H11BrO): 215.09 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.30-7.14 (m, 2H,), 6.79 (m, 1H), 5.59 (s, 1H), 3.35 
(m, 1H), 1.26 (d, 6H). 
13
C NMR (75 MHz, CDCl3): δ = 149.6, 136.4, 129.1, 125.7, 121.5, 110.8, 28.2, 22.6. 
The purity and identity of the literature known product was unambiguously 
confirmed.
26
 
 
2-Bromo-6-phenylphenol (32e). Compound 32e was prepared from 2-phenylphenol 
(6.81 g, 40 mmol) according to general procedure. Pale yellow liquid, 9.47 g, 95%. 
 
M (C12H9BrO): 249.11 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.59-7.26 (m, 7H,), 6.91 (m, 1H), 5.71 (s, 1H). 
 13
C NMR (75 MHz, CDCl3): δ = 149.3, 137.4, 131.6, 130.2, 129.7, 128.6, 127.9, 
121.5, 110.9. 
The purity and identity of the literature known product was unambiguously 
confirmed.
26
 
 
2-Bromo-6-tert-butylphenol (32f). Compound 32f was prepared from 2-tert-
butylphenol (6.01 g, 40 mmol) according to general procedure. Pale yellow liquid, 
8.80 g, 96%. 
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M (C10H13BrO): 229.12 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.34-7.20 (m, 2H,), 6.73 (t, J = 7.8, 1H), 5.79 (s, 
1H), 1.41(s, 9H). 
 13
C NMR (75 MHz, CDCl3): δ = 150.3, 137.6, 129.6, 126.5, 120.7, 112.1, 35.2, 29.4. 
The purity and identity of the literature known product was unambiguously 
confirmed.
130
 
 
2-Bromo-4,6-di-tert-butylphenol (32g). Compound 32g was prepared from 2,4-di-
tert-butylphenol (8.25 g, 40 mmol) according to general procedure. Pale yellow liquid, 
9.70 g, 85%. 
 
M (C10H13BrO): 285.23 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.33 (d, J = 2.3 1H,), 7.24 (d, J = 2.4, 1H), 5.66 (s, 
1H), 1.41(s, 9H), 1.29(s, 9H). 
 13
C NMR (75 MHz, CDCl3): δ = 148.1, 143.6, 136.6, 126.3, 123.7, 112.0, 35.7, 34.4, 
31.5, 29.4. 
The purity and identity of the literature known product was unambiguously 
confirmed.
26
 
 
2-Bromo-6-tert-pentylphenol (32h). Compound 32h was prepared from 2-tert-
pentylphenol (6.57 g, 40 mmol) according to general procedure. Pale yellow liquid, 
7.88 g, 81%. 
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M (C10H13BrO): 243.14 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.34-7.14(m, 2H,), 6.73 (t, J = 7.9, 1H), 5.77 (s, 
1H), 1.88 (q, J = 7.5, 2H), 1.35(s, 6H), 0.65 (t, J = 7.5, 3H). 
 13
C NMR (75 MHz, CDCl3): δ = 150.3, 136.1, 129.6, 127.8, 120.7, 112.1, 39.1, 32.7, 
27.6, 9.5. 
IR (ATR) ~  [cm-1] = 3501, 2962, 2866, 1595, 1431, 1382, 1334, 1267, 1243, 1184, 
1145, 1092, 845, 782, 736, 679.  
GC-MS (70 eV) m/z (%) = 244 (32), 242 (32), 213 (100), 185 (100), 134 (57), 115 
(32), 77 (29), 51 (15). 
The purity and identity of the literature known product was unambiguously 
confirmed.
130
 
 
2-Bromo-4,6-di-tert-pentylphenol (32i). Compound 32i was prepared from 2,4-di-
tert-pentylphenol (9.38 g, 40 mmol) according to general procedure. Pale yellow 
liquid, 11.28 g, 90%. 
 
M (C10H13BrO): 313.28 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.25 (s, 1H,), 7.11 (s, 1H), 5.61 (s, 1H), 1.86 (q, J = 
7.5, 2H), 1.59(q, J = 7.5, 2H), 1.35(s, 6H), 1.24(s, 6H), 0.70-0.61 (m, 6H). 
 13
C NMR (75 MHz, CDCl3): δ = 147.6, 141.6, 134.6, 126.8, 125.7, 111.7, 39.0, 37.4, 
36.9, 32.6, 28.4, 27.4, 9.3, 9.0. 
IR (ATR) ~  [cm-1] = 3508, 2968, 2869, 1595, 1569, 1469, 1403, 1376, 1362, 1335, 
1299, 1273, 1249, 1173, 1092, 1056, 939, 895, 866, 829, 779, 743, 705.  
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GC-MS (70 eV) m/z (%) = 314 (8), 312 (32), 285 (95), 283 (100), 257 (8), 255 (8), 
241 (4), 205 (6), 131 (5), 115 (6), 91 (5), 71 (9), 43 (10). 
The purity and identity of the literature known product was unambiguously 
confirmed.
130
 
5.2.2.2. Synthesis of borane-protected phosphanyl phenols of type 34. 
 
 
General procedure: 1). Under an argon atmosphere bromophenol 32 (1.0 eq.) and 
DABCO (1.2 eq.) were dissolved in dry CH2Cl2 and stirred 15 min at room 
temperature. The resulting solution was cooled to 0 °C, and chlorophosphine (1.2 eq.) 
was added dropwise via syringe over 30 min. The resulting white suspension was 
stirred for 10 min at this temperature, then allowed to warm to room temperature and 
stirred for another 2 h. The reaction mixture was then cooled to 0 °C again and a 
solution of BH3·THF (1M, 2.0 eq.) was added via syringe. The suspension was stirred 
for 10 min at 0 °C, then allowed to warm to room temperature and stirred for another 
1 h. The reaction mixture was quenched with deionized water, the organic layer was 
separated and the aqueous layer was extracted with MTBE. The combined organic 
layers were washed with brine, dried over MgSO4. The solvent was removed under 
reduced pressure to give the crude product which was used without further 
purification. 
2). Under an argon atmosphere borane-protected phosphinite 33 (1.0 eq.) was 
dissolved in dry THF. The solution was cooled to 0 °C before n-BuLi (1.5 eq.) was 
added via syringe over 30 min. The resulting solution was stirred for 2 h at 0 °C and 
then quenched with deionized water. The mixture was transferred into a separatory 
funnel and the organic layer was collected. The aqueous layer was extracted with 
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MTBE. The combined organic layers were washed with saturated aqueous NH4Cl 
solution, dried over MgSO4 and filtered through a glass frit. Removal of solvent 
under reduced pressure afforded the crude product 34 as colorless oil, which was 
purified by flash chromatography to provide the borane-protected phosphanyl phenols 
as white solids. 
 
2-Boranatodiphenylphosphanyl-phenol (34a)  
Compound 34a was prepared from bromophenol 32a (4.33 g, 25 mmol) according to 
general procedure 1) and 2). White solid, 6.57 g, 90%. 
 
M (C18H18BOP): 292.12 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.57-7.39 (m, 12H), 7.03-6.87 (m, 3H).  
13
C NMR (75 MHz, CDCl3): δ = 160.6 (d, J = 9.0 Hz, Cq), 134.4 (d, J = 3.4 Hz, 
CHAr), 134.1 (d, J = 1.89 Hz, CHAr), 133.0 (d, J = 10.1 Hz, CHAr), 131.6 (d, J = 2.5 
Hz, CHAr), 129.0 (d, J = 10.7 Hz, CHAr), 128.1 (d, J = 61.7 Hz, Cq), 120.7 (d, J = 7.8 
Hz, CHAr), 118.4 (d, J = 6.2 Hz, CHAr), 111.7 (d, J = 58.7 Hz, Cq). 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 12.71 (d, J = 66.3 Hz).  
IR (ATR) 
~  [cm-1] = 3374, 3055, 2953, 2381, 1585, 1580, 1433, 1332, 1285, 1214, 
1103, 1057, 832, 754, 741, 691  
 
2-Boranatodiphenylphosphanyl-6-methylphenol (34b) 
Compound 34b was prepared from bromophenol 32b (4.68 g, 25 mmol) according to 
general procedure 1) and 2). White solid, 6.81 g, 89%. 
 
EXPERIMENTAL SECTION 
98 
 
M (C19H20BOP): 306.15 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.63 (s, 1H) 7.56-7.27 (m, 11H), 6.82-6.67 (m, 2H). 
2.28 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 158.6 (d, J = 9.5 Hz, Cq), 135.1 (d, J = 2.1 Hz, 
CHAr), 133.1 (d, J = 9.8 Hz, CHAr), 132.0 (d, J = 3.1 Hz, CHAr), 131.6 (d, J = 2.5 Hz, 
CHAr), 129.0 (d, J = 10.7 Hz, CHAr), 128.2 (d, J = 61.8 Hz, Cq), 127.6 (d, J = 6.2 Hz, 
CHAr), 120.3 (d, J = 8.4 Hz, CHAr), 110.9 (d, J = 58.7 Hz, Cq), 16.3. 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 12.48 (d, J = 66.9 Hz).  
IR (ATR) 
~  [cm-1] = 3360, 3055, 2953, 2856, 2374, 1585, 1480, 1456, 1435, 1422, 
1378, 1345, 1225, 1181, 1151, 1102, 1067, 999, 865, 827, 741, 691, 650. 
 
2-Boranatodiphenylphosphanyl-6-ethylphenol (34c) 
Compound 34c was prepared from bromophenol 32c (5.03 g, 25 mmol) according to 
general procedure 1) and 2). White solid, 7.04 g, 88%. 
 
M (C20H22BOP): 320.18 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.63 (s, 1H) 7.56-7.31 (m, 11H), 6.83-6.73 (m, 2H), 
2.68(q, J = 7.5 Hz, 2H), 1.23(t, J = 7.5 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 158.5 (d, J = 9.5 Hz, Cq), 133.6 (d, J = 5.9 Hz, 
CHAr), 133.4 (d, J = 2.1 Hz, CHAr), 133.0 (d, J = 9.9 Hz, CHAr), 131.9 (d, J = 3.1 Hz, 
CHAr), 129.0 (d, J = 10.7 Hz, CHAr), 128.2 (d, J = 61.8 Hz, Cq), 120.3 (d, J = 8.5 Hz, 
CHAr), 110.1 (d, J = 58.6 Hz, Cq), 23.3 (d, J = 1.7 Hz), 13.7. 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 12.48 (d, J = 68.3 Hz).  
IR (ATR) 
~  [cm-1] = 3360, 3053, 2963, 2921, 2377, 1585, 1481, 1436, 1341, 1222, 
1178, 1149, 1105, 1181, 1151, 1065, 1027, 999, 833, 741, 691. 
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2-Boranatodiphenylphosphanyl-6-isopropylphenol (34d) 
Compound 34d was prepared from bromophenol 32d (5.03 g, 25 mmol) according to 
general procedure a) and b). White solid, 7.38 g, 81%. 
 
M (C21H24BOP): 334.21 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.66 (s, 1H) 7.60-7.30 (m, 11H), 6.86-6.73 (m, 2H), 
1.25(m, 1H), 1.24(d, J = 6.9 Hz, 6H) 
13
C NMR (75 MHz, CDCl3): δ = 157.3 (d, J = 9.5 Hz, Cq), 137.8 (d, J = 5.8 Hz, Cq), 
133.1 (d, J = 9.9 Hz, CHAr), 132.1 (d, J = 8.9 Hz, Cq), 131.7,131.5, 130.5, 128.9 (d, J 
= 10.7 Hz, CHAr), 120.4 (d, J = 8.5 Hz, CHAr), 111.1 (d, J = 58.8 Hz, Cq), 26.9, 22.7. 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 12.48 (d, J = 69.8 Hz).  
IR (ATR) 
~  [cm-1] = 3360, 3055, 2959, 2921, 2376, 1584, 1481, 1437, 1342, 1222, 
1175, 1148, 1103, 1062, 1151, 1065, 1027, 997, 831, 740, 690. 
 
2-Boranatodiphenylphosphanyl-6-phenylphenol (34e) 
Compound 34e was prepared from bromophenol 32e (6.23 g, 25 mmol) according to 
general procedure 1) and 2). White solid, 8.28 g, 90%. 
 
M (C24H22BOP): 368.22 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.65-7.58 (m, 4H), 7.56-7.34 (m, 12H), 7.16 (s, 1H), 
7.14-7.08 (m, 1H), 7.01-6.99 (m, 1H). 
13
C NMR (75 MHz, CDCl3): δ = 156.7 (d, J = 6.8 Hz, Cq), 136.9 (Cq), 134.9, 134.4 
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(d, J = 5.5 Hz, CHAr), 133.1(d, J = 9.9 Hz, CHAr), 131.5(d, J = 1.9 Hz, CHAr), 130.5(d, 
J = 6.0 Hz, Cq), 129.4, 128.9 (d, J = 10.6 Hz, CHAr), 128.6, 127.8, 127.6 (d, J = 65.4 
Hz, Cq), 120.9 (d, J = 9.4 Hz, CHAr), 113.4 (d, J = 57.4 Hz, Cq). 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 14.78 (d, J = 66.9 Hz).  
IR (ATR) 
~  [cm-1] = 3335, 3055, 2381, 2921, 1965, 1576, 1481, 1435, 1342, 1222, 
1185, 1148, 1097, 1063, 1021, 967, 907, 831, 797, 740, 698. 
 
2-Boranatodiphenylphosphanyl-6-tert-butylphenol (34f) 
Compound 34f was prepared from bromophenol 32f (5.73 g, 25 mmol) according to 
general procedure 1) and 2). White solid, 7.57 g, 87%. 
 
M (C22H26BOP): 348.23 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.76 (d, J = 2.1 Hz, 1H) 7.56-7.43 (m, 11H), 6.82-
6.66 (m, 2H), 1.40(s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 159.6 (d, J = 9.7 Hz, Cq), 138.9 (d, J = 5.5 Hz, Cq), 
133.1 (d, J = 9.9 Hz, CHAr), 132.1 (d, J = 3.4 Hz, CHAr), 131.6(d, J = 2.5 Hz, CHAr), 
131.3(d, J = 1.9 Hz, CHAr), 128.9 (d, J = 10.6 Hz, Cq), 128.3 (d, J = 61.9 Hz, CHAr), 
120.3 (d, J = 8.9 Hz, CHAr), 112.3 (d, J = 58.9 Hz, Cq), 35.4, 29.7. 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 12.88 (d, J = 73.3 Hz).  
IR (ATR) 
~  [cm-1] = 3350, 3057, 2955, 2376, 1578, 1481, 1467, 1436, 1422, 1391, 
1364, 1342, 1261, 1233, 1201, 1160, 1151, 1119, 1105, 1065, 1027, 999, 907, 831, 
738, 690, 637. 
 
2-Boranatodiphenylphosphanyl-4,6-di-tert-butylphenol (34g) 
Compound 34g was prepared from bromophenol 32g (5.73 g, 25 mmol) according to 
general procedure 1) and 2). White solid, 8.90 g, 88%. 
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M (C26H34BOP): 404.34 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.60-7.40 (m, 12H), 6.67 (dd, J = 11.6 Hz, 2.4 Hz, 
1H), 1.44(s, 9H), 1.13(s, 9H). 
13
C NMR (75 MHz, CDCl3): δ = 157.4 (d, J = 9.8 Hz, Cq), 142.3 (d, J = 8.1 Hz, Cq), 
138.1 (d, J = 5.9 Hz, Cq), 133.1 (d, J = 9.8 Hz, CHAr), 131.6(d, J = 2.5 Hz, CHAr), 
129.0(d, J = 10.6 Hz, CHAr), 128.9 (d, J = 3.9 Hz, CHAr) 128.8(d, J = 61.7 Hz, Cq), 
128.6 (d, J = 2.0 Hz, CHAr), 111.5 (d, J = 59.3 Hz, Cq), 35.6, 34.5, 31.4, 29.7. 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 13.69 (d, J = 54.4 Hz).  
IR (ATR) ~  [cm-1] = 3360, 3047, 2955, 2906, 2869, 2368, 1960, 1810, 1575, 1465, 
1432, 1391, 1342, 1289, 1247, 1219, 1188, 1141, 1105, 1065, 1025, 999, 912, 819, 
736, 696, 639. 
 
2-Boranatodiphenylphosphanyl-6-tert-pentylphenol (34h) 
Compound 34h was prepared from bromophenol 32h (6.08 g, 25 mmol) according to 
general procedure 1) and 2). White solid, 7.97 g, 88%. 
 
M (C23H28BOP): 362.26 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.65 (d, J = 2.0 Hz, 1H) 7.57-7.38 (m, 11H), 6.82-
6.64 (m, 2H), 1.86(q, J = 7.5 Hz, 2H), 1.37(s, 6H), 0.64(t, J = 7.5 Hz, 3H) 
13
C NMR (75 MHz, CDCl3): δ = 159.5 (d, J = 9.5 Hz, Cq), 137.3 (d, J = 5.5 Hz, Cq), 
133.1 (d, J = 9.9 Hz, CHAr), 132.8 (d, J = 1.9 Hz, CHAr), 132.1(d, J = 3.4 Hz, CHAr), 
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131.7(d, J = 2.5 Hz, CHAr), 129.0 (d, J = 10.6 Hz, CHAr), 128.3 (d, J = 61.9 Hz, Cq), 
120.2 (d, J = 8.7 Hz, CHAr), 112.3 (d, J = 59.3 Hz, Cq), 38.9(d, J = 1.4 Hz, Cq), 32.8, 
27.9, 9.7. 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 12.97 (d, J = 73.8 Hz).  
IR (ATR) 
~  [cm-1] = 3353, 3056, 2959, 2376, 1579, 1481, 1467, 1436, 1422, 1386, 
1362, 1342, 1227, 1201, 1160, 1151, 1122, 1105, 1069, 1027, 999, 912, 831, 744, 700, 
691. 
 
2-Boranatodiphenylphosphanyl-4,6-di-tert-butylphenol (34i) 
Compound 34i was prepared from bromophenol 32i (7.83 g, 25 mmol) according to 
general procedure 1) and 2). White solid, 9.73 g, 90%. 
 
M (C28H38BOP): 432.39 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.56-7.33 (m, 12H), 6.59 (dd, J = 11.6 Hz, 2.4 Hz, 
1H), 1.85(q, J = 7.4 Hz, 2H), 1.46-1.34 (m, 8H), 1.06(s, 6H), 0.65-0.53 (m, 6H). 
13
C NMR (75 MHz, CDCl3): δ = 157.0 (d, J = 9.8 Hz, Cq), 140.3 (d, J = 7.9 Hz, Cq), 
136.1 (d, J = 5.9 Hz, Cq), 133.0 (d, J = 9.8 Hz, CHAr), 131.4(d, J = 1.5 Hz, CHAr), 
130.6, 129.3(d, J = 3.4 Hz, CHAr), 128.7(d, J = 10.5 Hz, CHAr) 128.6(d, J = 61.6 Hz, 
Cq), 111.8 (d, J = 59.5 Hz, Cq), 38.9, 37.4, 36.8, 32.9, 28.3.4, 27.7, 9.5, 9.0. 
31
P NMR {
1
H} (121 MHz, CDCl3): δ = 13.61 (d, J = 51.4 Hz).  
IR (ATR) 
~  [cm-1] = 3360, 3045, 2957, 2864, 2376, 1952, 1810, 1585, 1454, 1434, 
1381, 1360, 1340, 1294, 1234, 1186, 1132, 1103, 1065, 1025, 999, 903, 762, 736, 690. 
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5.2.3. Synthesis of ligands of type 30 
General Procedure: A flame-dried Schlenk-flask was charged under argon with the 
borane-protected phosphine 34 (1.0 eq.) and DABCO (8.0 eq.), and CH2Cl2. The 
mixture was stirred 10 min at r.t. before it was cooled to 0 °C. PCl3 (2 M in CH2Cl2, 
1.2 eq.) was added dropwise via syringe pump over 30 min. The resulting slurry was 
stirred at 0 °C for 30 min, then allowed to warm to r.t. and stirred for 3 h. After 
cooling to 0 °C, the corresponding (R,R)-TADDOL or (S,S)-BINOL (1.5 eq.), 
dissolved in CH2Cl2 (0.2 M), was added dropwise via syringe pump over 30 min. The 
resulting suspension was stirred for 30 min at 0 °C, then for 20 h at r.t.. The reaction 
mixture was filtered over silica gel and, after concentration of the filtrate by rotary 
evaporation, the crude product was purified by flash column chromatography on silica 
gel to give desired ligand as white foam. 
 
(3aR,8aR)-6-(2-(diphenylphosphanyl)phenoxy)-2,2-dimethyl-4,4,8,8-
tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30a)  
According to general procedure, the borane-protected phosphine 34a (1.17 g, 4.0 
mmol, 1.0 eq.) and DABCO (3.59 g, 32.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 2.4 mL, 4.8 mmol, 1.2 eq.) and the (R,R)-Taddol 145 a (2.80 g, 6.0 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (10:1 cyclohexane/EtOAc) to yield the ligand 30a (2.01 g, 
65%) as white foam. 
 
M (C49H42O5P2): 772.82 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.58-7.47 (m, 4H), 7.46-7.39 (m, 2H), 7.35-7.14 (m, 
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25H), 7.00-6.91 (m, 2H), 6.70-6.55 (m, 1H), 5.18 (d, J = 8.7 Hz, 1H), 5.11 (d, J = 8.7 
Hz, 1H), 0.93(s, 3H), 0.37 (s, 3H). 
IR (ATR) 
~  [cm-1] = 3084, 3052, 2986, 2932, 1713, 1690, 1593, 1580, 1566, 1493, 
1465, 1447, 1433, 1380, 1370, 1350, 1318, 1214, 1165, 1088, 1050, 1032, 1011, 975, 
886, 848, 767, 740, 722, 693. 
 
(3aR,8aR)-6-(2-(diphenylphosphanyl)-6-methylphenoxy)-2,2-dimethyl-4,4,8,8-
tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30b) 
According to general procedure, the borane-protected phosphine 34b (1.22 g, 4.0 
mmol, 1.0 eq.) and DABCO (3.59 g, 32.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 2.4 mL, 4.8 mmol, 1.2 eq.) and the (R,R)-Taddol 145a (2.80 g, 6.0 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (30:1 cyclohexane/EtOAc) to yield the ligand 30b (1.92 g, 
61%) as white foam. 
 
M (C50H44O5P2): 786.84 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.61-7.47 (m, 3H), 7.36-7.30 (m, 4H), 7.27-7.01 (m, 
24H), 6.91-6.81 (m, 1H), 6.61-6.55 (m, 1H), 5.06 (m, 2H), 2.28 (s, 3H), 0.96(s, 3H), 
0.35 (s, 3H). 
IR (ATR) 
~  [cm-1] = 3059, 2992, 2967, 2938, 2869, 1599, 1587, 1593, 1495, 1449, 
1436, 1380, 1372, 1350, 1338, 1264, 1254, 1208, 1183, 1166, 1088, 1050, 1033, 1017, 
933, 886, 848, 769, 740, 722, 697. 
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(3aR,8aR)-6-(2-(diphenylphosphanyl)-6-ethylphenoxy)-2,2-dimethyl-4,4,8,8-
tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30c) 
According to general procedure, the borane-protected phosphine 34c (1.28 g, 4.0 
mmol, 1.0 eq.) and DABCO (3.59 g, 32.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 2.4 mL, 4.8 mmol, 1.2 eq.) and the (R,R)-Taddol 145a (2.80 g, 6.0 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (30:1 cyclohexane/EtOAc) to yield the ligand 30c (1.83 g, 
57%) as white foam. 
 
M (C51H46O5P2): 800.87 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.76 (d, J = 7.8 Hz, 2H), 7.61-7.50 (m, 6H), 7.33-
7.27 (m, 15H), 7.23-7.17 (m, 8H), 7.01 (t, J =7.8 Hz, 1H), 6.73 (d, J = 7.8 Hz, 1H), 
5.19 (s, 2H), 2.97 (m, 1H), 2.78 (m, 1H), 1.18 (t, J =7.5Hz, 3H)1.12(s, 3H), 0.45 (s, 
3H). 
13
C NMR (75 MHz, CDCl3): δ = 153.8, 153.7, 146.0, 145.7, 141.8, 141.3, 137.7, 
137.7, 137.6, 137.5, 137.0, 134.2, 134.1, 134.0, 133.9, 132.7, 130.5, 131.2, 129.5, 
129.3, 128.6, 128.4, 128.3, 127.9, 127.8, 127.6, 127.5, 127.3, 124.8, 112.9, 85.7, 85.6, 
83.2, 83.1, 82.4, 82.2, 81.6, 81.5, 27.6, 26.1, 24.1, 14.5. 
IR (ATR) 
~  [cm-1] = 3053, 2960, 2938, 2873, 1619, 1587, 1509, 1465, 1449, 1435, 
1365, 1353, 1328, 1264, 1234, 1204, 1189, 1105, 1070, 1036, 1019, 958, 898, 852, 
785, 743, 697. 
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(3aR,8aR)-6-(2-(diphenylphosphanyl)-6-isopropylphenoxy)-2,2-dimethyl-4,4,8,8-
tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30d) 
According to general procedure, the borane-protected phosphine 34d (1.34 g, 4.0 
mmol, 1.0 eq.) and DABCO (3.59 g, 32.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 2.4 mL, 4.8 mmol, 1.2 eq.) and the (R,R)-Taddol 145a (2.80 g, 6.0 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (30:1 cyclohexane/EtOAc) to yield the ligand 30d (2.31 g, 
71%) as white foam. 
 
M (C52H48O5P2): 814.90 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.62-7.49 (m, 3H), 7.38-7.23 (m, 12H), 7.20-7.04 
(m, 16H), 6.92 (m, 1H), 6.61 (m, 1H), 5.07 (m, 2H), 3.64 (m, 1H), 1.08 (d, J =6.6Hz, 
3H), 1.01 (d, J =6.6Hz, 3H), 0.97(s, 3H), 0.35 (s, 3H). 
IR (ATR) 
~  [cm-1] = 3056, 2990, 2965, 2933, 2870, 1600, 1587, 1496, 1449, 1435, 
1365, 1383, 1371, 1338, 1264, 1254, 1208, 1181, 1165, 1090, 1048, 1035, 1019, 933, 
888, 769, 738, 697. 
 
 (3aR,8aR)-6-((3-(diphenylphosphanyl)-[1,1'-biphenyl]-2-yl)oxy)-2,2-dimethyl-
4,4,8,8-tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30e) 
According to general procedure, the borane-protected phosphine 34e (1.47 g, 4.0 
mmol, 1.0 eq.) and DABCO (3.59 g, 32.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 2.4 mL, 4.8 mmol, 1.2 eq.) and the (R,R)-Taddol 145a (2.80 g, 6.0 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
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by column chromatography (40:1 cyclohexane/EtOAc) to yield the ligand 30e (1.66 g, 
49%) as white foam. 
 
M (C55H46O5P2): 848.92 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.54-7.50 (m, 2H), 7.45-7.42 (m, 2H), 7.35-7.05 (m, 
31H), 6.89-6.83 (m, 3H), 4.97 (m, 2H), 0.93 (s, 3H), 0.33 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 145.7, 145.4, 145.3, 140.7, 138.4, 137.3, 134.4, 
134.0, 133.7, 132.7, 131.1, 131.0, 128.8, 128.7, 128.5, 128.4, 128.3, 127.6, 127.5, 
127.0, 124.8, 113.1, 85.9, 82.9, 82.1, 81.4, 27.2, 25.3. 
IR (ATR) 
~  [cm-1] = 3053, 3025, 2986, 2934, 1954, 1812, 1736, 1601, 1587, 1496, 
1445, 1435, 1405, 1385, 1370, 1244, 1214, 1189, 1165, 1090, 1034, 978, 888, 765, 
740, 697. 
 
(3aR,8aR)-6-(2-(tert-butyl)-6-(diphenylphosphanyl)phenoxy)-2,2-dimethyl-
4,4,8,8-tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30f) 
 
According to general procedure, the borane-protected phosphine 34f (1.39 g, 4.0 
mmol, 1.0 eq.) and DABCO (3.59 g, 32.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 2.4 mL, 4.8 mmol, 1.2 eq.) and the (R,R)-Taddol 145a (2.80 g, 6.0 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (4:1 cyclohexane/CH2Cl2) to yield the ligand 30f (1.56 g, 
47%) as white foam. 
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M (C53H50O5P2): 828.93 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.54-7.30 (m, 10H), 7.23-7.16 (m, 13H), 7.15-7.04 
(m, 8H), 6.95-6.87 (m, 2H), 5.37 (d, J =8.1Hz, 1H), 5.16 (d, J =8.1Hz, 1H), 1.35 (s, 
9H), 0.83 (s, 3H), 0.44 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 145.7, 145.4, 141.8, 141.3, 135.2, 133.5, 133.4, 
133.3, 132.2, 129.3, 129.2, 128.5, 128.4, 128.3, 128.2, 128.1, 127.7, 127.6, 127.5, 
127.3, 127.2, 127.1, 127.0, 123.2, 113.6, 86.2, 83.3, 82.0, 81.2, 35.3, 30.8, 27.2, 26.3. 
IR (ATR) 
~  [cm-1] = 3059, 2958, 1586, 1496, 1448, 1435, 1405, 1385, 1214, 1189, 
1166, 1090, 1050, 979, 907, 886, 850, 810, 799, 767, 730, 697, 667. 
 
(3aR,8aR)-6-(2,4-di-tert-butyl-6-(diphenylphosphanyl)phenoxy)-2,2-dimethyl-
4,4,8,8-tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30g) 
According to general procedure, the borane-protected phosphine 34g (1.62 g, 4.0 
mmol, 1.0 eq.) and DABCO (3.59 g, 32.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 2.4 mL, 4.8 mmol, 1.2 eq.) and the (R,R)-Taddol 145a (2.80 g, 6.0 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (60:1 cyclohexane/EtOAc) to yield the ligand 30g (2.12 g, 
60%) as white foam. 
 
M (C57H58O5P2): 885.03 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.56-7.43 (m,8H), 7.33-7.01 (m, 23H), 6.99-6.90 
(m, 1H), 5.42 (d, J =8.1 Hz, 1H), 5.18 (d, J =8.1 Hz, 1H), 1.37 (s, 9H), 1.09 (s, 9H), 
0.82 (s, 3H), 0.46 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 146.3, 145.7, 145.3, 144.5, 141.8, 141.4, 140.0, 
138.9, 138.4, 138.2, 133.5, 133.2, 133.0, 132.1, 129.2, 128.9, 127.7, 127.7, 127.5, 
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127.4, 127.1, 127.0, 126.0, 113.3, 86.7, 83.2, 81.7, 81.0, 35.7, 34.4, 31.3, 30.7, 27.1, 
26.2. 
IR (ATR) 
~  [cm-1] = 3059, 2963, 1586, 1496, 1478, 1449, 1435, 1420, 1395, 1371, 
1217, 1199, 1090, 1035, 1011, 959, 907, 886, 810, 729, 697. 
 
(3aR,8aR)-6-(2-(diphenylphosphanyl)-6-(tert-pentyl)phenoxy)-2,2-dimethyl-
4,4,8,8-tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30h) 
 
According to general procedure, the borane-protected phosphine 34h (1.81 g, 5.0 
mmol, 1.0 eq.) and DABCO (4.49 g, 40.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 3.0 mL, 6.0 mmol, 1.2 eq.) and the (R,R)-Taddol 145a (3.38 g, 7.25 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (4:1 cyclohexane/CH2Cl2) to yield the ligand 30h (2.28 g, 
60%) as white foam. 
 
M (C54H52O5P2): 842.95 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.59-7.43 (m,8H), 7.34-7.09 (m, 23H), 6.95-6.88 
(m, 2H), 5.40 (d, J =8.2 Hz, 1H), 5.19 (d, J =8.2 Hz, 1H), 1.97 (q, J =7.2Hz, 2H), 1.43 
(s, 3H), 1.28 (s, 3H), 0.88 (s, 3H), 0.50 (t, J =7.4 Hz, 2H), 0.46 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 156.5, 156.1, 145.8, 145.5, 141.9, 141.8, 141.4, 
139.8, 138.8, 138.6, 138.5, 137.9, 137.8, 135.0, 133.5, 133.4, 133.3, 133.2, 130.5, 
129.2, 129.0, 128.4, 128.3, 128.2, 128.0, 127.7, 127.6, 127.5, 127.4, 127.2, 127.1, 
127.0, 123.2, 113.6, 86.9, 86.7, 83.3, 82.0, 81.8, 81.3, 81.1, 39.2, 33.8, 29.2, 28.9, 
26.3, 9.8. 
31
P-NMR {1H} (121 MHz, CDCl3): δ = 139.4 (d, J = 151.8 Hz), -19.7 (d, J = 151.8 
Hz) 
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IR (ATR) 
~  [cm-1] = 3055, 2960, 2872, 1952, 1814, 1586, 1492, 1478, 1446, 1435, 
1403, 1383, 1271, 1247, 1207, 1167, 1090, 1048, 1033, 1011, 883, 798, 739, 695. 
 
(3aR,8aR)-6-(2-(diphenylphosphanyl)-4,6-di-tert-pentylphenoxy)-2,2-dimethyl-
4,4,8,8-tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (30i) 
According to general procedure, the borane-protected phosphine 34i (2.16 g, 5.0 
mmol, 1.0 eq.) and DABCO (4.49 g, 40.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 3.0 mL, 6.0 mmol, 1.2 eq.) and the (R,R)-Taddol 145a (3.38 g, 7.25 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (4:1 cyclohexane/CH2Cl2) to yield the ligand 30i (2.74 g, 
61%) as white foam. 
 
M (C59H62O5P2): 913.09 g/mol 
1
H NMR (300 MHz, CDCl3): δ = 7.60-7.39 (m, 8H), 7.26-7.00 (m, 23H), 6.85 (s, 1H), 
5.36 (d, J =8.2 Hz, 1H), 5.16 (d, J =8.2 Hz, 1H), 1.92 (q, J =7.0 Hz, 2H), 1.52-1.35 
(m, 5H), 1.29 (s, 3H), 1.05 (s, 3H), 1.03 (s, 3H), 0.85 (s, 3H), 0.54-0.46 (m, 6H,), 0.45 
(s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 153.8, 153.5, 145.6, 145.3, 142.7, 141.7, 141.3, 
139.2, 139.1, 138.8, 138.2, 133.4, 133.3, 133.2, 132.9, 132.6, 129.1, 128.9, 128.1, 
128.0, 127.9, 127.8, 127.6, 127.4, 127.2, 126.9, 126.8, 125.9, 125.8, 113.4, 86.5, 86.4, 
82.9, 81.9, 81.0, 39.2, 37.6, 36.9, 33.8, 28.9, 28.6, 28.4, 26.1, 9.7, 9.0. 
31
P-NMR {1H} (121 MHz, CDCl3): δ = 139.9 (d, J = 148.5 Hz), -18.6 (d, J = 148.5 
Hz) 
IR (ATR) 
~  [cm-1] = 3057, 2961, 2871, 1952, 1808, 1586, 1493, 1449, 1435, 1424, 
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1385, 1210, 1169, 1090, 1051, 1037, 1012, 981, 909, 886, 849, 812, 792, 732, 697. 
 
(11bS)-4-((3-(diphenylphosphanyl)-[1,1'-biphenyl]-2-yl)oxy)dinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepine (30j) 
 
According to general procedure, the borane-protected phosphine 34e (0.74 g, 2.0 
mmol, 1.0 eq.) and DABCO (1.79 g, 16.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 1.2 mL, 2.4 mmol, 1.2 eq.) and the (S)-BINOL (0.859 g, 3.0 mmol, 1.5 
eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (50:1 cyclohexane/EtOAc) to yield the ligand 30j (0.895 
g, 67%) as white foam. 
 
M (C44H30O2P2): 668.67 g/mol 
1
H NMR (300 MHz, CDCl3): δ = 7.98-7.36 (m, 26H), 7.19 (m, 3H), 7.07 (m, 1H). 
31
P NMR (121 MHz, CDCl3): 144.4 (d, J = 43.8 Hz), -16.9 (d, J = 43.8 Hz). 
IR (ATR) 
~  [cm-1] = 3067, 3054, 2961, 2901, 1716, 1619, 1601, 1580, 1495, 1484, 
1450, 1435, 1422, 1345, 1315, 1228, 1190, 1150, 1105, 1066, 1024, 999, 909, 835, 
801, 759, 740, 697, 625. 
 
(11bS)-4-(2,4-di-tert-butyl-6-(diphenylphosphanyl)phenoxy)dinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepine (30k) 
According to general procedure, the borane-protected phosphine 34g (0.81 g, 2.0 
mmol, 1.0 eq.) and DABCO (1.79 g, 16.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 1.2 mL, 2.4 mmol, 1.2 eq.) and the (S)-BINOL (0.859 g, 3.0 mmol, 1.5 
eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
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The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (40:1 cyclohexane/EtOAc) to yield the ligand 30k (1.0 g, 
71%) as white foam. 
 
M (C46H42O2P2): 704.79 g/mol 
1
H NMR (300 MHz, CDCl3): δ = 7.98-7.81 (m, 2H), 7.70 (d, J = 8.7 Hz, 1H), 7.54-
7.30 (m, 17H), 7.29-7.17 (m, 2H), 6.97-6.86 (m, 2H), 1.28 (s, 9H), 1.12 (s, 9H). 
31
P NMR (121 MHz, CDCl3): 142.6 (d, J = 144.9 Hz), -14.9 (d, J = 144.9 Hz). 
IR (ATR) 
~  [cm-1] = 3064, 3052, 2958, 2901, 1714, 1617, 1590, 1509, 1465, 1433, 
1417, 1362, 1325, 1212, 1201, 1156, 1105, 1069, 1024, 979, 956, 915, 865, 849, 822, 
779, 747, 697. 
 
(11bS)-4-(2-(diphenylphosphanyl)-4,6-di-tert-pentylphenoxy)dinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepine (30l) 
 
According to general procedure, the borane-protected phosphine 34i (0.87 g, 2.0 
mmol, 1.0 eq.) and DABCO (1.79 g, 16.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 1.2 mL, 2.4 mmol, 1.2 eq.) and the (S)-BINOL (0.859 g, 3.0 mmol, 1.5 
eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (4:1 cyclohexane/CH2Cl2) to yield the ligand 30l (0.586 g, 
40%) as white foam. 
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M (C48H46O2P2): 732.84 g/mol 
1
H NMR (300 MHz, CDCl3): δ = 7.95-7.81 (m, 3H), 7.69 (d, J = 8.7 Hz, 1H), 7.50-
7.14 (m, 18H), 6.82-6.78 (m, 2H), 1.71-1.55 (m, 2H), 1.44-1.41 (m, 2H), 1.27 (s, 3H), 
1.18 (s, 3 H), 1.08 (s, 3 H), 1.06 (s, 3 H), 0.56 (t, J =7.5Hz, 3H), 0.47 (t, J = 7.5 Hz5). 
31
P NMR (121 MHz, CDCl3): 143.3 (d, J = 146.3 Hz), -14.7 (d, J = 146.3 Hz). 
IR (ATR) 
~  [cm-1] = 3064, 3051, 2958, 2871, 1619, 1589, 1465, 1433, 1420, 1362, 
1327, 1264, 1231, 1201, 1188, 1105, 1070, 979, 956, 899, 851, 822, 783, 747, 697. 
 
(3aR,8aR)-4,4,8,8-tetrakis(3,5-dimethylphenyl)-6-(2-(diphenylphosphanyl)-6-
isopropylphenoxy)-2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-
e][1,3,2]dioxaphosphepine (30m) 
According to general procedure, the borane-protected phosphine 34d (1.10 g, 3.0 
mmol, 1.0 eq.) and DABCO (2.69 g, 40.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 1.8 mL, 3.6 mmol, 1.2 eq.) and the (R,R)-Taddol 145b (2.60 g, 7.25 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (50:1 cyclohexane/EtOAc) to yield the ligand 30m (1.08 
g, 39%) as white foam. 
 
M (C60H64O5P2): 927.11 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.55 (s, 2H), 7.38-6.96 (m, 18H), 6.85-6.79 (m, 4H); 
6.78-6.67 (m, 1H), 4:99 (q, J = 8.1 Hz; 2H;), 3.95 (m, 1H), 2.32-2.17 (m, 18H), 2.14 
(s, 6H), 1.31 (s, 3H), 1.19 (d, J = 6.9 Hz, 6H), 0.38 (s, 3H). 
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13
C NMR (75 MHz, CDCl3): δ = 153.1, 152.8, 146.3, 145.8, 141.8, 141.5, 140.9, 
138.1, 137.9, 137.3, 136.8, 136.6, 136.3, 133.9, 133.7, 133.6, 132.5, 130.7, 130.6, 
129.4, 128.9, 128.4, 128.3, 128.2, 127.7, 127.3, 127.0, 125.3, 125.2, 124.8, 124.6, 
123.9, 112.2, 84.2, 83.2, 82.9, 82.7, 82.6, 27.9, 27.1, 26.0, 23.2, 22.0, 21.8. 
31
P-NMR {1H} (121 MHz, CDCl3): δ = 150.0 (d, J = 73.6 Hz), -18.1 (d, J = 73.6 Hz). 
IR (ATR) 
~  [cm-1] = 3093, 2914, 2862, 2243, 1944, 1792, 1601, 1452, 1431, 1416, 
1379, 1334, 1244, 1214, 1147, 1080, 1070, 1040, 904, 884, 853, 800, 758, 724, 687. 
 
 (3aR,8aR)-4,4,8,8-Tetrakis(3,5-dimethylphenyl)-6-((3-(diphenylphosphanyl)-
[1,1'-biphenyl]-2-yl)oxy)-2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-
e][1,3,2]dioxaphosphepine (30n) 
According to general procedure, the borane-protected phosphine 34e (1.93 g, 5.0 
mmol, 1.0 eq.) and DABCO (4.49 g, 40.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 3.0 mL, 6.0 mmol, 1.2 eq.) and the (R,R)-Taddol 145b (4.20 g, 7.25 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (50:1 cyclohexane/EtOAc) to yield the ligand 30n (0.91 g, 
19%) as white foam. 
 
M (C63H62O5P2): 961.13 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 7.53-7.46 (m, 3H), 7.44-7.04 (m, 16H), 6.97-6.75 
(m, 11H), 4.79 (s, 2H), 2.26 (s, 12H), 2.23 (s, 6H), 2.16 (s, 6H), 1.35 (s, 3H), 0.18 (s, 
3H). 
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13
C NMR (75 MHz, CDCl3): δ = 151.8, 151.5, 146.1, 145.5, 140.7, 140.5, 139.0, 
137.9, 137.7, 137.0, 136.8, 136.6, 136.1, 135.9, 134.2, 134.1, 133.8, 133.7, 132.8, 
132.4, 131.1, 129.1, 128.9, 128.6, 128.5, 128.4, 128.2, 127.4, 127.2, 127.0, 126.8, 
125.7, 125.2, 124.9, 117.9, 112.1, 83.5, 83.3, 83.2, 83.0, 82.7, 82.6, 27.8, 25.6, 22.0, 
21.9. 
31
P-NMR {1H} (121 MHz, CDCl3): δ = 150.4 (d, J = 59.1 Hz), -17.1 (d, J = 59.1 Hz). 
IR (ATR) 
~  [cm-1] = 3047, 2917, 2865, 2247, 1949, 1888, 1796, 1605, 1449, 1435, 
1406, 1385, 1246, 1215, 1162, 1085, 1070, 1042, 941, 909, 887, 856, 805, 762, 726, 
691. 
 
(3aR,8aR)-6-(2,4-di-tert-butyl-6-(diphenylphosphanyl)phenoxy)-4,4,8,8-
tetrakis(3,5-dimethylphenyl)-2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-
e][1,3,2]dioxaphosphepine (30o) 
According to general procedure, the borane-protected phosphine 34g (1.21 g, 3.0 
mmol, 1.0 eq.) and DABCO (2.69 g, 40.0 mmol, 8.0 eq.) were reacted with PCl3 (2 M 
in CH2Cl2, 1.8 mL, 3.6 mmol, 1.2 eq.) and the (R,R)-Taddol 145b (2.60 g, 7.25 mmol, 
1.5 eq.). The reaction mixture was filtered over SiO2 to remove the precipitated solids. 
The solvents were removed under reduced pressure and the raw product was purified 
by column chromatography (40:1 cyclohexane/EtOAc) to yield the ligand 30o (1.77 g, 
59%) as white foam. 
 
M (C65H74O5P2): 997.25 g/mol 
1
H NMR (300 MHz, CDCl3): δ = 7.52 (s, 2H), 7.41 (d, J = 2.4 Hz, 1H), 7.22-6.75 (m, 
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21H), 5.15-4.99 (m, 2H), 2.29 (s, 6H), 2.24 (s, 6H), 2.20 (s, 6H), 2.09 (s, 6H), 1.57 (s, 
9H), 1.23 (s, 3H), 1.14 (s, 9H), 0.37 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 153.8, 153.5, 146.1, 144.7, 141.7, 141.1, 140.1, 
139.6, 137.1, 137.0, 136.6, 136.3, 136.1, 133.7, 133.2, 132.0, 129.3, 129.1, 128.8, 
128.5, 128.2, 128.1, 127.9, 127.8, 127.7, 126.8, 127.6, 127.5, 127.2, 126.9, 126.3, 
125.7, 125.2, 124.6, 124.0, 112.5, 86.5, 84.5, 83.1, 82.8, 82.7, 35.9, 34.7, 31.6, 31.4, 
27.8, 26.1, 21.8, 21.7. 
31
P-NMR {1H} (121 MHz, CDCl3): δ = 145.3 (d, J = 159.6 Hz), -19.4 (d, J = 159.6 
Hz). 
IR (ATR) 
~  [cm-1] = 3097, 2961, 2916, 2867, 2729, 1888, 1746, 1605, 1465, 1437, 
1423, 1394, 1374, 1239, 1218, 1162, 1108, 1085, 070, 1046, 946, 923, 905, 887, 856, 
805, 747, 724, 691. 
 
5.3. Synthesis of 2-(1-alkynyl)-2-alken-1-ones 
5.3.1. Synthesis of (Z)-2-bromo-3-(4-methoxyphenyl)acrylaldehyde
 
 
To a solution of 4-methoxycinnamaldehyde (147b, 16.22g, 100 mmol, 1.0 eq.) in 130 
mL dichloromethane, was added 6.23 mL Br2 (120 mmol, 1.2 eq.) in 10 min. at 0 ºC. 
The reaction mixture was stirred for 15 min. followed by the addition of Et3N (23.75 
mL, 170 mmol, 1.7 eq.). The resulting mixture was stirred 15 min at 0 ºC, then was 
diluted with dichloromethane and washed with a 10% NaHSO3 solution, H2O, and 
brine. The organic layer was dried over Na2SO4, filtered, and concentrated to yield an 
orange oil. The mixture was pushed through a plug of SiO2 with dichloromethane to 
yield a 1:1 mixture of Z/E isomers as a yellow oil. After 3 days at room temperature, 
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the mixture crystallized completely as the isomerized desired Z isomer to give 21.94 g 
(91%) of (Z)-2-bromo-3-(4-methoxyphenyl)acrylaldehyde as a yellow solid.  
 
 
M (C10H9BrO2): 241.08 g/mol. 
1
H NMR (300 MHz, CDCl3): δ = 9.29 (s, 1H), 8.03 (d, J = 8.7 Hz, 2H), 7.81 (s, 1H), 
7.01 (d, J = 8.7 Hz, 2H), 3.88 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 187.1, 162.4, 149.2, 133.4, 125.6, 121.7, 114.3, 55.6. 
The purity and identity of the literature known product was unambiguously 
confirmed.
131
 
5.3.2. Synthesis of 2-alkynyl cinnamaldehydes (149a-d) via 
Sonogashira coupling 
 
 
Synthesis of (E)-2-benzylidene-4-phenylbut-3-ynal (149a) 
A flame-dried 250 mL round bottom flask was charged with Pd(PPh3)4 (144.4 mg, 
1.25 mmol, 0.25 mol%) and CuI (119.0 mg, 12.5 mmol, 1.25 mol%). To this was 
added freshly distilled THF (50 mL) and Et3N (50 mL). The mixture was set stirring 
and (Z)-α-bromocinnamaldehyde (10.6 g, 50 mmol, 1.0 eq.) was added. Finally 
phenylacetylene (6.1g, 60 mmol, 1.2 eq.) was added dropwise by using a syringe over 
30 min. Then the mixture was stirred overnight at room temperature. After the starting 
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material was consumed, the mixture was quenched with NH4Cl aqueous. Ether was 
added and the reaction mixture transferred to a separatory funnel. The organic residue 
was isolated, the aqueous layer back extracted with ether, combined the organic layer, 
and the solvent was removed in vacuo. The crude residue was purified by flash 
chromatography (Cyclohexane/EtOAc 10:1) to afford desired product (E)-2-
benzylidene-4-phenylbut-3-ynal (11.034g, 95%) as yellow oil. The spectroscopic data 
are in agreement with that previously reported.
123 
 
M (C17H12O): 232.28 g/mol. 
Rf (Cyclohexane/EtOAc = 4:1) = 0.39. 
1
H NMR (300 MHz, CDCl3): δ = 9.48 (s, 1H), 8.14-8.09 (m, 1H), 7.60-7.52 (m, 3H), 
7.53 (s, 1H), 7.49-7.34 (m, 6H). 
13
C NMR (75 MHz, CDCl3) δ = 191.0, 151.2, 134.2, 132.2, 131.7, 130.8, 129.3, 
129.06, 128.6, 122.8, 122.7, 101.0, 83.1. 
 
Synthesis of (E)-2-(4-methoxybenzylidene)-4-phenylbut-3-ynal (149b) 
Compound 149b was prepared from (Z)-2-bromo-3-(4-methoxyphenyl)acrylaldehyde 
(12.054 g, 50 mmol, 1.0 eq.) and phenylacetylene (6.1 g, 60 mmol, 1.2 eq.) according 
to the similar method for 149a. Yellow oil, 12.07 g, 92%. 
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M (C18H14O2): 262.31 g/mol. 
Rf (Cyclohexane/EtOAc = 5:1) = 0.30. 
1
H NMR (300 MHz, CDCl3): δ = 9.56 (s, 1H), 8.13-8.10 (m, 2H), 7.61-7.56 (m, 2H), 
7.48 (s, 1H), 7.39-7.35 (m, 3H), 6.97-6.90 (m, 2H), 3.87 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 191.1, 162.3, 151.4, 132.7, 131.5, 128.8, 128.3, 
127.0, 122.6, 120.1, 116.1, 114.6, 114.2, 100.2, 83.4, 55.5. 
The purity and identity of the literature known product was unambiguously 
confirmed.
132
 
 
Synthesis of (E)-2-benzylidenehept-3-ynal (149c) 
Compound 149c was prepared from (Z)-α-bromocinnamaldehyde (8.44 g, 40 mmol, 
1.0 eq.) and n-propylacetylene (3.27 g, 48 mmol, 1.2 eq.) according to the similar 
method for 149a. Yellow oil, 6.50 g, 82%. 
 
 
M (C14H14O): 198.27 g/mol. 
Rf (Cyclohexane/EtOAc = 10:1) = 0.25. 
1
H NMR (300 MHz, CDCl3): δ = 9.52 (s, 1H), 8.10-8.08 (m, 2H), 7.44-7.38(m, 4H), 
2.54-2.49 (t, J = 7.2 Hz, 2H), 1.71-1.64 (t, J = 7.2, 14.4 Hz, 2H), 1.10-1.05 (t, J = 7.2 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 191.3, 150.6, 134.0, 131.0, 128.3, 123.2, 103.1, 74.3, 
21.6, 13.3. 
The purity and identity of the literature known product was unambiguously 
confirmed.
133 
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Synthesis of (E)-2-benzylideneoct-3-ynal (149d) 
Compound 149d was prepared from (Z)-α-bromocinnamaldehyde (8.44 g, 40 mmol, 
1.0 eq.) and n-butylacetylene (3.94 g, 48 mmol, 1.2 eq.) according to the similar 
method for 149a. Yellow oil, 6.71 g, 79%. 
 
M (C15H16O): 212.29 g/mol. 
Rf (cyclohexane/EtOAc = 10:1) = 0.26. 
1
H NMR (300 MHz, CDCl3): δ = 9.56 (s, 1H), 8.13-7.41 (m, 6H), 2.59 (t, J = 7.2 Hz, 
2H), 1.71-1.49 (m, 4H), 0.98 (t, J = 7.5 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 191.7, 150.9, 134.4, 131.3, 130.4, 128.6, 123.6, 
103.4, 74.5, 30.6, 22.1, 19.9, 13.5. 
The purity and identity of the literature known product was unambiguously 
confirmed.
134  
5.3.3. Synthesis of 2-(1-alkynyl)-2-alken-1-ones 
 
 
 
Synthesis of (3E)-3-benzylidene-5-phenylpent-4-yn-2-one (146a) 
This 2-(1-alkynyl)-2-alken-1-one was prepared from (E)-2-benzylidene-4-phenylbut-
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3-ynal (149a) by following a procedure from the literature.
101
 4.646g 149a (20 mmol, 
1.0 eq.) was dissolved in dry THF (45 mL), the resulting solution was cooled to -
78 °C. Then the mixture was added MeLi (1.6 M in diethyl ether, 13.2 mL, 21 mmol, 
1.05 eq.). The resulting mixture was stirred at the same temperature for 30 min and 
quenched with satd aq. NH4Cl (30 mL). The mixture was extracted with Et2O (180 
mL). The organic layer was washed with brine (20 mL), dried over anhydrous MgSO4, 
concentrated under reduced pressure. The above compound was dissolved in dry THF 
(250 mL). To this solution was added MnO2 (34.77 g, 400 mmol, 20 eq.), followed by 
stirring at room temperature for overnight. The reaction mixture was filtered through 
a short pad of Celite with rinsing by EtOAc. The combined organic layer was 
concentrated under reduced pressure, and the residue was purified by flash column 
chromatography (silica gel, cyclohexane/EtOAc 20:1) to afford 2.51 g 146a (51% 
over two steps) as a yellow solid. 
 
 
M (C18H14O): 246.31 g/mol. 
Mp: 62.8-63.7 °C. 
Rf (cyclohexane/EtOAc = 9:1) = 0.55. 
1
H NMR (300 MHz, CDCl3): δ = 8:13 (d, J = 7.5 Hz, 2H), 7.85 (s, 1H), 7.60-7.56 (m, 
2H), 7.47-7.41 (m, 6H), 2.65 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 196.2, 143.0, 134.5, 131.4, 130.8, 128.9, 128.6, 
122.8, 120.0, 99.1, 87.0, 28.2. 
The purity and identity of the literature known product was unambiguously 
confirmed.
101 
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Synthesis of (E)-3-(4-methoxybenzylidene)-5-phenylpent-4-yn-2-one (146b) 
Compound 146b was prepared from (E)-2-(4-methoxybenzylidene)-4-phenylbut-3-
ynal (10.49 g, 40 mmol, 1.0 eq.) according to the similar method for 146a. Light 
yellow solid, 6.85 g, 62%. 
 
M (C19H16O2): 276.34 g/mol. 
Rf (cyclohexane/EtOAc = 9:1) = 0.47. 
1
H NMR (300 MHz, CDCl3): δ = 8.12 (d, J = 9.0 Hz, 2H), 7.82 (s, 1H), 7.61-7.55 (m,  
2H), 7.44-7.41 (m, 3H), 6.99 (s, 1H), 6.66 (s, 1H), 3.88 (s, 3H), 2.62 (s, 3H).  
13
C NMR (75 MHz, CDCl3) δ = 196.4, 161.7, 142.7, 132.8, 131.3, 128.7, 128.6, 
127.4, 117.4, 98.7, 87.5, 55.4, 28.1. 
 
Synthesis of (E)-3-benzylideneoct-4-yn-2-one (146c) 
Compound 146c was prepared from (E)-2-benzylidenehept-3-ynal 149c (0.634 g, 3.2 
mmol, 1.0 eq.) according to the similar method for 146a. Yellow oil, 0.394 g, 58%. 
 
M (C15H16O): 212.49 g/mol. 
Rf (cyclohexane/EtOAc = 25:1) = 0.25. 
1
H NMR (300 MHz, CDCl3): 8.10-8.09 (m, 2H), 7.68 (s, 1H), 7.43-7.30(m, 3H), 2.55 
(t, J = 6.9 Hz, 2H), 2.53 (s, 3H) 1.74-1.61 (m, 2H), 1.03 (t, J = 7.2 Hz, 3H). 
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13
C NMR (75 MHz, CDCl3) δ = 196.9, 146.3, 135.0, 131.7, 131.4, 129.3, 122.1, 
103.1, 77.3, 31.5, 28.9, 24.8, 15.1. 
 
Synthesis of (E)-3-benzylidenenon-4-yn-2-one (146d) 
Compound 146d was prepared from (E)-2-benzylideneoct-3-ynal 149d (4.245 g, 20 
mmol, 1.0 eq.) according to the similar method for 146a. Yellow oil, 2.49 g, 55%. 
 
M (C16H18O): 226.32 g/mol. 
Rf (cyclohexane/EtOAc = 10:1) = 0.28. 
1
H NMR (300 MHz, CDCl3): δ = 8.10-8.00 (m, 2H), 7.70 (s, 1H), 7.42-7.31 (m, 3H), 
2.53 (t, J = 6.6 Hz, 2H), 2.51 (s, 3H), 1.70-1.45 (m, 4H), 0.97 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 196.8, 141.6, 134.6, 130.4, 130.3, 128.4, 120.7, 
101.2, 78.1, 30.4, 27.9, 22.1, 19.6, 13.6. 
5.4. Synthesis of pyrazolidin-3-one ylides 
General procedure for the synthesis of pyrazolidin-3-one ylides 
All pyrazolidin-3-one ylides were prepared following the reported procedures from 
the corresponding aldehydes.
125, 126
 
 
EXPERIMENTAL SECTION 
124 
 
To a solution of hydrazine monohydrate (717.5 mmol, 35 mL) in 300 mL of ethanol 
was added dropwise methylacrylate (787.5 mmol, 70 mL). After addition, the mixture 
was heated to reﬂux for 9 h. Then the solvent and the volatile components were 
removed under reduced pressure gave to crude pyrazolidin-3-one as a colorless oil in 
85% yield.  
 
The aldehyde (1.0 eq.) was added to a solution of pyrazolidin-3-one (1.2 eq.) in 
MeOH (approx. 1.5 M ). The resulting mixture was stirred for 10-24 h (depending on 
TLC monitor) at room temperature. After removing the solvent under vacuum, the 
crude product was recrystallized in hot ethanol to afford desired pyrazolidin-3-one 
ylides. 
 
Benzylidene-5-oxopyrazolidin-2-ium-1-ide (138a). Benzaldehyde (80 mmol, 8.489g) 
was added to a solution of pyrazolidin-3-one (96 mmol) in 60 mL MeOH. The 
resulting mixture was stirred for 24 h at room temperature. After removing the solvent 
under vacuum, the crude product was recrystallized in hot ethanol to afford desired 
138a as a white solid (10.59 g, 76%). 
 
 
M (C10H10N2O): 174.20 g/mol. 
1
H NMR (CDCl3, 300MHz): δ = 8.30-8.28 (m, 2H), 7.47-7.46 (m, 3H), 7.13 (s, 1H), 
4.53-4.47 (m, 2H), 2.82-2.79 (m, 2H).  
13
C NMR (CDCl3, 75 MHz): δ = 184.7, 132.6, 131.8; 131.7, 130.2, 128.7, 58.2, 29.7. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
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2-(4-Methoxybenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138b). Compound 138b 
was prepared from pyrazolidin-3-one and p-anisaldehyde (20 mmol) according to the 
method for 138a. White solid, 2.90 g, 71%. 
 
M (C11H12N2O2): 204.23 g/mol. 
1
H NMR (CDCl3, 300 MHz): δ = 8.29 (d, J = 8.7 Hz, 2H), 7.82 (d, J = 8.6 Hz, 2H), 
7.13 (s, 1H), 4.57 (t, J = 8.1 Hz, 2H), 3.88 (s, 3H), 2.92 (t, J = 8.2 Hz, 2H). 
13
C NMR (CDCl3, 75 MHz): δ = 184.6, 162.1, 133.5, 132.8, 121.7, 114.2, 57.1, 55.3, 
29.6. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
 
 
2-(4-Methoxybenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138c). Compound 138c 
was prepared from pyrazolidin-3-one and m-anisaldehyde (20 mmol) according to the 
method for 138a. White solid, 2.82 g, 69%. 
 
 
M (C11H12N2O2): 204.23 g/mol. 
1
H NMR(CDCl3, 300 MHz): δ = 8.08 (t, J = 2.2 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 
7.36 (t, J = 8.2 Hz, 2H), 7.07 (s, 1H), 4.52 (t, J = 8.2 Hz, 2H), 3.88 (s, 3H), 2.83 (t, J = 
8.2 Hz, 2H). 
13
C NMR (CDCl3, 75 MHz): δ = 184.9, 159.8, 132.8, 130.5, 129.7, 118.2, 115.8, 58.1, 
55.4, 29.5. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126 
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2-(2-Methoxybenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138d). Compound 138d 
was prepared from pyrazolidin-3-one and o-anisaldehyde (20 mmol) according to the 
method for 138a. White solid, 2.74 g, 67%. 
 
M (C11H12N2O2): 204.23 g/mol. 
1
H NMR (CDCl3, 300 MHz): δ = 9.22 (dd, J = 1.7, 8.2 Hz, 1H), 7.65 (s, 1H), 7.44-
7.42 (m, 1H), 7.08 (dd, J = 8.2, 7.9 Hz, 2H), 6.93 (t, J = 8.5 Hz, 1H), 4.55-4.46 (m, 
2H), 3.91 (s, 3H), 2.86-2.77 (m, 2H). 
13
C NMR (CDCl3, 75 MHz): δ = 184.9, 158.1, 133.3, 132.8, 127.8, 118.2, 110.1, 58.2, 
55.6, 29.3. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
 
 
2-(4-Fluorobenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138e). Compound 138e 
was prepared from pyrazolidin-3-one and 4-fluorobenzaldehyde (30 mmol) according 
to the method for 138a. White solid, 4.44 g, 77%. 
 
M (C10H9FN2O): 192.19 g/mol. 
1
H NMR (CDCl3, 300 MHz): δ = 8.39-8.31 (m, 2H), 7.16 (t, J = 8.7 Hz, 2H), 7.10 (s, 
1H), 4.53 (t, J = 8.3 Hz, 2H), 2.82 (t, J = 8.2 Hz, 2H). 
13
C NMR (CDCl3, 75 MHz): δ = 184.9, 158.1, 164.7, 134.0, 131.3, 125.8, 116.1, 58.2, 
57.8, 29.3. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
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2-(4-Chlorobenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138f). Compound 138f 
was prepared from pyrazolidin-3-one and 4-chlorobenzaldehyde (30 mmol) according 
to the method for 138a. White solid, 4.01g, 64%. 
 
 
M (C10H9ClN2O): 208.65 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 9.14-9.09 (m, 1H), 7.74 (s, 1H), 7.64-7.59 (m, 
1H), 7.56-7.47 (m, 2H), 4.69 (t, J = 8.7 Hz, 2H), 2.59 (t, J = 8.1 Hz, 2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 185.4, 133.7, 132.6, 132.2, 130.4, 127.8, 127.9, 
126.6, 59.0, 29.4. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
 
 
2-(4-Bromobenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138g). Compound 138g 
was prepared from pyrazolidin-3-one and 4-bromobenzaldehyde (30 mmol) according 
to the method for 138a. Yellow solid, 4.63 g, 61%. 
 
 
M (C10H9BrN2O): 253.10 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 8.24 (t, J = 8.7 Hz, 2H), 7.75 (t, J = 8.7 Hz, 2H), 
7.67 (s, 1H), 4.55 (t, J = 7.8 Hz, 2H), 2.57 (t, J = 7.9 Hz, 2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 184.9, 133.0, 132.3, 131.0, 129.7, 124.8, 58.2, 
29.5. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
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2-(4-Nitrobenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138h). Compound 138h was 
prepared from pyrazolidin-3-one and 4-nitrobenzaldehyde (30 mmol) according to the 
method for 138a. Yellow solid, 4.27g, 65%. 
 
 
M (C10H9N3O3): 219.20 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 8.50 (t, J = 8.8 Hz, 2H), 7.36 (d, J = 8.9 Hz, 2H), 
7.83 (s, 1H), 4.67 (t, J = 7.8 Hz, 2H), 2.61 (t, J = 8.0 Hz, 2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 185.8, 147.8, 136.1, 131.9, 129.3, 124.4, 58.8, 
29.3. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
 
 
2-(4-Methylbenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138i). Compound 138i 
was prepared from pyrazolidin-3-one and 4-methylbenzaldehyde (30 mmol) 
according to the method for 138a. White solid, 3.22g, 57%. 
 
 
M (C11H12N2O): 188.23 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 8.17 (d, J = 8.1 Hz, 2H), 7.58 (s, 1H), 7.35 (d, J 
= 8.2 Hz, 2H), 4.53 (t, J = 8.0 Hz, 2H), 2.55 (t, J = 8.3 Hz, 2H), 2.37 (s, 3H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 184.9, 141.9, 132.8, 131.3, 129.7, 127.4, 57.4, 
29.6, 21.4. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
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2-(4-t-Butylbenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138j). Compound 138j 
was prepared from pyrazolidin-3-one and 4-tert-butylbenzaldehyde (20 mmol) 
according to the method for 138a. White solid, 2.49 g, 54%. 
 
 
M (C14H18N2O): 230.31 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 8.20 (d, J = 8.7 Hz, 2H), 7.62 (s, 1H), 7.57 (d, J 
= 8.7 Hz, 2H), 4.54 (t, J = 8.1 Hz, 2H), 2.58-2.52 (m, 2H), 1.30 (s, 9H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 184.7, 154.6, 132.85, 131.3, 127.8, 126.0, 57.6, 
35.3, 31.3, 29.8. 
 
2-(4-Hydroxybenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138k). Compound 138k 
was prepared from pyrazolidin-3-one and 4-hydroxybenzaldehyde (20 mmol) 
according to the method for 138a. Brown solid, 2.02 g, 53%. 
 
 
M (C10H10N2O2): 190.20 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 10.37 (s, 1H), 8.16 (d, J = 8.7 Hz, 2H), 7.52 (s, 
1H), 6.91 (d, J = 9.0 Hz, 2H), 4.48 (t, J = 7.8 Hz, 2H), 2.54-2.50 (m, 2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 184.1, 160.7, 133.9, 133.2, 121.2, 116.1, 57.0, 
30.0. 
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2-(4-Cyanobenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138l). Compound 138l was 
prepared from pyrazolidin-3-one and 4-cyanobenzaldehyde (5 mmol) according to the 
method for 138a. Off-white solid, 0.73 g, 73%. 
 
 
 
M (C11H9N3O): 199.21 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 8.43 (d, J = 8.7 Hz, 2H), 7.99 (d, J = 8.4 Hz, 
2H), 7.62 (s, 1H), 4.63 (t, J = 7.5 Hz, 2H), 2.60 (t, J = 8.1 Hz, 2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 185.4, 134.3, 133.0, 131.3, 129.7, 119.0, 58.6, 
29.4. 
 
2-(3-Nitrobenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138m). Compound 138m 
was prepared from pyrazolidin-3-one and 3-nitrobenzaldehyde (20 mmol) according 
to the method for 138a. Yellow solid, 2.85g, 65%. 
 
 
M (C10H9N3O3): 219.20 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 9.33 (s, 1H), 8.53 (d, J = 8.1 Hz, 1H), 8.33 (d, J 
= 9.6 Hz, 1H), 7.87-7.80 (m, 2H), 4.64 (t, J = 8.4 Hz, 2H), 2.62 (t, J = 8.1 Hz, 2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 185.3, 148.4, 137.0, 131.8, 130.8, 129.5, 125.4, 
125.0,58.4, 29.5. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
 
 
EXPERIMENTAL SECTION 
131 
 
2-(2-Nitrobenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138n). Compound 138n was 
prepared from pyrazolidin-3-one and 3-nitrobenzaldehyde (20 mmol) according to the 
method for 138a. Yellow solid, 2.67g, 61%. 
 
 
M (C10H9N3O3): 219.20 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 9.37 (d, J = 8.4 Hz, 1H), 8.94 (d, J = 8.1 Hz, 
1H), 8.77-8.6 (m, 2H), 8.54 (m, 1H), 5.43 (t, J = 8.4 Hz, 2H), 3.42 (t, J = 8.1 Hz, 2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 185.7, 149.1, 134.7, 132.5, 127.2, 126.0, 125.1, 
59.2, 30.7. 
 
Benzylidene-4-methyl-5-oxopyrazolidin-2-ium-1-ide (138o). Compound 138o was 
prepared from 4-methylpyrazolidin-3-one and benzaldehyde (20 mmol) according to 
the method for 138a. White solid, 2.45 g, 65%. 
 
 
M (C11H12N2O): 188.23 g/mol. 
1
H NMR (d6-DMSO, 300MHz): δ = 8.30-8.26 (m, 2H), 7.63 (s, 1H), 7.51-7.47 (m, 
3H), 4.78-4.69 (m, 1H), 4.22-4.15 (m, 1H), 2.76-2.67 (m, 1H), 1.16 (d, J = 7.3 Hz, 
3H).  
13
C NMR (d6-DMSO, 75 MHz): δ = 187.6, 132.6, 131.5; 131.4, 130.4, 129.1, 64.6, 
35.2, 15.9.  
The purity and identity of the literature known product was unambiguously 
confirmed.
126
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2-(2-Chlorobenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138p). Compound 138p 
was prepared from pyrazolidin-3-one and 2-chlorobenzaldehyde (30 mmol) according 
to the method for 138a. White solid, 3.76 g, 60%. 
 
 
M (C10H9ClN2O): 208.65 g/mol. 
1
H NMR (d6-DMSO, 300 MHz): δ = 8.31 (d, J = 8.4 Hz, 2H), 7.67 (s, 1H), 7.61 (d, J 
= 8.7 Hz, 2H), 4.57 (t, J = 8.1 Hz, 2H), 2.57 (t, J = 7.8 Hz, 2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 185.0, 135.8, 132.9, 130.9, 129.3, 58.0, 29.6. 
The purity and identity of the literature known product was unambiguously 
confirmed.
126
 
 
(Furan-2-ylmethylene)-5-oxopyrazolidin-2-ium-1-ide (138q). Compound 138q was 
prepared from pyrazolidin-3-one and 2-furaldehyde (15 mmol) according to the 
method for 138a. Dark yellow solid, 1.7g, 69%. 
 
 
M (C8H8N2O2): 164.16 g/mol. 
1
H NMR (d6-DMSO, 300MHz): δ = 7.98 (s, 1H), 7.78 (s, 1H), 7.58 (d, J = 3.3 Hz, 
1H), 6.80-6.78 (m, 1H), 4.49 (t, J = 8.1 Hz, 2H), 2.58 (t, J = 8.1 Hz, 2H).  
13
C NMR (CDCl3, 75 MHz): δ = 184.4, 147.0, 146.7, 121.2, 119.4, 113.8, 56.3, 30.4.  
The purity and identity of the literature known product was unambiguously 
confirmed.
126
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2-((5-methylfuran-2-yl)methylene)-5-oxopyrazolidin-2-ium-1-ide (138r). 
Compound 138r was prepared from pyrazolidin-3-one and 5-methylfurfural (30 mmol) 
according to the method for 138a. Dark yellow solid, 3.10 g, 58%. 
 
 
M (C9H10N2O2): 178.19 g/mol. 
1
H NMR (d6-DMSO, 300MHz): δ = 7.69 (s, 1H), 7.51 (d, J = 3.3 Hz, 1H), 6.45 (d, J 
= 3.3 Hz, 1H), 4.44 (t, J = 8.1 Hz, 2H), 2.56 (t, J = 7.8 Hz, 2H), 2.37 (s, 3H)  
13
C NMR (d6-DMSO, 75 MHz): δ = 184.2, 156.7, 145.4, 121.3, 110.6, 56.0, 30.5, 
14.0.  
 
2-(3,5-Dimethoxybenzylidene)-5-oxopyrazolidin-2-ium-1-ide (138s). Compound 
138s was prepared from pyrazolidin-3-one and 3,5-dimethoxybenzaldehyde (15 mmol) 
according to the method for 138a. Off-white solid, 2.42 g, 69%. 
 
 
M (C12H14N2O3): 234.26 g/mol. 
1
H NMR(d6-DMSO, 300 MHz): δ = 7.57 (s, 1H), 7.52 (d, J = 2.1 Hz, 2H), 6.67 (t, J = 
2.1 Hz, 1H), 7.36 (t, J = 8.2 Hz, 2H), 4.55 (t, J = 8.1 Hz, 2H), 3.79 (s, 6H), 2.55 (m, 
2H). 
13
C NMR (d6-DMSO, 75 MHz): δ = 184.8, 160.7, 132.1, 131.9, 109.3, 103.4, 58.1, 
55.9, 29.5. 
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5.5. AuPPh3Cl-catalyzed [3+3]cycloadditions of 2-(1-
alkynyl)-2-alken-1-ones with azomethine imines 
General procedure of the AuPPh3Cl-catalyzed cycloadditions of 2-(1-alkynyl)-2-
alken-1-ones with azomethine imines. 
Under an atmosphere of argon, a flame-dried Schlenk-flask was charged with 
Ph3PAuCl (4.98 mg, 0.01 mmol), AgOTf (2.57 mg, 0.01 mmol) and CH3CN (0.5 mL). 
The resulting mixture was stirred for 1 h. at room temperature. Then the solution of 2-
(1-alkynyl)-2-alken-1-one (0.2 mmol, 1.0 eq.), azomethine imine (0.24 mmol, 1.2 eq.) 
in 1.5 mL CH3CN was added to this mixture. The resulting mixture was stirred for 24 
hours at room temperature. The mixture was passed through a short silica gel column 
and then concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel to afford the corresponding product rac-151. 
5.6. Enantioselective gold(I)-catalyzed [3+3]cycloadditions of 
2-(1-alkynyl)-2-alken-1-ones with azomethine imines 
General procedure for enantioselective gold(I)-catalyzed cycloadditions of 2-(1-
alkynyl)-2-alken-1-ones with azomethine imines 
Under an atmosphere of argon, a flame-dried Schlenk-flask was charged with 
Me2SAuCl (8.83 mg, 0.03 mmol, 10 mol%), corresponding ligand (0.015 mmol, 5 
mol%) and CH2Cl2 (1.0 mL). The resulting mixture was stirred for 2 h at room 
temperature for ligand exchange; then, the CH2Cl2 was removed in vacuo directly on 
the Schlenk-line to yield the catalytically active gold complex. Then a solution of 
AgOTf (3.85 mg, 0.015 mmol, 5 mol%) in 1 mL CH3CN was transferred to the above 
catalyst solution at room temperature, and the resulting mixture was stirred for 30 min. 
at the same temperature. Then, azomethine imine (0.36 mmol) was added into the 
mixture solution and stirred for 10 min. at room temperature. Subsequently, a solution 
of 2-(1-alkynyl)-2-alken-1-one (0.3 mmol, 1.0 eq.) in 2.0 mL CH3CN was added to 
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above mixture. The resulting mixture was stirred for 24 hours at room temperature. 
The mixture was passed through a small of silica gel and then concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica 
gel to afford the corresponding product 151. 
 
(4R,10R)-3-methyl-1,4,10-triphenyl-7,8-dihydro-4H,6H,10H-furo[3,4-
d]pyrazolo[1,2-a]pyridazin-6-one (151a) 
According to general procedure: Under an atmosphere of argon, a flame-dried 
Schlenk-flask was charged with Me2SAuCl (8.83 mg, 0.03 mmol, 10 mol%), 
corresponding ligand 30m (13.9 mg, 0.015 mmol, 5 mol%) and CH2Cl2 (1.0 mL). The 
resulting mixture was stirred for 2 h at room temperature for ligand exchange; then, 
the CH2Cl2 was removed in vacuo directly on the Schlenk-line to yield the 
catalytically active gold complex. Then a solution of AgOTf (3.85 mg, 0.015 mmol, 5 
mol%) in 1 mL CH3CN was transferred to the above catalyst solution at room 
temperature, and the resulting mixture was stirred for 30 min. at the same temperature. 
Then, 138a (62.71 mg, 0.36 mmol) was added into the mixture solution and stirred for 
10 min. at room temperature. Subsequently, a solution of 146a (73.89 mg, 0.3 mmol, 
1.0 eq.) in 2.0 mL CH3CN was added to above mixture. The resulting mixture was 
stirred for 24 hours at room temperature. The mixture was passed through a small of 
silica gel and then concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel to afford the corresponding product 151a 
as a white solid with 85% ee (112.3 mg, 89% yield). 
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M (C28H24N2O2): 420.51 g/mol. 
M.p.: 198.8-200.2 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.28. 
1
H NMR (300 MHz, CDCl3): δ = 7.56 (dd, J = 7.8 Hz, J = 1.5 Hz, 2H, CHAr), 7.43-
7.27 (m, 12H, CHAr), 7.20-7.16 (m, 1H, CHAr), 6.46 (s, 1H, H4), 5.23 (s, 1H, H1), 
3.50-3.33 (m, 2H, H2), 2.10 (s, 3H, H7), 1.80-1.71 (m, 1H, H3), 1.09-1.96 (m, 1H, 
H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.6 (C=O), 146.4 (C8), 144.8, 140.2 (C6), 136.8, 
130.6, 129.5, 129.0, 128.8, 128.6, 128.1, 126.8, 126.8, 124.2, 119.3 (C9), 115.6 (C5), 
64.0 (C1), 51.5 (C4), 46.6(C2), 30.0(C3), 12.5(C7). 
IR (ATR) 
~  [cm-1] = 3030 (w), 2919 (w), 2245 (w), 1669 (s), 1603 (w), 1567 (w), 
1494 (w), 1455 (w), 1430 (w), 1407 (m), 1322 (w), 1301 (w), 1275 (w), 1249 (w), 
1173 (w), 1140 (w), 1120 (w), 1070 (w), 1027 (w), 963 (w), 907 (s), 880 (w), 858 (w), 
832 (w), 803 (w), 765 (w), 729 (s), 706 (s), 650 (w), 616 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 420 ([M]
 +
, 100), 336 (62), 321 (5), 293 (10), 278 
(4), 259 (32), 244 (4), 215 (23), 189 (4), 165 (5), 115 (5), 91 (12), 73 (2), 43 (7). 
HR-MS (ESI): calcd. for [M+Na]
+
: 433.1729, found: 433.1733. 
α
20 
λ : [α]436 = +124.60 °, [α]546 = +30.16 °, [α]579 = +19.52 °, [α]589 =+13.81 ° (c = 0.42 
in CHCl3). 
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(4R,10R)-10-(4-methoxyphenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151b) 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 73.53 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138b in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151b as a white solid with 90% ee (117.6 mg, 87% 
yield). 
 
M (C29H26N2O3): 450.54 g/mol. 
M.p.: 198.5-200.1 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.26. 
1
H NMR (300 MHz, CDCl3): δ = 7.55 (d, J = 7.8 Hz, 2H, CHAr), 7.43-7.25 (m, 10H, 
CHAr), 6.93 (d, J = 8.7 Hz, 2H, CHAr), 6.43 (s, 1H, H4), 5.18 (s, 1H, H1), 3.81 (s, 1H, 
H10), 3.51-3.30 (m, 2H, H2), 2.09 (s, 3H, H7), 1.82-1.74 (m, 1H, H3), 1.19-1.06 (m, 
1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.5 (C=O), 159.8, 146.3 (C8), 144.8 (C6), 140.2, 
138.1, 130.6, 129.7, 128.5, 128.1, 126.7, 124.2, 122.1, 119.1 (C9), 115.5(C5), 115.5, 
113.7, 63.4 (C1), 55.3(C4), 51.4 (C10), 46.5(C2), 30.2(C3), 12.5(C7). 
IR (ATR) 
~  [cm-1] = 3062 (w), 3032 (w), 2931 (w), 2838 (w), 2245 (w), 1676 (s), 
1606 (m), 1510 (s), 1494 (w), 1454 (w), 1405 (m), 1305 (w), 1254 (s), 1176 (s), 1115 
(w), 1070 (w), 1030 (m), 910 (m), 879 (w), 867 (w), 825 (m), 799 (m), 764 (m), 731 
(s), 700 (s), 647 (w), 605 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 450 ([M]
 +
, 100), 366 (49), 351 (6), 335 (48), 289 
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(24), 245 (14), 230 (3), 215 (5), 189 (3), 165 (3), 144 (7), 121 (4), 105 (11), 77 (8), 43 
(10). 
HR-MS (ESI): calcd. for [M+Na]
+
: 473.1836, found: 473.1838. 
α
20 
λ : [α]546 = +18.21 °, [α]579 = +11.17 °, [α]589 = +8.06 ° (c = 0.51 in CHCl3). 
 
 
(4R,10R)-10-(4-fluorophenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151c) 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 69.19 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138e in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151c as a white solid with 87% ee (117.6 mg, 94% 
yield). 
 
M (C28H23FN2O2): 438.50 g/mol. 
M.p.: 127.0-129.3 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.39. 
1
H NMR (400 MHz, CDCl3): δ = 7.58-7.54 (m, 2H, CHAr), 7.41-7.28 (m, 9H, CHAr), 
7.22-7.18 (m, 1H, CHAr), 7.14-7.09 (m, 2H, CHAr), 6.45 (s, 1H, H4), 5.24 (s, 1H, H1), 
3.50-3.42 (m, 1H, H2), 3.33 (t, J = 7.8 Hz, H2), 2.10 (s, 3H, H7), 1.84-1.78 (m, 1H, 
H3), 1.16-1.07 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.3 (C=O), 164.6, 161.3 (C8), 146.5 (C6), 144.8, 
140.1, 132.8, 131.1, 131.0, 130.5, 128.6, 128.1, 126.9, 124.2, 119.1 (C9), 116.2, 115.9, 
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115.5 (C5), 63.2 (C1), 51.5 (C4), 46.5 (C2), 30.1 (C3), 12.5 (C7). 
19
F NMR (376 MHz, CDCl3) δ = -112.38 (s, 1F) 
IR (ATR) 
~  [cm-1] = 3063 (w), 2920 (w), 2246 (w), 1673 (m), 1602 (w), 1567 (w), 
1506 (m), 1494 (w), 1456 (w), 1405 (w), 1322 (w), 1298 (w), 1228 (w), 1160 (w), 
1140 (w), 1070 (w), 1025 (w), 1013 (m), 963 (w), 906 (m), 880 (w), 846 (w), 825 (w), 
805 (m), 764 (m), 764 (m), 726 (vs), 699 (s), 647 (m), 602 (m). 
MS (GC-MS, 70 eV): E: m/z (%) = 438 ([M]
 +
, 100), 354 (53), 339 (2), 311 (9), 277 
(17), 259 (18), 233 (32), 215 (10), 183 (2), 138 (9), 105 (21), 77 (16), 43 (37). 
HR-MS (ESI): calcd. for [M+Na]
+
: 461.1636.1581, found: 461.1634. 
α
20 
λ : [α]436 = +49.14 °, [α]546 = -3.79 °, [α]579 = -7.24 °, [α]589 = -8.34 ° (c = 0.58 in 
CHCl3). 
 
 
(4R,10R)-10-(4-chlorophenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151d) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 75.11 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138f in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151d as a white solid with 93% ee (125.6 mg, 92% 
yield). 
 
M (C28H23ClN2O2): 454.95 g/mol. 
M.p.: 168.1-170.0 °C. 
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Rf (Cyclohexane/EtOAc = 3:1) = 0.24. 
1
H NMR (300 MHz, CDCl3): δ = 7.55 (d, J = 7.8 Hz, 2H, CHAr), 7.41-7.34 (m, 7H, 
CHAr), 7.33-7.28 (m, 4H, CHAr), 7.23-7.17 (m, 1H, CHAr), 6.44 (s, 1H, H4), 5.22 (s, 
1H, H1), 3.51-3.40 (m, 1H, H2), 3.32 (t, J = 9.9 Hz, H2), 2.09 (s, 3H, H7), 1.86-1.77 
(m, 1H, H3), 1.22-1.09 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.3 (C=O), 146.6 (C8), 144.9, 140.0 (C6), 135.5, 
134.9, 130.6, 130.5, 129.2, 128.6, 128.1, 127.0, 124.2, 118.8 (C9), 115.4 (C5), 63.3 
(C1), 51.5 (C4), 46.5 (C2), 30.1 (C3), 12.5 (C7). 
MS (GC-MS, 70 eV): E: m/z (%) = 454 ([M]
 +
, 100), 411 (3), 370 (23), 354 (4), 335 
(56), 320 (5), 291 (19), 276 (4), 259 (17), 244 (8), 215 (25), 189 (6), 165 (5), 146 (9), 
126 (4), 105 (36), 78 (21), 43 (49). 
IR (ATR) 
~  [cm-1] = 3061 (w), 3031 (w), 2921 (w), 2241 (w), 1673 (s), 1601 (w), 
1567 (w), 1487 (m), 1455 (w), 1403 (s), 1322 (w), 1300 (w), 1272 (w), 1248 (w), 
1176 (w), 1139 (w), 1120 (w), 1070 (m), 1015 (m), 964 (w), 908 (m), 879 (w), 864 
(w), 843 (w), 817 (m), 794 (m), 763 (m), 730 (vs), 698 (s), 672 (w), 653 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 454 ([M
+
], 100), 411 (3), 370 (23), 354 (4), 335 
(56), 320 (5), 291 (19), 276 (4), 259 (17), 244 (8), 215 (25), 189 (6), 165 (5), 146 (9), 
126 (4), 105 (36), 78 (21), 43 (49). 
HR-MS (ESI): calcd. for [M+Na]
+
: 477.1340, found: 477.1339. 
α
20 
λ : [α]436 = +316.89 °, [α]546 = +110.67 °, [α]579 = +88.09 °, [α]589 = +80.89 ° (c = 
0.375 in CHCl3). 
 
 
(4R,10R)-10-(4-bromophenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151e) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 91.12 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138g in 1.0 mL of CH3CN 
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were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151e as a white solid with 95% ee (139.3 mg, 93% 
yield). 
 
M (C28H23BrN2O2): 499.41 g/mol. 
M.p.: 252.9-254.1 °C. 
Rf (Cyclohexane/EtOAc = 4:1) = 0.35. 
1
H NMR (300 MHz, CDCl3): δ = 7.54 (d, J = 8.4 Hz, 4H, CHAr), 7.40-7.18 (m, 10H, 
CHAr), 6.44 (s, 1H, H4), 5.20 (s, 1H, H1), 3.52-3.41 (m, 1H, H2), 3.36-3.29 (m, 1H, 
H2), 2.09 (s, 3H, H7), 1.87-1.78 (m, 1H, H3), 1.23-1.10 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.3 (C=O), 146.6 (C8), 144.9, 140.0 (C6), 136.60, 
132.2, 130.9, 130.4, 128.7, 128.0, 127.0, 124.2, 123.1, 118.7 (C9), 115.4 (C5), 63.4 
(C1), 51.5 (C4), 46.5 (C2), 30.1(C3), 12.5(C7). 
IR (ATR) 
~  [cm-1] = 3676 (w), 3061 (w), 2988 (b), 2242 (w), 1682 (vs), 1602 (w), 
1586 (w), 1567 (w), 1482 (w), 1455 (w), 1404 (s), 1328 (w), 1301 (w), 1249 (w), 
1173 (w), 1130 (w), 1071 (s), 1011 (m), 965 (w), 910 (w), 863 (w), 834 (w), 816 (m), 
794 (m), 734 (s), 699 (m), 654 (w), 617 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 498 ([M-H]
+
, 61), 459 (4), 429 (5), 414 (30), 399 
(4), 370 (5), 355 (3), 335 (100), 320 (14), 292 (30), 276 (8), 259 (28), 244 (11), 292 
(11), 207 (58),191 (8), 165 (8), 145 (9), 115 (15), 91 (27), 65 (12), 44 (15). 
HR-MS (ESI): calcd. for [M+Na]
+
: 521.0835, found: 521.0834. 
α
20 
λ : [α]436 = +111.84 °, [α]546 = +36.46 °, [α]579 = +28.91 °, [α]589 = +26.87 ° (c = 0.49 
in CHCl3). 
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(4R,10R)-3-methyl-10-(4-nitrophenyl)-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151f) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 78.91 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138h in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151f as a light yellow solid with 83% ee (128.5 mg, 
92% yield).  
 
M (C28H23N3O4): 465.51 g/mol. 
M.p.: 228.9-230.7°C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.27. 
1
H NMR (300 MHz, CDCl3): δ = 8.27 (d, J = 9.0 Hz, 2H, CHAr), 7.58-7.53 (m, 4H, 
CHAr), 7.41-7.28 (m, 7H, CHAr), 7.23-7.18 (m, 1H, CHAr), 6.47 (s, 1H, H4), 5.37 (s, 
1H, H1), 3.55-3.47 (m, 1H, H2), 3.38-3.31 (m, 1H, H2), 2.12 (s, 3H, H7), 1.90-1.81 
(m, 1H, H3), 1.19-1.06 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.0 (C=O), 148.0 (C8), 147, 145.3 (C6), 144.6, 
139.8, 130.1, 128.7, 128.3, 128.1, 127.3, 124.1, 124.0, 118.0 (C9), 115.2 (C5), 63.2 
(C1), 51.6 (C4), 46.5 (C2), 30.1 (C3), 12.5 (C7). 
IR (ATR) 
~  [cm-1] = 3062 (w), 2921 (b), 2243 (w), 1680 (s), 1603 (m), 1567 (w), 
1520 (s), 1494 (s), 1455 (w), 1401 (m), 1347 (s), 1276 (w), 1248 (w), 1178 (w), 1109 
(w), 1071 (w), 1027 (m), 1014 (w),  910 (w), 881 (m), 859 (w), 826 (w), 765 (w), 732 
(s), 699 (m), 654 (w), 636 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 465 ([M]
 +
, 6), 435 (100), 419 (7), 392 (8), 376 
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(19), 350 (50), 331 (8), 308 (37), 293 (33), 263 (26), 245 (19), 230 (47), 206 (35), 182 
(34), 167 (17), 150 (17), 131 (28), 114 (8), 92 (33), 73 (63), 43 (28). 
HR-MS (ESI): calcd. for [M+Na]
+
: 488.1581, found: 488.1583. 
α
20 
λ : [α]546 = +134.75 °, [α]579 = +103.83 °, [α]589 = +89.67 ° (c = 0.4 in CHCl3). 
 
 
(4R,10R)-3-methyl-1,4-diphenyl-10-(p-tolyl)-7,8-dihydro-4H,6H,10H-furo[3,4-
d]pyrazolo[1,2-a]pyridazin-6-one (151g) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 67.76 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138i in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151g as a white solid with 85% ee (108.2 mg, 83% 
yield).  
 
M (C29H26N2O2): 434.54 g/mol. 
M.p.: 123.1-126.0 °C. 
Rf (Cyclohexane/EtOAc = 3:1) = 0.26. 
1
H NMR (300 MHz, CDCl3): δ = 7.57-7:54 (m, 2H, CHAr), 7.44-7.40 (m, 2H, CHAr), 
7.36-7.25 (m, 5H, CHAr), 7.23-7.14 (m, 5H, CHAr), 6.44 (s, 1H, H4), 5.19 (s, 1H, H1), 
3.45-3.34 (m, 2H, H2), 2.36 (s, 3H, H7), 2.09 (s, 3H, H10), 1.79-1.70 (m, 1H, H3), 
1.12-1.01 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.7 (C=O), 146.3 (C8), 144.6 (C6), 140.2, 138.6, 
133.7, 130.7, 129.7, 129.3, 128.6, 128.5, 128.1, 128.0, 126.7, 124.2, 119.5 (C9), 115.6 
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(C5), 63.8 (C1), 51.4 (C4), 46.6 (C2), 30.1 (C3), 21.2 (C10), 12.5 (C7). 
IR (ATR) 
~  [cm-1] = 3033 (w), 2922 (w), 2247 (w), 1670 (s), 1603 (w), 1510 (w), 
1494 (m), 1455 (w), 1409 (m), 1334 (w), 1299 (w), 1248 (w), 1177 (w), 1117 (w), 
1070 (w), 1025 (w), 963 (w), 90s (s), 881 (w), 835 (w), 817 (w), 792 (w), 764 (w), 
729 (vs), 700 (s), 648 (w), 624 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 434 ([M]
 +
, 100), 350 (21), 335 (54), 320 (5), 291 
(7), 273 (10), 246 (3), 230 (4), 215 (15), 189 (7), 152 (5), 128 (5), 105 (29), 77 (26), 
43 (22). 
HR-MS (ESI): calcd. for [M+Na]
+
: 457.1890, found: 457.1891. 
α
20 
λ : [α]436 = +108.46 °, [α]546 = +37.69 °, [α]579 = +29.69 °, [α]589 = +26.09 ° (c = 
0.52 in CHCl3). 
 
 
(4R,10R)-10-(4-t-butylphenyl)-3-methyl-1,10-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151h) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 82.91 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138j in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151h as a white solid with 94% ee (124.4 mg, 87% 
yield). 
 
M (C28H23FN2O2): 476.62 g/mol. 
M.p.: 268.9-271.1 °C. 
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Rf (Cyclohexane/EtOAc = 4:1) = 0.28. 
1
H NMR (300 MHz, CDCl3): δ = 7.56 (d J = 7.0 Hz, 2H, CHAr), 7.48-7.32 (m, 8H, 
CHAr), 7.31-7.26 (m, 3H, CHAr), 7.21-7.15 (m, 1H, CHAr), 6.45 (s, 1H, H4), 5.20 (s, 
1H, H1), 3.46-3.31 (m, 2H, H2), 2.09 (s, 3H, H7), 1.79-1.70 (m, 1H, H3), 2.09 (s, 9H, 
H11), 1.03-0.94 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.6 (C=O), 152:0, 146.3 (C8), 144.6 (C6), 140.3, 
133.6, 130.7, 129.1, 128.6, 128.1, 128.0, 126.6, 125.8, 124.2, 123.7, 119.6 (C9), 115.6 
(C5), 63.7 (C1), 51.4 (C4), 46.6 (C2), 34.6 (C10), 31.4 (C11), 30.1 (C3), 12.5 (C7). 
IR (ATR) 
~  [cm-1] = 3032 (w), 2963 (w), 2867 (w), 2244 (w), 1672 (s), 1602 (w), 
1566 (w), 1507 (w), 1494 (m), 1455 (w), 1401 (s), 1364 (m), 1334 (w), 1323 (w), 
1298 (w), 1269 (w), 1202 (w), 1173 (w), 1119 (w), 1106 (w), 1070 (m), 1038 (m), 963 
(w), 907 (m), 878 (m), 848 (w), 836 (w), 798 (w), 764 (m), 722 (vs), 698 (s), 654 (w), 
623 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 476 ([M]
 +
, 51), 457 (4), 419 (3), 393 (8), 374 (3), 
335 (85), 320(6), 292 (4), 258 (10), 241 (5), 215 (8), 167 (4), 128 (6), 105 (26), 77 
(20), 57 (100), 41 (36). 
HR-MS (ESI): calcd. for [M+Na]
+
: 499.2356, found: 499.2354. 
α
20 
λ : [α]546 = +50.12 °, [α]579 = +39.97 °, [α]589 =+35.22 ° (c = 0.81 in CHCl3). 
 
 
4-((4R,10R)-1-methyl-8-oxo-3,10-diphenyl-7,8-dihydro-4H,6H,10H-furo[3,4-
d]pyrazolo[1,2-a]pyridazin-4-yl)benzonitrile (151i) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 71.72 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138l in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151i as a white solid with 77% ee (127.0 mg, 95% 
yield). 
EXPERIMENTAL SECTION 
146 
 
 
M (C29H23N3O2): 445.52 g/mol. 
M.p.: 143.9-145.3 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.23. 
1
H NMR (300 MHz, CDCl3): δ = 7.71 (d, J = 8.0 Hz, 2H, CHAr), 7.55-7.49 (m, 4H, 
CHAr), 7.40-7.30 (m, 7H, CHAr), 7.24-7.19 (m, 1H, CHAr), 6.45 (s, 1H, H4), 5.30 (s, 
1H, H1), 3.56-3.45 (m, 1H, H2), 3.32 (d, J = 10.8 Hz, 2H, CHAr), 2.10 (s, 3H, H7), 
1.89-1.80 (m, 1H, H3), 1.11-1.02 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 169.9 (C=O), 146.90 (C7), 145.2 (C8), 142.5 (C6), 
139.8, 132.6, 130.1, 128.7, 128.3, 128.0, 127.2, 124.1, 124.2, 123.7, 118.2, 118.0, 
115.3 (C9), 112.8 (C5), 63.5 (C1), 51.6 (C4), 46.5 (C2), 30.0 (C3), 12.5 (C7). 
IR (ATR) 
~  [cm-1] = 3061 (w), 3033 (w), 2920 (b), 2230 (w), 1675 (s), 1603 (w), 
1567 (w), 1494 (w), 1456 (w), 1400 (m), 1322 (s), 1299 (w), 1272 (w), 1247 (w), 
1188 (w), 1172 (w), 1139 (w), 1120 (w), 1070 (w), 1037 (w), 966 (w), 909 (m), 880 
(w), 847 (w), 835 (w), 824 (w), 799 (w), 761 (w), 727 (vs), 699 (m), 655 (w), 623 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 445 ([M]
 +
, 100), 429 (18), 406 (6), 376 (8), 361 
(51), 343 (13), 318 (12), 288 (11), 259 (21), 241 (18), 203 (7), 180 (6), 153 (10), 131 
(11), 105 (24), 77 (23), 43 (33). 
HR-MS (ESI): calcd. for [M+Na]
+
: 468.1682, found: 468.1683. 
α
20 
λ : [α]436 = +128.80 °, [α]546 = +36.40 °, [α]579 = +26.93 °, [α]589 =+23.33 ° (c = 0.5 
in CHCl3). 
 
 
 
 
EXPERIMENTAL SECTION 
147 
 
(4R,10R)-10-(3-methoxyphenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151k) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 73.53 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138c in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151k as a white solid with 81% ee (123.0 mg, 91% 
yield). 
 
M (C28H26N2O3): 450.54 g/mol. 
M.p.: 204.6-206.3 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.29. 
1
H NMR (300 MHz, CDCl3): δ = 7.57 (d, J = 7.8 Hz, 2H, CHAr), 7.44 (d, J = 7.5 Hz, 
2H, CHAr), 7.40-7.27(m, 6H, CHAr), 7.21-7.15 (m, 1H, CHAr), 6.99-6.87 (m, 3H, 
CHAr), 6.46 (s, 1H, H4), 5.19 (s, 1H, H1), 3.79 (s, 3H, H10) 3.44-3.34 (m, 2H, H2), 
2.09 (s, 3H, H7), 1.82-1.73 (m, 1H, H3), 1.22-1.09 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.6 (C=O), 159.9, 146.4 (C8), 144.8 (C6), 140.3, 
138.4, 130.6, 129.9, 128.6, 128.1, 126.8, 124.3, 122.0, 119.2 (C9), 115.6 (C5), 115.5, 
113.8, 63.9 (C1), 55.4(C4), 51.4 (C10), 46.7 (C2), 30.2 (C3), 12.5 (C7). 
IR (ATR) 
~  [cm-1] = 3061 (w), 3031 (w), 2937 (w), 2837 (w), 2245 (w), 1671 (s), 
1598 (m), 1582 (m), 1489 (w), 1454 (w), 1404 (m), 1324 (w), 1263 (m), 1171 (w), 
1158 (w), 1137 (w), 1070 (m), 1038 (w), 1011 (w), 996 (w), 878 (w), 832 (w), 755 
(w), 763 (m), 727 (s), 698 (s), 650 (w), 616 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 450 ([M]
 +
, 100), 366 (38), 343 (19), 323 (6), 307 
EXPERIMENTAL SECTION 
148 
 
(3), 289 (27), 274 (3), 259 (17), 244(2), 215 (10), 189 (6), 165 (4), 144 (13), 121 (3), 
105 (23), 77 (17), 43 (21). 
HR-MS (ESI): calcd. for [M+Na]
+
: 473.1836, found: 473.1836. 
α
20 
λ : [α]436 = +109.43 °, [α]546 = +20.31 °, [α]579 = +13.33 °, [α]589 = +10.19 ° (c = 
0.53 in CHCl3). 
 
 
(4R,10R)-10-(2-methoxyphenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151l) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 73.53 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138d in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151l as a white solid with 65% ee (116.2 mg, 86% 
yield). 
 
M (C29H26N2O3): 450.54 g/mol. 
M.p.: 252.9-254.1 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.19. 
1
H NMR (300 MHz, CDCl3): δ = 7.57 (d, J = 8.1 Hz, 2H, CHAr), 7.44 (J = 7.5 Hz, 2H, 
CHAr), 7.37-7.25(m, 6H, CHAr), 7.19-7.13 (m, 1H, CHAr), 7.02 (d, J = 8.4 Hz, 2H, 
CHAr), 6.93-6.88 (m, 1H, CHAr), 6.47 (s, 1H, H4), 6.09 (s, 1H, H1), 4.05 (s, 3H, H10) 
3.55-3.47 (m, 1H, H2), 3.39-3.28 (m, 1H, H2), 2.10 (s, 3H, H7), 1.86-1.77 (m, 1H, 
H3), 1.28-1.22 (m, 1H, H3). 
EXPERIMENTAL SECTION 
149 
 
13
C NMR (75 MHz, CDCl3) δ = 170.9 (C=O), 156.9, 146.1 (C8), 144.2 (C6), 140.3, 
130.7, 130.5, 130.0, 128.6, 128.4, 128.1, 128.0, 126.4, 125.4, 123.8, 121.5, 119.9 (C9), 
115.8 (C5), 110.6, 55.8 (C1), 54.8(C4), 51.4 (C10), 46.1 (C2), 30.7 (C3), 12.5 (C7). 
IR (ATR) 
~  [cm-1] = 3032 (w), 2963 (w), 2867 (w), 2244 (w), 1672 (s), 1602 (w), 
1566 (w), 1507 (w), 1494 (m), 1455 (w), 1401 (s), 1364 (m), 1334 (w), 1323 (w), 
1298 (w), 1269 (w), 1202 (w), 1173 (w), 1119 (w), 1106 (w), 1070 (m), 1038 (m), 963  
(w), 907 (m), 878 (m), 848 (w), 836 (w), 798 (w), 764 (m), 722 (vs), 698 (s), 654 (w), 
623 (w).  
MS (GC-MS, 70 eV): E: m/z (%) = 450 ([M]
 +
, 100), 366 (36), 351 (15), 335 (23), 
307 (4), 289 (21), 261 (6), 245 (22), 215 (13), 189 (3), 144 (13), 121 (3), 105 (23), 77 
(10), 43 (15). 
HR-MS (ESI): calcd. for [M+Na]
+
: 473.1835, found: 473.1835. 
α
20 
λ : [α]436 = +57.49 °, [α]546 = +3.64 °, [α]589 = -1.38 ° (c = 0.65 in CHCl3). 
 
 
(4R,10R)-3-methyl-10-(3-nitrophenyl)-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151m) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 78.91 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138m in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151m as a yellow solid with 80% ee (129.9 mg, 93% 
yield).  
 
EXPERIMENTAL SECTION 
150 
 
M (C28H23N3O4): 465.51 g/mol. 
M.p.: 224.0-225.9 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.24. 
1
H NMR (300 MHz, CDCl3): δ = 8.33 (s, 1H, CHAr), 8.27 (d, J = 7.8 Hz, 1H, CHAr), 
7.65-7.53 (m, 4H, CHAr), 7.40-7.28 (m, 7H, CHAr), 7.24-7.18 (m, 1H, CHAr), 6.48 (s, 
1H, H4), 5.39 (s, 1H, H1), 3.58-3.47 (m, 1H, H2), 3.39-3.31 (m, 1H, H2), 2.12 (s, 3H, 
H7), 1.90-1.81 (m, 1H, H3), 1.14-1.01 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.0 (C=O), 148.4, 146.9 (C8), 145.2 (C6), 139.8, 
139.3, 135.0, 130.2, 128.8, 128.7, 128.3, 128.1, 127.2, 124.1, 123.8, 118.0 (C9), 115.4 
(C8), 63.3 (C1), 51.7 (C4), 46.4 (C2), 30.0(C3), 12.5(C7). 
IR (ATR) 
~  [cm-1] = 3062 (w), 2921 (w), 2246 (w), 1675 (s), 1603 (w), 1586 (w), 
1567 (w), 1529 (s), 1494 (m), 1455 (w), 1403 (m), 1349 (s), 1301 (w), 1275 (w), 1248 
(w), 1196 (w), 1140 (w), 1120 (w), 1098 (w), 1071 (w), 1026 (m), 1011 (w), 966 (w), 
908 (m), 878 (m), 831 (w), 798 (w), 764 (m), 730 (vs), 699 (s), 651 (w), 616 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 465 ([M]
 +
, 3), 435 (100), 420 (5), 395 (4), 379 
(5), 350 (40), 335 (5), 304 (5), 274 (7), 258 (7), 230 (20), 202 (6), 167 (8), 128 (7), 
105 (15), 77 (23), 43 (30). 
HR-MS (ESI): calcd. for [M+Na]
+
: 488.1580, found: 488.1577. 
α
20 
λ : [α]546 = -158.81 °, [α]579 = -176.59 ° (c = 0.42 in CHCl3). 
 
(4R,10R)-3-methyl-10-(2-nitrophenyl)-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151n) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 78.91 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138n in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151n as a yellow solid with 76% ee (125.7 mg, 90% 
yield). 
EXPERIMENTAL SECTION 
151 
 
 
M (C28H23N3O4): 465.51 g/mol. 
M.p.: 114.1-116.3 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.32. 
1
H NMR (300 MHz, CDCl3): δ = 8.01 (d, J = 8.0 Hz, 1H, CHAr), 7.56-7.48 (m, 6H, 
CHAr), 7.41-7.28 (m, 6H, CHAr), 7.25-7.13 (m, 1H, CHAr), 6.48 (s, 1H, H4), 6.44 (s, 
1H, H1), 3.47-3.31 (m, 2H, H2), 2.12 (s, 3H, H7), 1.91-1.82 (m, 1H, H3), 1.18-1.05 
(m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.4 (C=O), 150.0, 146.6 (C8), 145.5 (C6), 139.7, 
133.3, 131.6, 131.4, 130.1, 129.7, 128.7, 128.3, 128.1, 127.3, 125.2, 124.2, 117.9 (C9), 
115.4 (C8), 56.2 (C1), 51.6 (C4), 46.5 (C2), 30.3(C3), 12.4(C7). 
IR (ATR) 
~  [cm-1] = 3062 (w), 3032 (w), 2920 (w), 2245 (w), 1679 (s), 1603 (w), 
1586 (w), 1566 (w), 1525 (s), 1494 (m), 1455 (w), 1446 (w), 1401 (m), 1345 (m), 
1298 (w), 1274 (w), 1250 (w), 1172 (w), 1147 (w), 1071 (w), 1025 (m), 1011 (w), 965 
(w), 908 (m), 880 (w), 832 (w), 786 (w), 764 (m), 728 (vs), 698 (s), 655 (w), 615 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 465 ([M]
 +
, 6), 435 (100), 419 (24), 381 (10), 350 
(87), 335 (18), 301 (8), 274 (20), 247 (7), 231 (7), 230 (47), 206 (8), 179 (8), 152 (8), 
137 (7), 105 (15), 85 (13), 68 (8), 43 (45). 
HR-MS (ESI): calcd. for [M+Na]
+
: 488.1580, found: 488.1578. 
α
20 
λ : [α]546 = +127.99 °, [α]579 = +95.19 °, [α]589 = +86.66 ° (c = 0.755 in CHCl3). 
 
 
 
 
 
EXPERIMENTAL SECTION 
152 
 
(4R,10S)-10-(2-chlorophenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151o) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 75.11 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138p in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151o as a white solid with 75% ee (117.4 mg, 86% 
yield). 
 
M (C28H23ClN2O2): 454.95 g/mol. 
M.p.: 115.2-118.1 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.31. 
1
H NMR (300 MHz, CDCl3): δ = 7.58-7.46 (m, 5H, CHAr), 7.41-7.27 (m, 6H, CHAr), 
7.26-7.13 (m, 3H, CHAr), 6.48 (s, 1H, H4), 6.09 (s, 1H, H1), 3.61 (t, J = 9.6 Hz, 2H, 
H2), 3.45-3.34 (m,1H, H2), 2.11 (s, 3H, H7), 1.90-1.80 (m, 1H, H3), 1.22-1.12 (m, 
1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.7 (C=O), 146.4 (C8), 144.9 (C6), 140.0, 134.7, 
133.8, 131.2, 130.3, 130.1, 130.0, 128.6, 128.2, 128.1, 127.7, 118.8 (C9), 115.5 (C5), 
58.4 (C1), 51.4 (C4), 46.2 (C2), 30.5 (C3), 12.5 (C7). 
IR (ATR) 
~  [cm-1] = 3061 (w), 3032 (w), 2919 (w), 2244 (w), 1676 (s), 1602 (w), 
1587 (w), 1567 (w), 1494 (m), 1463 (w), 1455 (w), 1442 (w), 1400 (m), 1325 (w), 
1274 (w), 1248 (w), 1172 (w), 1142 (w), 1121 (w), 1070 (w), 1036 (w), 1011 (w), 964 
(w), 907 (m), 880 (w), 851 (w), 833 (w), 802 (m), 762 (m), 727 (vs), 698 (s), 654 (w), 
615 (w). 
EXPERIMENTAL SECTION 
153 
 
MS (GC-MS, 70 eV): E: m/z (%) = 454 ([M]
 +
, 93), 438 (3), 412 (3), 372 (11), 335 
(100), 320 (5), 292 (10), 259 (7), 244 (3), 215 (7), 190 (3), 147 (5), 125 (5), 105 (16), 
77 (13), 43 (21). 
HR-MS (ESI): calcd. for [M+Na]
+
: 477.1340, found: 477.1341. 
α
20 
λ : [α]436 = +28.57 °, [α]546 = -21.19 °, [α]579 = -22.92 °, [α]589 =-24.29 ° (c = 0.56 in 
CHCl3). 
 
 
(4R,10R)-10-(3,5-dimethoxyphenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-
4H,6H,10H-furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151p) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 84.33 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138s in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151p as a white solid with 65% ee (134.0 mg, 93% 
yield).  
 
M (C30H28N2O4): 480.56 g/mol. 
M.p.: 178.2-181.1 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.26. 
1
H NMR (300 MHz, CDCl3): δ = 7.54 (d, J = 7.8 Hz, 2H, CHAr), 7.54 (d, J = 7.8 Hz, 
2H, CHAr), 7.38-7.28(m, 6H, CHAr), 7.22-7.17 (m, 1H, CHAr), 6.50-6.46 (m, 2H, 
CHAr), 6.42 (s, 1H, H4), 5.11 (s, 1H, H1), 3.80 (s, 6H, H10, H10 )´ 3.47-3.40 (m, 2H, 
H2), 2.08 (s, 3H, H7), 1.87-1.78 (m, 1H, H3), 1.37-1.25 (m, 1H, H3). 
EXPERIMENTAL SECTION 
154 
 
13
C NMR (75 MHz, CDCl3) δ = 170.7 (C=O), 161.0, 147.2 (C8), 146.4 (C6), 140.2, 
139.2, 130.6, 128.6, 128.0, 126.8, 124.4, 118.7 (C9), 115.5 (C5), 107.8, 100.1, 64.0 
(C1), 55.5 (C4), 51.3 (C10), 46.8 (C2), 30.3 (C3), 12.5 (C7). 
IR (ATR) 
~  [cm-1] = 3062 (w), 2938 (b), 2839 (w), 2247 (w), 1672 (s), 1593 (s), 
1484 (w), 1456 (m), 1430 (m), 1327 (w), 1295 (w), 1270 (w), 1204 (s), 1156 (s), 1120 
(w), 1065 (s), 1026 (m), 909 (w), 878 (w), 834 (w), 797 (w), 765 (w), 728 (vs), 698 
(s), 645 (w), 618 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 480 ([M]
 +
, 98), 465 (3), 450 (3), 410 (4), 395 
(100), 365 (17), 343 (26), 319 (42), 291 (6), 276 (8), 259 (28), 244 (8), 215 (9), 198 
(6), 175 (4), 159 (20), 128 (5), 105 (23), 77 (20), 43 (30). 
HR-MS (ESI): calcd. for [M+Na]
+
: 503.1940, found: 503.11938. 
α
20 
λ : [α]436 = +36.39 °, [α]546 = +4.58 °, [α]579 = +2.15 ° (c = 0.48 in CHCl3). 
 
 
(4R,10S)-10-(furan-2-yl)-3-methyl-1,4-diphenyl-7,8-dihydro-4H,6H,10H-furo[3,4-
d]pyrazolo[1,2-a]pyridazin-6-one (151r) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 59.10 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138q in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151r as a yellow solid with 86% ee (114.5 mg, 93% 
yield). 
 
 
EXPERIMENTAL SECTION 
155 
 
M (C26H22N2O3): 410.47 g/mol. 
M.p.: 89.1-92.0 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.23. 
1
H NMR (300 MHz, CDCl3): δ = 7.55-7.50 (m, 2H, CHAr), 7.45 (d, J = 7.5 Hz, 2H, 
CHAr), 7.42-7.32 (m, 7H, H13+CHAr), 7.30-7.19 (m, 1H, CHAr), 6.41 (dd, J = 3.3 Hz, 
J = 1.8 Hz, 2H, H12), 6.38 (s, 1H, H4), 6.19 (d, J = 3.0 Hz, 1H, H11), 5.99 (d, J = 2.4 
Hz, 1H, H12), 5.35 (s, 1H, H1), 3.61-3.41 (m, 2H, H2), 2.07 (s, 3H, H7), 2.03-1.94 (m, 
1H, H3), 1.46-1.36 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.6 (C=O), 151.0 (C10), 146.5 (C8), 145.0 (C6), 
143.2 (C13), 140.1, 130.5, 128.7, 128.6, 128.1, 126.9, 124.2, 117.3 (C9), 115.2 (C5), 
111.9 (C11), 111.5 (12), 57.1 (C1), 51.2 (C4), 47.3 (C2), 29.6(C3), 13.7(C14), 
12.5(C7). 
MS (GC-MS, 70 eV): E: m/z (%) = 410 ([M]
 +
, 42), 326 (100), 311 (3), 297 (6), 283 
(7), 265 (6), 253 (11), 239 (7), 207 (10), 178 (6), 105 (20), 91 (7), 77 (13), 51 (4). 
HR-MS (ESI): calcd. for [M+Na]
+
: 433.1523, found: 433.1526. 
α
20 
λ : [α]546 = +17.54 °, [α]579 = +12.39 °, [α]589 = +10.43 ° (c = 0.46 in CHCl3). 
 
 
(4R,10S)-3-methyl-10-(5-methylfuran-2-yl)-1,4-diphenyl-7,8-dihydro-
4H,6H,10H-furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-onee (151s) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 64.12 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138r in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146a (73.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151s as a yellow solid with 96% ee (122.3 mg, 91% 
yield). 
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M (C27H24N2O3): 424.50 g/mol. 
M.p.: 213.7-216.8 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.29. 
1
H NMR (300 MHz, CDCl3): δ = 7.52 (dd, J = 7.8 Hz, J = 1.5 Hz, 2H, CHAr), 7.45 (d, 
J = 7.5 Hz, 2H, CHAr), 7.39-7.31 (m, 5H, CHAr), 7.30-7.19 (m, 1H, CHAr), 6.37 (s, 1H, 
H4), 6.05 (d, J = 3.0 Hz, 1H, H11), 5.99 (d, J = 2.4 Hz, 1H, H12), 5.28 (s, 1H, H1), 
3.62-3.41 (m, 2H, H2), 2.37 (s, 3H, H7), 2.06 (s, 3H, H14), 2.04-1.96 (m, 1H, H3), 
1.55-1.42 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.8 (C=O), 153.1 (C10), 148.9 (C13), 146.4 (C8), 
144.9 (C6), 130.6, 128.7, 128.6, 128.1, 128.0, 126.8, 124.2, 127.3, 124.1, 117.5 (C9), 
115.3 (C5), 112.4 (C11), 107.8 (12), 57.2 (C1), 51.2 (C4), 47.3 (C2), 29.7(C3), 
13.7(C14), 12.5(C7). 
IR (ATR) 
~  [cm-1] = 3062 (w), 3033 (w), 2920 (b), 2244 (w), 1674 (s), 1603 (w), 
1568 (w), 1547 (w), 1494 (m), 1431 (w), 1405 (m), 1324 (w), 1293 (w), 1249 (w), 
1218 (w), 1170 (w), 1140 (w), 1119 (w), 1070 (w), 1022 (m), 966 (w), 952 (w), 908 
(m), 884 (w), 830 (w), 788 (w), 764 (w), 729 (vs), 699 (m), 651 (m), 629 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 424 ([M]
 +
, 48), 340 (100), 325 (4), 297 (15), 282 
(4), 253 (8), 215 (3), 191 (2), 170 (2), 105 (11), 77 (4), 43 (11). 
HR-MS (ESI): calcd. for [M+Na]
+
: 447.1679, found: 447.1680. 
α
20 
λ : [α]546 = +2.37 °, [α]579 = -0.59 °, [α]589 =-1.86 ° (c = 0.45 in CHCl3). 
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(4R,10R)-4-(4-methoxyphenyl)-3-methyl-1,10-diphenyl-7,8-dihydro-4H,6H,10H-
furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151t) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 62.71 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138a in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146b (82.87 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151t as a white solid with 89% ee (124.3 mg, 92% 
yield). 
 
M (C29H26N2O3): 450.54 g/mol. 
M.p.: 206.6-209.5 °C. 
Rf (Cyclohexane/EtOAc = 2:1) = 0.31. 
1
H NMR (300 MHz, CDCl3): 7.48 (d, J = 8.7 Hz, 2H, CHAr), 7.43-7.14 (m, 9H, 
CHAr), 7.20-7.14 (m, 1H, CHAr), 6.92-6.86 (m, 2H, CHAr), 6.42 (s, 1H, H4), 5.21 (s, 
1H, H1), 3.82 (s, 3H, H10), 3.49-3.31 (m, 2H, H2), 2.10 (s, 3H, H7), 1.79-1.70 (m, 
1H, H3), 1.08-0.95 (m, 1H, H3). 
13
C NMR (75 MHz, CDCl3) δ = 170.4 (C=O), 159.3, 146.4 (C8), 144.7 (C6), 136.8, 
132.7, 130.6, 129.5, 129.3, 129.0, 128.7, 128.5, 126.7, 124.2, 119.3 (C9), 115.9(C8), 
113.5, 64.0 (C1), 51.2 (C4), 50.9 (C10), 46.6 (C2), 30.1(C3), 12.5(C7). 
IR (ATR) 
~  [cm-1] = 3060 (w), 3033 (w), 2934 (b), 2836 (w), 2242 (w), 1674 (s), 
1607 (w), 1584 (w), 1567 (w), 1510 (s), 1493 (w), 1445 (w), 1445 (w), 1402 (m), 
1322 (w), 1302 (w), 1247 (m), 1174 (m), 1140 (w), 1108 (w), 1070 (w), 1033 (m), 
1010 (w), 961 (w), 908 (m), 880 (w), 860 (w), 846 (w), 826 (w), 803 (w), 764 (m), 
755 (w), 728 (vs), 705 (s), 693 (m), 661 (w), 646 (w). 
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MS (GC-MS, 70 eV): E: m/z (%) = 450 ([M]
 +
, 100), 433 (2), 366 (72), 351 (7), 335 
(37), 307 (3), 289 (56), 274 (7), 258 (25), 231 (5), 215 (18), 189 (5), 165 (4), 144 (10), 
121 (7), 105 (22), 77 (14), 43 (23). 
α
20 
λ : [α]436 = +58.02 °, [α]546 = +2.51 °, [α]579 = -1.69 °, [α]589 = -3.61 ° (c = 0.73 in 
CHCl3). 
 
 
(4R,10R)-1-butyl-3-methyl-4,10-diphenyl-7,8-dihydro-4H,6H,10H-furo[3,4-
d]pyrazolo[1,2-a]pyridazin-6-one (151u) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 62.71 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138a in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146c (63.75 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151u as a gray solid with 11% ee (81.2 mg, 70% 
yield). 
 
M (C25H26N2O2): 386.50 g/mol. 
M.p.: 68.9-72.1 °C. 
Rf (Cyclohexane/EtOAc = 3:1) = 0.22. 
1
H NMR (300 MHz, CDCl3): δ = 7.49 (dd, J = 9.1 Hz, J = 1.8 Hz, 2H, CHAr), 7.38-
7.20 (m, 8H, CHAr), 6.41 (s, 1H, H4), 4.93 (s, 1H, H1), 3.40-3.23 (m, 2H, H2), 2.30 
(td, J = 7.2 Hz, J = 4.2 Hz, 2H, H10), 2.02 (s, 3H, H7), 1.82-1.73 (m, 1H, H3), 1.41-
1.33 (m, 2H, H11), 1.31-1.25 (m, 1H, H3), 0.69 (t, J = 7.2 Hz, 3H, H13)..  
13
C NMR (75 MHz, CDCl3) δ = 170.6 (C=O), 147.7 (C8), 144.5 (C6), 140.4, 138.3, 
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129.5, 129.1, 128.6, 128.5, 128.4, 127.9, 127.8, 117.7(C9), 113.2 (C5), 62.9 (C1), 
51.3 (C4), 46.5 (C2), 30.2(C10), 28.3(C3), 21.1 (C11), 13.6 (C12), 12.3 (C7). 
IR (ATR) 
~  [cm-1] = 3061 (w), 2960 (w), 2929 (w), 2873 (w), 1677 (s), 1601 (w), 
1493 (w), 1455 (w), 1432 (w), 1405 (m), 1296 (w), 1260 (w), 1183 (w), 1110 (w), 
1073 (w), 1044 (w), 1030 (w), 958 (m), 924 (w), 859 (w), 831 (w), 807 (w), 752 (s), 
701 (s), 665 (w), 616 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 386 ([M]
 +
, 20), 301 (3), 273 (21), 231 (4), 215 
(19), 230 (47), 195 (42), 178 (3), 152 (8), 115 (8), 97 (2), 78 (99), 63 (4), 43 (100). 
HR-MS (ESI): calcd. for [M+Na]
+
: 409.1886, found: 409.1888. 
α
20 
λ : [α]436 = +22.30 °, [α]546 = -9.21 °, , [α]589 = -7.62 ° (c = 0.42 in CHCl3). 
 
 
(4R,10R)-3-methyl-4,10-diphenyl-1-propyl-7,8-dihydro-4H,6H,10H-furo[3,4-
d]pyrazolo[1,2-a]pyridazin-6-one (151v) 
 
According to general procedure, 8.83 mg (0.03 mmol, 10 mol%) of Me2SAuCl, 13.9 
mg (0.015 mmol, 5 mol%) of ligand 30m, 3.85 mg (0.015 mmol, 5 mol%) of AgOTf, 
and 62.71 mg (0.36 mmol, 1.2 eq.) of azomethine imine 138a in 1.0 mL of CH3CN 
were reacted with a solution of ketone 146d (67.89 mg, 0.3 mmol, 1.0 eq.) in 2.0 mL 
of CH3CN to afford the product 151v as a gray solid with 18% ee (87.7 mg, 73% 
yield). 
 
M (C26H28N2O2): 400.52 g/mol. 
M.p.: 61.7-63.3 °C. 
Rf (Cyclohexane/EtOAc = 3:1) = 0.17. 
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1
H NMR (300 MHz, CDCl3): δ = 7.50 (dd, J = 7.8 Hz, J = 1.2 Hz, 2H, CHAr), 7.40-
7.21 (m, 8H, CHAr), 6.41 (s, 1H, H4), 4.93 (s, 1H, H1), 3.44-3.27 (m, 2H, H2), 2.32 
(td, J = 7.5 Hz, J = 1.8 Hz, 2H, H10), 2.02 (s, 3H, H7), 1.82-1.74 (m, 1H, H3), 1.38-
1.25 (m, 1H, H3), 1.17-1.03 (m, 2H, H11), 0.97-0.84 (m, 2H, H12), 0.74 (t, J = 7.2 Hz, 
3H, H13). 
13
C NMR (75 MHz, CDCl3) δ = 170.6 (C=O), 147.9 (C8), 144.4 (C6), 140.4, 138.3, 
135.5, 129.5, 129.3, 129.1, 129.0, 128.9, 127.9, 127.6, 128.5, 127.9, 12.8, 127.7, 
117.5(C9), 113.2 (C5), 62.9 (C1), 51.4 (C4), 46.5 (C2), 30.2(C10), 27.8(C11), 26.0 
(C3), 22.0 (C12), 13.7 (C13), 12.3 (C7). 
IR (ATR) 
~  [cm-1] = 3061 (w), 2960 (w), 2929 (w), 2873 (w), 1671 (s), 1601 (w), 
1493 (w), 1455 (w), 1411 (w), 1296 (w), 1260 (w), 1215 (s), 1102 (w), 1073 (w), 
1044 (w), 958 (m), 924 (w), 807 (w), 746 (vs), 704 (m), 668 (w). 
MS (GC-MS, 70 eV): E: m/z (%) = 400 ([M]
 +
, 100), 385 (2), 316 (28), 300 (3), 273 
(62), 258 (4), 239 (13), 215 (14), 195 (21), 178 (4), 153 (4), 128 (5), 108 (4), 78 (12), 
43 (29). 
HR-MS (ESI): calcd. for [M+Na]
+
: 423.2043, found: 423.2244. 
α
20 
λ : [α]436 = +20.30 °, [α]546 = -11.41 °, , [α]589 = -8.93 ° (c = 0.42 in CHCl3) 
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7. Appendix 
7.1. List of abbreviations 
Å Angstrom 
Ac acetyl  
Alk alkyl group  
aq. aqueous  
Ar aryl group  
Boc tert-butyloxycarbonyl  
Bn benzyl  
BINOL 1,1'-bi-2-naphthol  
BINAP  (1,1’-binaphthalene-2,2’-
diyl)bis(diphenylphosphine)  
t-Bu tert-butyl  
Cat.  catalyst  
conc. concentrate  
COSY Correlation spectroscopy 
DCC dicyclohexylcarbodiimide  
DCE 1,2-dichloroethane  
DCM dichloromethane  
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone  
DMF N,N-dimethyl formamide  
DMSO dimethylsulfoxide  
dppm bis(diphenylphosphino)methane  
d.r. diastereomeric ratio  
ee enantiomeric excess  
er enantiomeric ratio 
ent  enantiomer  
eq. equivalent  
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Et ethyl  
GC gas chromatography  
H hour  
HMQC Heteronuclear multiple-quantum correlation 
spectroscopy 
HPLC High performance liquid chromatography  
HR-MS High resolution mass spectrometry  
Hz Hertz  
J Coupling constant 
Me methyl  
Min minute  
MS molecular sieves  
Naph naphthyl  
NMR nuclear magnetic resonance  
°C degree celsius 
Ph phenyl  
Piv pivaloyl  
ppm parts per million  
Pr propyl  
i-Pr iso-propyl  
quant quantitative  
rac. racemic  
Rf retention factor  
r.t. room temperature  
sat. saturated  
TBS tert-butyldimethylsilyl  
TFA trifluoroacetic acid  
TFAA trifluoroacetic anhydride  
THF tetrahydrofuran  
TIPS triisopropylsilyl  
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TLC thin-layer chromatography  
TMEDA N,N,N ,´N -´tetramethylethylenediamine  
TMS trimethylsilyl  
TMS tetramethylsilane  
Tol p-tolyl  
tR retention time 
TS transition state  
Ts p-toluenesulfonyl  
UV ultraviolet  
vs. versus  
Xyl xylyl, xylenyl 
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7.2. X-ray crystallographic data 
7.2.1. (4S,10S)-3-methyl-1,4,10-triphenyl-7,8-dihydro-4H,6H,10H-furo[3,4-
d]pyrazolo[1,2-a]pyridazin-6-one (rac-151a) 
 
Table 1. Crystal data and structure refinement for qwdu382. 
Identification code  qwdu382 
Empirical formula  C28 H24 N2 O2 
Moiety formula  C28 H24 N2 O2 
Formula weight  420.49 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.6283(3) Å 
99.4720(10)°. 
 b = 9.8785(4) Å 
94.4470(10)°. 
 c = 16.9564(7) Å 
95.0270(10)°. 
Volume 1086.13(8) Å3 
Z 2 
Density (calculated) 1.286 Mg/m3 
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Absorption coefficient 0.642 mm-1 
F(000) 444 
Crystal size 0.350 x 0.200 x 0.150 mm3 
Theta range for data collection 4.867 to 72.263°. 
Index ranges -8<=h<=8, -10<=k<=12, -20<=l<=20 
Reflections collected 18768 
Independent reflections 4244 [R(int) = 0.0499] 
Completeness to theta = 67.679° 99.4 %  
Absorption correction Multiscan 
Max. and min. transmission 0.7536 and 0.5386 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4244 / 0 / 290 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0437, wR2 = 0.1111 
R indices (all data) R1 = 0.0462, wR2 = 0.1134 
Extinction coefficient n/a 
Largest diff. peak and hole 0.306 and -0.278 e.Å-3 
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7.2.2. (4S,10S)-3-methyl-10-(4-nitrophenyl)-1,4-diphenyl-7,8-dihydro-
4H,6H,10H-furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (rac-151f) 
 
 
Table 1. Crystal data and structure refinement for qwdu424n. 
Identification code  qwdu424n 
Empirical formula  C28 H23 N3 O4 
Moiety formula  C28 H23 N3 O4 
Formula weight  465.49 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.5305(2) Å 
74.4220(10)°. 
 b = 12.9780(3) Å 
83.3040(10)°. 
 c = 14.2009(4) Å 
83.4120(10)°. 
Volume 1147.06(5) Å3 
Z 2 
Density (calculated) 1.348 Mg/m3 
Absorption coefficient 0.744 mm-1 
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F(000) 488 
Crystal size 0.250 x 0.200 x 0.100 mm3 
Theta range for data collection 3.244 to 72.212°. 
Index ranges -8<=h<=7, -16<=k<=16, -17<=l<=17 
Reflections collected 42634 
Independent reflections 4502 [R(int) = 0.0487] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Multiscan 
Max. and min. transmission 0.7536 and 0.5579 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4502 / 0 / 317 
Goodness-of-fit on F2 1.073 
Final R indices [I>2sigma(I)] R1 = 0.0398, wR2 = 0.0963 
R indices (all data) R1 = 0.0456, wR2 = 0.1000 
Extinction coefficient n/a 
Largest diff. peak and hole 0.234 and -0.293 e.Å-3 
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7.2.3. (4R,10R)-10-(4-bromophenyl)-3-methyl-1,4-diphenyl-7,8-dihydro-
4H,6H,10H-furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151e) 
 
Table 1. Crystal data and structure refinement for qwdu457_0m_a. 
Identification code  qwdu457_0m_a 
Empirical formula  C28 H23 Br N2 O2 
Moiety formula  C28 H23 Br N2 O2 
Formula weight  499.39 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 10.6956(3) Å  
 b = 6.7724(2) Å 
105.3450(10)°. 
 c = 16.4517(5) Å . 
Volume 1149.19(6) Å3 
Z 2 
Density (calculated) 1.443 Mg/m3 
Absorption coefficient 2.660 mm-1 
F(000) 512 
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Crystal size 0.300 x 0.200 x 0.100 mm3 
Theta range for data collection 2.785 to 72.151°. 
Index ranges -13<=h<=13, -7<=k<=8, -19<=l<=20 
Reflections collected 16141 
Independent reflections 4422 [R(int) = 0.0322] 
Completeness to theta = 67.679° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7536 and 0.4735 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4422 / 1 / 299 
Goodness-of-fit on F2 1.076 
Final R indices [I>2sigma(I)] R1 = 0.0225, wR2 = 0.0566 
R indices (all data) R1 = 0.0230, wR2 = 0.0568 
Absolute structure parameter 0.042(6) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.283 and -0.655 e.Å-3 
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7.2.4. (4R,10S)-3-methyl-10-(5-methylfuran-2-yl)-1,4-diphenyl-7,8-dihydro-
4H,6H,10H-furo[3,4-d]pyrazolo[1,2-a]pyridazin-6-one (151s) 
 
 
Table 1. Crystal data and structure refinement for Qwdu469_0m. 
Identification code  Qwdu469_0m 
Empirical formula  C27 H24 N2 O3 
Moiety formula  C27 H24 N2 O3 
Formula weight  424.48 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.7418(8) Å  
 b = 16.225(2) Å  
 c = 19.555(2) Å  
Volume 2139.1(5) Å3 
Z 4 
Density (calculated) 1.318 Mg/m3 
Absorption coefficient 0.692 mm-1 
F(000) 896 
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Crystal size 0.250 x 0.070 x 0.070 mm3 
Theta range for data collection 3.539 to 72.264°. 
Index ranges -8<=h<=8, -12<=k<=19, -24<=l<=24 
Reflections collected 24798 
Independent reflections 4209 [R(int) = 0.0457] 
Completeness to theta = 67.679° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7536 and 0.4552 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4209 / 0 / 292 
Goodness-of-fit on F2 1.174 
Final R indices [I>2sigma(I)] R1 = 0.0355, wR2 = 0.0870 
R indices (all data) R1 = 0.0381, wR2 = 0.0932 
Absolute structure parameter 0.08(5) 
Extinction coefficient 0.0112(9) 
Largest diff. peak and hole 0.571 and -0.528 e.Å-3 
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